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Meta-analysis of the treatment of latent tuberculosis infection (LTBI) in HIV-
infected adults has shown significant reduction in the incidence of 
tuberculosis in participants with a positive tuberculin skin test (TST), but not 
in those with a negative TST. However, there are insufficient data on patients 
with advanced HIV disease from high tuberculosis incidence areas.  
 
It is important to exclude tuberculosis prior to such preventive therapy, but 
this can be difficult in patients with symptomatic HIV disease. A tuberculosis 
screening instrument is thus needed to ensure that patients placed on 
preventive therapy do not have tuberculosis. Furthermore, to ensure 
adherence and avoid drug resistance optimal supervision of the treatment 




Patients with clinically advanced HIV disease were screened for active 
tuberculosis using a symptom questionnaire, measured weight loss, chest 
radiography, sputum microscopy and culture prior to receiving tuberculosis 
preventive therapy. Once tuberculosis was excluded, a randomized double-
blind trial was conducted comparing INH with placebo among TST negative 
status participants with WHO Stage 3 or 4 HIV disease. INH/placebo was 
administered for 12 months by patient-nominated supervisors.  
 
TST-positive participants were given open-label INH. Participants who did not 
have access to ART were followed up for 24 months with 6-monthly sputum 
culture and chest radiography. All those enrolled for the trial were required to 











intermittent supervised administration of INH/placebo to assess for 




A total of 118 participants were enrolled: TST was negative in 98. 
Tuberculosis was diagnosed in 11 of 129 patients screened. A simple 
screening instrument of two or more of the symptoms cough, night sweats or 
fever, (plus measured weight loss) had a sensitivity of 100% and specificity of 
88.1% (against the gold standard of sputum culture) and positive and 
negative predictive values of 44% and 100%, respectively. In the randomized 
trial arms, the incidence of tuberculosis was 18/100 person-years (py) in the 
INH arm and 11.6/100 py in the placebo arm [hazard ratio 1.59, 95% 
confidence interval (CI) 0.57-49)].  
 
There was no significant difference in mortality, hospitalization rate or CD4+ 
lymphocyte decline. Patient adherence for INH/placebo was 85% and was 
significantly higher among participants with work-based treatment 
supervisors than among those who were supervised by home-based or 
community-based treatment supervisors. 
 
The daily self-administered treatment (SAT) of cotrimoxazole (CTX) showed 
a good adherence especially among the TST positive participants, where a 
greater benefit in terms of survival among participants with good 




A simple screening instrument can effectively exclude tuberculosis in patients 
with advanced HIV disease, prior to isoniazid preventive therapy (IPT). Once 
tuberculosis has been excluded, TST can be done to assess eligibility for 
preventive therapy. No association between IPT and reduction of 











found. High levels of adherence were observed with patient nominated 
supervisors.  
 
This study also shows that there was a greater benefit in terms of survival 
among participants with a threshold of ≥70% cotrimoxazole adherence. 
The mortality in the <70% cotrimoxazole adherence group was lower but 
not significant as the ≥70% cotrimoxazole adherence group (HR 1.28; 95% 
CI: 0.59 – 2.70).  It was observed that the participants with a positive TST 
had significantly better cotrimoxazole adherence as compared to the 
participants with a negative TST.  
 
A simple screening instrument had shown to effectively exclude 
tuberculosis in patients with advanced HIV disease. Hence, it is 
recommended that once tuberculosis has been excluded, TST can be 
done to assess eligibility for IPT. This should be included as component of 
active tuberculosis case finding integrated into HIV management at 
primary care and VCT. Because good adherence was attributed to patient 
nominated supervisors, it is recommended that in resource-limited settings 
it should also become an integral component of IPT.  
 
Although no benefit was associated with IPT in participants with clinically 
advanced HIV and negative TSTs, (consistent with meta-analyses), 
access to antiretroviral therapy (ART) is increasing in resource-limited 
settings and hence there is a need for further investigation of the role of 
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CHAPTER 1: INTRODUCTION  
 
1.1 Tuberculosis: plague of the 21st century 
 
1.1.1 Identification of Mycobacterium tuberculosis: 19th century 
milestone 
Tuberculosis has been present in human settlements since time 
immemorial. To date there has been no conclusive evidence where and 
when Man first became afflicted with tuberculosis.  
 
The isolation and identification of Mycobacterium tuberculosis (MTb) by 
Robert Koch in 1882 is still today regarded as a milestone for tuberculosis 
in the 19th century. This event became the catalyst for dramatic 
developments towards progress in the prevention, management and 
control of tuberculosis in that era. Today, in spite of these successes, 
tuberculosis returns to become one of the major killer infectious diseases 
of the 21st century. 
 
Robert Koch aptly described tuberculosis morbidity and mortality: “If the 
number of victims which a disease claims is the measure of its 
significance, then all diseases, particularly the most dreaded infectious 
diseases, such as bubonic plague, Asiatic cholera, must rank far behind 
tuberculosis" (Koch R, 1882). With the advent of the HIV/AIDS pandemic, 
this statement made more than 100 years ago remains valid to this day, 
despite the tremendous strides made in the treatment of tuberculosis in 












1.1.2 Transmission of Mycobacterium tuberculosis (MTb) 
The transmission of MTb, the causative agent for tuberculosis, occurs 
predominantly by means of airborne transmission. The risk of infection is 
largely dependent on the dose of droplet infection, duration of exposure 
and host susceptibility. This can take place when one is in contact with a 
sputum smear-positive individual with pulmonary tuberculosis (PTB). HIV-
uninfected tuberculosis patients with undetected active or untreated PTB 
are infectious and can remain infectious or 1-2 years, infecting an average 
of 10 people per year (Styblo K, 1980). However, in poorly resourced 
countries this untreated case of pulmonary tuberculosis (PTB) could 
remain infectious for two years or more (Styblo K, 1980).   
 
An infected person may remain latently infected (without being infectious) 
for life without developing active tuberculosis, if they are not subjected to 
the risk factors for active tuberculosis. Since HIV impairs the immune 
system, it has become the main risk factor for the development of 
tuberculosis. Other historical risk factors fuelling the tuberculosis epidemic 
include environmental factors (i.e. poverty, malnutrition, overcrowding), 
host factors (i.e. other diseases, tobacco use, substance abuse, 
silicosis/silica dust exposure, stress) and health service factors (i.e. quality 
of screening, diagnosis, adherence, latent tuberculosis Treatment (LTBT) 
for HIV positive patients). 
 
1.1.3 Tuberculosis is a Global Public Health Emergency 
On Friday April 23, 1993, the World Health Organisation (WHO) declared 
tuberculosis a global public health emergency (Editorial, CHASA, 1993). 
This heralded official acknowledgement of the worldwide resurgence of 
tuberculosis in the wake of the HIV pandemic, accompanied by an 
alarming increase in multi-drug resistant tuberculosis (MDR-TB); high 
mortality rates; lengthy and expensive treatment and poor rates of 











public health emergency aimed to support the global Tuberculosis Control 
Programme (TBCP), which had already recorded increased mortality rates 
in HIV/TB co-infected patients (WHO, 1992).  
 
At least one-third (2 billion) of the world‟s population is estimated to be 
infected with tuberculosis (WHO 2003).  In 2000, tuberculosis incidence 
rates were highest in the WHO African Region (290/100 000 per year; 
range: 265/100 000-331/100 000). In individuals between the ages of 15-
49 years (in the WHO African Region), 31% of tuberculosis cases notified 
were attributable to HIV. Furthermore, an estimated 1.8 million (5th - 95th 
percentiles, 1.6 - 2.2 million) deaths were because of tuberculosis among 
those aged 15-49 years, (Corbett EL et al, 2003). Of these deaths, 12% 
were attributed to HIV and tuberculosis was reported to be the cause of 
11% of all adult AIDS deaths (Corbett EL et al, 2003). 
 
Developing countries account for 95% of all cases of HIV infection and 
more than 99% of HIV-related deaths. It has been estimated that 95% of 
tuberculosis cases occur in developing countries resulting in 98% of 
tuberculosis-related deaths. The lifetime risk of active tuberculosis among 
HIV-infected adults is 50% as compared to 5-10% risk in adults without 
HIV infection (Pape JW, 2004). Furthermore, a study of HIV-infected 
adults attending HIV Clinics at the University of Cape Town between 
January 1986 and May 1996 reported an annual tuberculosis incidence 
exceeding 30% in patients with clinically advanced HIV disease from high 
tuberculosis burden communities. (Wood R et al, 2000).  
 
In Africa, tuberculosis is thus the most common life-threatening 
opportunistic infection associated with HIV and the major cause of death 
among patients with acquired immunodeficiency syndrome (AIDS). The 











the negative impact of HIV/AIDS (Lee, JW & Kumaresan, JA, 2002) on the 
Tuberculosis Control Programme (TBCP).  
 
1.1.4 The Need for New Strategies in Tuberculosis Control 
Tuberculosis is preventable, treatable and curable; yet we have not been 
able to conquer this age-old disease. To date there is no reliable vaccine 
against tuberculosis. With the emergence of multi-drug resistant (MDR-TB) 
strains, our first line of defence, the six-month tuberculosis treatment 
regimen to cure patients with tuberculosis, is now threatened.  
 
The emergence of Mycobacterium tuberculosis with extensive resistance 
to second line drugs is termed extensively drug resistant tuberculosis and 
termed as extensive drug resistant tuberculosis (XDR-TB).  This too does 
not augur well for the global TBCP.  Analysis of 17,690 tuberculosis 
isolates from 25 reference laboratories on 6 continents showed 20% multi-
drug resistant (MDR) and 2% XDR-TB in a CDC-WHO survey conducted 
between 2000 and 2004 (MMWR, 2006). The recent outbreak of XDR-TB 
in Kwazulu Natal in South Africa, with alarmingly high mortality rates as 
was reported at the XVI International AIDS Conference in Toronto in 
August, 2006, (Gandhi NR et al, 2006), raised major public health 
concerns. 
 
The WHO‟s Millennium Development Goals (WHO-MDG) for the global 
Tuberculosis Control Programme (TBCP) involve five principal targets. 
The first and second targets focus on the successful treatment of at least 
85% of new smear positive cases and the detection of at least 70% of new 
smear positive cases by 2005.  The third and fourth targets focus on 
attempts to at least halt and begin to reverse tuberculosis incidence by 
2015; and halve tuberculosis prevalence between 1990 and 2015. The fifth 
target is focused on an attempt to halve the tuberculosis death rate 











The TUBERCULOSIS burden in developing countries has overwhelmed 
the health services, especially in Sub-Saharan Africa where the vast 
majority of persons with HIV live (Corbett EL et al, 2003).  The WHO 
global targets for tuberculosis control were postponed from 2000 to 2005 
and evidence indicates that further postponement may be necessary as a 
result of the impact of the HIV pandemic (Harries AD et al, 2005). The 
advent of HIV has further exacerbated tuberculosis globally, particularly in 
vulnerable communities subjected to poverty and lack or absence of health 
resource settings and those whose immunity is reduced by HIV. 
 
As in the case of other emerging and re-emerging diseases, there is now 
an urgent need to develop innovative strategies in the battle against 
tuberculosis in the 21st Century. In countries where HIV has contributed to 
a substantial increase in tuberculosis incidence, the focus should remain 
on tuberculosis Control Programmes where diagnosis and treatment of 
active tuberculosis cases should be a priority.  
 
The use of directly observed treatment short course chemotherapy 
(DOTS) that could be incorporated into an intensive community-based 
programme that  focuses focus on early diagnosis and treatment of HIV 
and AIDS-associated tuberculosis is but one of the strategies that could be 
implemented in resource poor settings (Narain JP & Lu YR, 2004; Maher 
D et al, 2005). A combination of highly active anti-retroviral treatment 
(HAART) in high HIV prevalence areas plus tuberculosis case finding 
curing tuberculosis would be effective in reducing tuberculosis incidence 
and deaths over the next 10 years. However, this would require high level 
of coverage and adherence to HAART (Currie CSM et al, 2003). Thus, the 
focus on reducing HIV incidence in preventing tuberculosis incidence and 












Thus, a four pronged strategy in reducing the incidence of tuberculosis 
would involve the 70% of tuberculosis detection rate and curing 85% of the 
tuberculosis active cases; reducing HIV incidence; initiating social 
upliftment programmes for socially vulnerable groups in the community 
and the prevention of tuberculosis by latent tuberculosis treatment (LTBT); 
(Mohammed, A, 2000). 
 
In a cost effectiveness study (Bell JC et al, 1999) that was conducted 
among HIV-infected individuals in sub-Saharan Africa regarding preventive 
tuberculosis therapy, it was concluded that LTBT taken among TST 
positive HIV-infected in this region could extend life expectancy, reduce 
tuberculosis incidence and reduce health care and social costs. This study 
(Bell JC et al, 1999) recommends that tuberculosis control policy in sub-
Saharan Africa should include preventive therapy.  
 
The prevention of tuberculosis and tuberculosis deaths with Isoniazid 
Preventive Therapy (IPT) in HIV-infected patients from communities where 
tuberculosis is endemic has a modest effect and should be complemented 
with treatment of active tuberculosis cases and HAART (Currie CSM et al, 
2003). However, to sustain effective tuberculosis control in the long term, 
latent tuberculosis treatment (LTBT) should be considered to complement 
the intensive strategy of treating active tuberculosis cases.  
 
1.2 Co-infection (Tuberculosis and HIV) 
 
1.2.1 Impact of tuberculosis and HIV co-Infection 
There is a strong association between tuberculosis and HIV and the 
number of persons co-infected with tuberculosis and HIV is on the 
increase as the global prevalence of HIV increases. The prevalence of 











coinfection prevalence rates of 5% or more in eight African countries 
(Corbett EL et al, 2003). And in South Africa it is estimated that the 
MTb/HIV coinfection to be 2 million in a population of 47 million. 
 
The WHO report identifies 22 countries (all, except Russia, developing 
countries), including South Africa, that are considered to have „high 
burden‟ tuberculosis infection rates.  Every year it is estimated that 8 
million people develop tuberculosis, of which 80% are notifications from 
these 22 „high burden‟ countries (WHO 2003). Almost 70% of tuberculosis 
-HIV co-infected people live in Sub-Saharan Africa, where HIV is the 
primary driving force behind the tuberculosis epidemic (Corbett EL et al, 
2003). Tuberculosis, unlike other opportunistic infections, which occur in 
HIV/AIDS patients, is the only infectious disease that poses a public health 
threat to the community. 
 
It has also been suggested that besides the increased susceptibility to 
tuberculosis subsequent to MTb infection, the increase of HIV-associated 
tuberculosis cases could increase MTb transmission rates at the 
community level and thus impacting on HIV-negative persons as well 
(Odiambo JA et al, 1999; Corbett EL et al, 2003)).  
 
Furthermore, several countries have reported epidemic outbreaks of 
tuberculosis that had been associated with HIV with many of these 
reported outbreaks involved multi-resistant outbreaks of MTb strains 
(Agerton TB et al, 1999; Moss AR et al, 1997).  
 
1.2.1.1 Tuberculosis Morbidity and Mortality in HIV-infected Adults 
Tuberculosis is acknowledged as the major cause of morbidity and 
mortality in HIV-infected adults in sub-Saharan Africa (Nunn PP et al, 











this region having experienced a marked increase in tuberculosis 
notifications (Nunn PP et al, 1994).  Prevention of tuberculosis is thus 
important for the reduction of HIV-related morbidity and mortality 
(especially in developing countries).  
 
1.2.1.2 Increased tuberculosis risk in HIV-infected Adults with 
Advanced Disease 
HIV is regarded as the most potent activator of tuberculosis. However, the 
risk is not linear, but increases progressively with advancing immune 
suppression from HIV disease. The risk of both reinfection and reactivation 
tuberculosis increases with advancing immune suppression as assessed 
by CD4+ lymphocyte count (Markowitz N et al,1997; Holmes CB, 2006) or 
clinically advanced HIV disease with WHO Clinical stage 3 or 4 (Wood R 
et al, 2000).  
 
1.2.2 Strategy to combat impact of TB/HIV co-infection  
The World Health Organization Millennium Development Goals (WHO-
MDG) strategy of 85% tuberculosis cure rate and 70% tuberculosis 
detection rate includes the prevention, management and control of HIV. 
This strategy could be achieved through intensified community-based 
interventions and early diagnosis of HIV along with treatment of AIDS and 
HIV-associated tuberculosis with anti-retroviral therapy (ART). An 
intensification of the DOTS strategy in managing tuberculosis would also 
be required (Narain JP & Lu YR, 2004; Maher D et al, 2005). 
 
Having a high tuberculosis cure rate and limiting the progression of active 
tuberculosis (especially among the HIV-infected) through the use of LTBT 
could play a vital role in the reduction of the tuberculosis incidence. 











improvements in the socio-economic conditions of more vulnerable groups 
residing in resource poor settings (Mohammed A, 1995). 
 
1.2.3 The use of INH in latent tuberculosis treatment (LTBT) 
Various combinations of drug therapy regimens and short course therapy 
as well as the directly observed short course (DOTS) strategy has been 
widely used for tuberculosis. However, preventive therapy with isoniazid 
(INH) has not been used consistently in the developed countries and its 
use in the developing countries has been rare. 
 
Just at the commencement of the era of HIV there were several 
recommendations made for those individuals that were recently exposed 
to MTb or were regarded as high risk individuals. These recommendations 
were made by the Joint Tuberculosis Committee of the British Thoracic 
Society (JTBCBTS 1994; Ormorod LP, 1990), the American Thoracic 
Society & Centre for Disease Control and Prevention (ATC & CDC, 1994; 
MMWR, 1990). 
 
The Cochrane Systematic Review of Isoniazid preventing tuberculosis in 
non-infected HIV infected persons (Smeja MJ et al, 1999), involving 11 
trials (conducted between 1962 – 1994), showed that INH was effective in 
preventing tuberculosis in 60% of the people when compared to the 
placebo, [RR 0.40; 95% CI: 0.31 to 0.52)]. This review also showed that 
the pooled relative risk of outcome of overall mortality was RR 1.10 (95% 
CI: 0.94 – 1.28), suggesting that INH had no effect on mortality. 
 
Individuals identified as being infected with MTb are termed as having 
latent tuberculosis infection (LTBI). Prophylaxis for LTBI includes various 
regimens with varying duration of treatment. Although IPT is 











other regimens include the use of Rifampin plus Isoniazid (RH) or 
Rifampin plus Pyrazinamide (RZ) or Rifampin plus Isoniazid plus 
Pyrazinamide (RHZ) or Rifampin (R) alone. 
 
Tuberculosis Preventive Therapy (TBPT) is recommended (WHO & 
UNAIDS, 1998) for HIV-infected persons who have tested positive for the 
tuberculin skin test (TST) and who do not have active tuberculosis. 
However, in settings where TST is not feasible individuals maybe 
considered for TBPT if infected with HIV in:  
 Populations with high prevalence tuberculosis infections estimate to 
be 30% 
 Health care workers 
 Household contacts of TB patients 
 Prisoners 
 Miners 
 Other groups at high risk of acquisition or transmission of TB  
 
TBPT has seen several terms used to describe this form of therapy, such 
as Preventive Therapy (PT) and Latent Tuberculosis Treatment (LTBT). 
However, these terms are interchangeable and LTBT is a much broader 
term referring to treatment of latent tuberculosis infection (LTBI) by one or 
a combination anti- tuberculosis drugs such as INH, Rifampicin (R) and 
Pyrazinamide (Z). For the purpose of this thesis the term IPT will be used 
referring to the use of prophylactic INH when referring to the participants 
enrolled for this trial, unless otherwise indicated. The term LTBT will be 
used in reference to other studies where it has been stated unless 












The use of IPT for those individuals with LTBI remains an effective tool for 
the prevention of tuberculosis. In the era prior to HIV, LTBT in developing 
countries was limited to select groups such as household contacts 
(especially children) who were exposed to active tuberculosis. However, 
today with the advent of the era of HIV, LTBT in developed countries, 
especially in the USA, is widely used in the prevention of tuberculosis.  
 
Although the benefit of LTBT appears to be limited to the HIV-infected 
individuals with a TST-positive status (Bucher HC et al 1999; Woldehanna 
S & Volmink J, 2004), the WHO has recommended the use of INH for 
LTBT in all HIV-infected individuals in countries where the prevalence of 
LTBI is greater than 30% and where TST for purified protein derivative 
(PPD) is not feasible (WHO, 1999).  However, it must be borne in mind 
that INH is not 100% effective and that subsequent tuberculosis exposure 
could result in the development of tuberculosis despite preventive therapy. 
Furthermore, IPT would not be able to prevent tuberculosis resulting from 
the exposure to INH resistant MTb. Also the effectiveness of the INH 
prophylaxis would largely be dependent on the adherence of the 
compliance of individuals to whom INH prophylaxis has been prescribed 
as well as the absorption of anti-tuberculosis drugs in AIDS patients has 
been shown not to be optimal (Peloquin CA et al, 1996).  
 
Before placing the HIV infected patients on LTBT, it is essential to exclude 
active tuberculosis in order to prevent the development of drug resistance. 
Tuberculosis screening of these patients is vital. WHO policy on LTBT 
recommends that all individuals living with HIV be screened for TB              
(including HIV–uninfected individuals) should be asked if they have had a 
persistent cough for than two weeks and if their response is in the 
affirmative, they should be screened for tuberculosis. This is based on the 
premise that most people with active tuberculosis, especially patients with 
advanced HIV, have constitutional symptoms. Until a valid screening test 











examined for each tuberculosis suspect patient before considering LTBT 
(WHO, 1999).  
 
LTBT has been demonstrated in several randomized controlled trials 
(RCTs) to reduce the risk of development of active tuberculosis in HIV-
infected patients, particularly among those with TST positive status.  Early 
INH prophylaxis studies among HIV infected adults indicated that INH is 
more effective in TST positive patients than in TST negative patients 
(Wilkinson D, 1999). Further studies conducted show a consistent benefit 
of preventive therapy among TST positive patients in general but not 
among TST negative patients (Wilkinson D, 1999; Bucher HC et al, 1999; 
Woldehanna S & Volmink J, 2004) 
 
In the Cochrane Systematic Review including 13 trials of differing HIV 
target populations and entry criteria, LTBT reduced the risk of tuberculosis 
by 36% (RR 0.64; 95% CI: 0.51 - 0.81). When INH versus placebo was 
considered, the tuberculosis risk reduction was 36%, RR 0.67; 95% CI: 
0.51 - 0.87 (Woldhanna S & Volmink J, 2004). This review also 
(Woldhanna S & Volmink J, 2004) demonstrated a tuberculosis risk 
reduction of 17% (RR 0.83; 95% CI: 0.58 - 1.18) in seven trials of PPD 
negative patients, which was not statistically significant.   However, it must 
be noted that this meta-analysis did not stratify response by CD4+ 
lymphocyte count or WHO clinical stage. Currently, there are insufficient 
data on the efficacy of IPT in patients with advanced HIV disease (WHO 
clinical stage 3 or 4) and negative TST in TB endemic areas with a high 
TB and HIV incidence. 
 
The duration of LTBT for 3-6 months could be termed as short-term LTBT. 
Whereas the duration of LTBT for greater than 6 months could be termed 
as long-term.  Short-term LTBT in HIV infected adults seem to merely 











(Whalen C et al, 1997) showed that the INH duration of benefit was 
limited. However, neither of these studies were designed to asses this 
outcome. Although short term LTBT may be more cost-effective (Masobe, 
P et al, 1995) long term LTBT has been recommended (Quigley MA et al, 
2001). A study by Comstock has shown that INH prophylaxis for 12 
months may be better than six months in HIV-negative 
immunocompromised individuals (Comstock GW, 1999). Fitzgerald and 
colleagues (Fitzgerald DW et al, 2000) presented data suggesting that INH 
prophylaxis has an effect on tuberculosis infection after treatment of LTBI, 
that is dependant on the duration of IPT, with long term INH prophylaxis 
said to be advantageous.   
 
A meta-analysis has shown that a regimen of Rifampicin and Isoniazid 
administered for three months compared to the regimen of Isoniazid 
administered for 6–12 months was equivalent in terms of efficacy, safety 
and mortality (Ena J & Valls V. 2005). To date, current literature has not 
provided any studies that have compared the effect of INH prophylaxis for 
6 and 12 months in HIV positive individuals.  
 
In a RCT that compared a 2-month regimen daily rifampin and pyrazinamide 
with a 12-month daily regimen of isoniazid in LTBT among HIV–infected 
individuals (Gordin F et al, 2000), showed no differences in terms of 
preventing tuberculosis, efficacy and safety when comparing the 2-month 
regimen with the 12-month regimen. According to 2005 Centre for Disease 
Control (CDC, 2005) Guidelines for Targeted Tuberculin Testing and 
Treatment of Latent Tuberculosis Infection, it is desirable to initiate 
intermittent LTBT if a patient is TST positive and is at high risk of HIV 
infection or being in contact with tuberculosis patient.  
 
Although a systematic review of RCTs (Volmink J et el, 2006) of DOTS for 











supervised LTBT as compared to self administered treatment (SAT). Data 
from a study (Heal G, 1998) with non-random allocation to treatment 
groups of DOTS versus SAT LTBT demonstrated that adherence had 
improved as a result of patient supervision. The need for patient 
nominated supervisors for directly observed LTBT will be further supported 
with additional findings in the Literature Review chapter. 
 
Thus it is reasoned that whilst focussing on the efficacy of the INH intake it 
could cause adverse effects and INH resistance. This risk could be 
reduced by the enhancement of adherence to LTBT with the introduction 
of a treatment supervisor nominated by the participant prior to the 
enrolment. This study thus proposes to assess IPT and the intermittent 
administration of supervised INH prophylaxis in clinically advanced HIV 
patients with a TST negative status.  
 
1.3 Research problem 
 
Anergic patients with advanced HIV disease (WHO clinical stage 3 or 4) 
were under-represented in previous RCT. To date there are the only two 
such trials (Rivero A et al, 2003; Gordin FM, 1997 et al) that enrolled 
anergic patients with a substantial proportion of AIDS patients. However, 
these trials were based in developed countries where tuberculosis is not 
endemic. Hence these results cannot be generalised to developing 
countries.  
 
The Whalen trial (Whalen CC et al, 1997) in Ugandans, had excluded 
patients with WHO clinical 4, but included some patients with WHO clinical 
stage 3 and had included a substantial number of anergic patients. This 
was a trial of three regimens to prevent tuberculosis among adults in 











among anergic patients that were administered INH or placebo for six 
months. The authors speculate the reason why INH among anergic 
patients did not confer same degree protection as that among TST positive 
patients could be attributed to drug malabsorption or other host factors 
associated with advanced disease. But more importantly the sample size 
of this anergic cohort was small and rendering the benefit of INH of 
anergic patients inconclusive. 
 
The question whether INH prophylaxis reduces tuberculosis for the patients 
in developing countries with negative TST (anergic) in HIV-infected adults 
with clinically advanced disease (WHO Clinical stage 3 or 4) still remains 
unanswered.  
 
1.4 Study rationale  
 
The rationale of preventive therapy is to eliminate LTBI in individuals and 
thus prevent the development of active tuberculosis. The Cochrane Review 
of INH prophylaxis among non-HIV infected patients (Smieja MJ et al, 
1999), proposed that one case of active tuberculosis could be prevented if 
nine high risk individuals with a positive TST, with silicosis and 20% (or 
higher) baseline risk of developing active tuberculosis, were administered 
INH prophylaxis for six months. Based on this premise, the question is: 
could such a similar benefit be obtained in HIV-infected patients with a 
negative TST and with a high baseline risk (advanced HIV disease) of 
developing tuberculosis who reside in a tuberculosis endemic setting? 
 
In (HIV) seronegative persons with LTBI, the lifetime risk of tuberculosis 
is about 10%, compared with 10% per annum if they are HIV co-infected 
(Selwyn PA et al 1989). Meta-analyses on the treatment of LTBI in HIV-
infected adults have shown a significant reduction in the incidence of 











TST (Woldehanna S & Volmink J, 2004; Bucher et al, 1999). In HIV-
infected patients, TST is more likely to be negative as the CD4+ 
lymphocyte count declines (Markowitz N et al, 1993). The risk of HIV-
associated tuberculosis increases with advancing immune suppression, 
as assessed by CD4+ lymphocyte count or disease stage (Holmes CB 
et al, 2006; Wood R et al, 2000). In areas such as South Africa, where 
tuberculosis is endemic, the majority of HIV-seronegative adults have 
LTBI, as assessed by a positive TST (Rangaka MX et al, 2007). In this 
setting, most HIV-infected patients with a negative TST will be anergic 
due to advanced HIV disease, and are thus at high risk of tuberculosis 
(Holmes CB et al, 2006; Wood R et al, 2000).  
 
It is therefore surprising that treatment of LTBI has been shown to be 
ineffective in TST-negative participants in trials conducted thus far 
(Woldehanna S & Volmink J, 2004; Bucher et al, 1999). This lack of 
effect could be explained by the fact that participants with advanced HIV 
disease were under-represented in placebo-controlled clinical trials 
conducted in areas where tuberculosis is endemic (Hawken MP et al, 
1997; Mwinga A et al, 1998; Pape JW et al, 1993; Fitzgerald DW et al, 
2001); TST negative participants were therefore more likely to be „true 
negatives‟, i.e., they did not have LTBI. Tuberculosis incidence in Cape 
Town, South Africa, exceeds 500 per 100 000 population (Wood R et al, 
2000; Rangaka MX et al, 2007) and the prevalence of TST positivity in 
HIV-seronegative individuals exceeds 80% Rangaka MX et al, 2007). 
Previously reported study shows an annual tuberculosis incidence 
exceeding 30% in HIV-infected adult patients with clinically advanced 
disease ((Wood R et al, 2000). 
 
This study is based on the premise that INH preventive therapy in HIV-
infected adults with clinically advanced disease (WHO Clinical stage 3 or 
4) who were TST negative might be effective in the setting of an endemic 











enhance the effectiveness of IPT by ensuring optimal adherence. This 
study took precautions that would reduce the risk of recruiting participants 
that may have been undiagnosed or misdiagnosed for tuberculosis. A 
vigorous tuberculosis screening procedure was introduced prior to the 
patients‟ enrolment into the trial to prevent treating participants with 
undetected tuberculosis with INH and thus reducing the risk of INH 
resistance. This provided an opportunity to validate a questionnaire based 
on the tuberculosis screening instrument and thus exclude undetected 
cases of active tuberculosis prior to enrolment of participants to the 
randomised clinically controlled trial. 
 
1.5 Hypothesis of the study  
 
Intermittent and supervised INH prophylaxis will result in a significant 
reduction of tuberculosis incidence among patients with negative TST and 
clinically advanced HIV disease (WHO Clinical stage 3 & 4) patients in a 
setting with a high tuberculosis incidence. 
 
1.6 Purpose of the study 
 
The purpose of this study was to investigate the efficacy of IPT, for 
patients with negative TST and clinically advanced HIV disease with WHO 
Clinical stage 3 & 4. 
 
1.7 Aim of the study  
 
The main aim of this study was to determine the efficacy of intermittent 
INH supervised prophylaxis in HIV-infected adults with advanced disease 











in a high tuberculosis endemic setting, by means of a double blinded 
randomised controlled trial.  
 
1.8 Objectives of the study 
 
1.8.1 Primary Objectives 
1.8.1.1 To develop and assess the validity of tuberculosis screening 
instrument for resource poor settings to detect active tuberculosis 
cases prior to INH/Placebo; 
1.8.1.2 To determine efficacy of intermittent directly observed INH 
prophylaxis in the prevention of tuberculosis in HIV-infected 
participants with advanced disease (WHO clinical stage 3 or 4) 
and who are TST-negative 
 
1.8.2 Secondary Objectives 
1.8.2.1 To compare the number of hospitalization events, CD4 decline 
and mortality in the INH and placebo groups; 
1.8.2.2 To evaluate the adherence of patients to IPT; 
1.8.2.3 To compare adherence to IPT in the different patient 
nominated supervisor categories (e.g. home, community or 
work-based); 
1.8.2.4 To compare adherence to unsupervised Cotrimoxazole with 
adherence to the intermittent and supervised INH/Placebo 















2.1.1 Background to tuberculosis control  
In 1947, due to the high prevalence of tuberculosis and the global 
distribution of this problem, WHO (WHO, 1947) was motivated to prioritize 
it‟s TBCP by promoting mass Bacillus Calmette-Guérin (BCG) vaccination 
campaigns (Comstock GW. 1994). 
 
The discovery of Streptomycin in 1944 and its introduction in 1946 as a 
standard treatment for tuberculosis marked the beginning of chemotherapy 
for tuberculosis control worldwide (Schartz A & Wakesman SA, 1944). The 
use of Streptomycin was followed by Isoniazid (INH) in 1952, after the first 
clinical trial began in 1951 at Sea View Hospital in Staten Island, New 
York. This was followed by the use of Pyrazinamide (1954), Cycloserine 
(1955), Ethambutol (1962) and Rifampicin (1963); introduced as anti- 
tuberculosis agents (University of Medical and Dentistry of New Jersey - 
UMDNJ, 1996). Further improvements in the tuberculosis control 
measures were the introduction of INH and Rifampicin (Raviglone MC & 
Pio A, 2002) in the implementation of short-course chemotherapy 
regimens (Fox W et al, 1999).   
 
In 1959 at the Arden House Conference (in the US), national efforts were 
refocused on eliminating tuberculosis from America. It recommended 
nationwide chemotherapy for all persons with active tuberculosis and 
support for the tuberculosis preventative treatment program for those with 











with a positive TST receive Isoniazid chemotherapy to prevent disease 
progression. To date, INH chemoprophylaxis (LTBT) is maintained to be 
one of the most effective regimen for preventing tuberculosis.  
 
The use of INH as treatment for those with LTBI still remains an effective 
tool for preventing active tuberculosis among the vulnerable individuals. In 
the era prior to HIV, INH chemoprophylaxis was limited to select groups 
such as household contacts who were exposed to active tuberculosis and 
persons with positive TST status in developed countries.   
 
With the advent of the HIV pandemic, INH chemoprophylaxis is now being 
used in HIV-infected individuals. The WHO guidelines recommend the use 
of IPT in HIV-infected individuals with a TST positive status or, in countries 
where the prevalence of LTBI is greater than 30% and where TST for PPD 
is not feasible (WHO, 1999).   
 
2.1.2 Era of tuberculosis prior to the advent of HIV/AIDS in South 
Africa 
In the era prior to the advent of HIV/AIDS, the TBCP in South Africa had 
tabled a policy on tuberculosis infection control (DOH SA TB Policy 
Statement, 1979). This Tuberculosis Infection Policy was aimed at 
reducing the risk of tuberculosis infection in the country to below 0.03% 
per annum for all population groups and ensuring effective treatment of all 
diagnosed tuberculosis cases. This goal was in line with the 
recommendations of international tuberculosis Policy.  The goal of this 
policy was to focus on two phases.  
 
Phase 1 was to manage and control the infectious pool which involved 
active and passive case finding, short course therapy and BCG 











pool and involved chemoprophylaxis for positive tuberculin persons, BCG 
vaccination and continuation of the methods of Phase 1. 
 
It has been estimated that 33% to 70% of close contacts of active PTB 
cases are subsequently infected. A geographical information system (GIS) 
evaluating the distribution of tuberculosis in a high-incidence community 
(Beyers N et al, 1996) demonstrated that more than one third of all 
dwellings had housed at least one tuberculosis case within the decade of 
the study and within this community tuberculosis cases were spread 
unevenly and occurred repeatedly in certain houses of that community.  
 
In an investigation of HIV-infected individuals based in a housing facility, 
30 were exposed to tuberculosis, of whom 11 (37%) developed active 
tuberculosis within four months. The number of new TSTs positive for PPD 
among this group of 30 individuals was determined to be four (13%) 
(Daley CL et al, 1992). 
 
In South Africa it was estimated that 8% of contacts had developed active 
tuberculosis in the early 1980‟s (Collins TFB, 1981; Benatar SR, 1982). By 
1983 the prevalence and risk of tuberculosis infection in adults were found 
to be on the decline, with the exception of the Coloured population in the 
Western Cape (Fourie PB, 1983).  The conclusion of this study is still 
controversial with Packard regarding the tuberculosis decline in the late 
1960s as an apparent decrease rather than a true decrease, dubbing this 
phenomenon an „optical illusion‟ (Packard, RM, 1990).  
 
Packard argues that the earlier rise in tuberculosis in the 1950s and the 
1960s in South Africa may have been influenced by increased case finding 
efforts rather than a true tuberculosis increase. Packard argues three 











Firstly the decrease in tuberculosis notifications after 1965 may be 
apparent rather than real because the social and economic conditions in 
urban areas among the disenfranchised (especially Africans) had 
deteriorated significantly. Secondly, Packard argues that the use of BCG 
and chemotherapy in curing tuberculosis cases and preventing its spread 
may have been only marginally effective and it may have contributed to 
the real rise in tuberculosis (because of poorly managed tuberculosis 
control programmes). Lastly, he argues that the mass removal of urban 
Africans resulted not in the decrease of tuberculosis incidence but rather 
displaced tuberculosis incidence to „bantustans‟ or „homelands‟ or „national 
states‟  (what has been referred to in South Africa by many as the „great 
disappearing act‟). 
 
By the early 1990s, it was quite evident that the South African TBCP goals 
were not being achieved.  Factors attributing to this failure are numerous. 
However, the following have been acknowledged as the main factors 
resulting in failure to achieve the goals of the South African TBCP 
(Coovadia HM & Benetar SR, 1991).   
 Weak Primary Health Care (PHC); 
 Poor central coordination of tuberculosis control; 
 Insufficient welfare system; 
 Lack of community involvement; 
 Inadequate support and referral systems; 
 Inappropriate health education of health workers; 
 Poor integration of health workers into the Tuberculosis Control 
Programme;  












A slightly different view on the failure in achieving the South African TBCP 
goals was aptly summed up almost a decade before it occurred, by 
Glatthaar (MRC Review of TB 1987): "The eradication of TB in our lifetime 
is an unattainable dream, and planning must be in terms of decades, not 
years. Our inability to eradicate TB can be blamed entirely on the 
unpredictable behaviour of the reservoir of infected persons in the 
Republic. We are burdened with this huge reservoir of infected persons 
and we can only decrease the inflow and arrest further expansion of the 
pool but we cannot control the outflow of the infectious cases." 
 
2.1.3 The advent of the HIV/AIDS era in South Africa 
The first diagnosed AIDS case in South Africa was reported in 1982, with 
HIV infections initially occurring mainly among gay White men.  By 1985 it 
was being reported in other sectors of society.  In 1990, the first (of 
subsequent annual) South African national antenatal HIV survey was 
conducted, showing 0.8% HIV sero-prevalence. In 1995 at the 
International Conference for People Living with HIV and AIDS, convened 
in South Africa, the then Deputy President Thabo Mbeki acknowledged the 
seriousness of the epidemic. The South African Ministry of Health 
announced that some 850 000 people (2.1%) of the total population were 
estimated to be HIV positive (Pope H, 1995).  By the end of 2005 there 
were five and a half million people living with HIV in South Africa, and 
almost 1 000 AIDS deaths occurring every day (UNAIDS, 2006).  
 
The complacency and inability of the government to set in place innovative 
preventive strategies and the frustration of health professionals in dealing 
with the early stages of the HIV epidemic, have been succinctly summed 
up in a letter to the editor in the Lancet (Carswell W, 1993): "Since 1984, I 
have been involved in several aspects of the HIV pandemic, in Africa and 
elsewhere.  Much of this work has been to encourage governments to 











Adviser to the South African Government's AIDS Unit.  A depressing 
feature of this pandemic is the certainty that when HIV arrives in a country 
the same cycle of responses has to be played out once again.  Countries 
find it difficult to learn from other's mistakes, and South Africa is no 
exception."  
 
By 1995, government and health authorities were being alerted to the 
pending health crisis presented by the increasing tuberculosis incidence 
and the fact that historic interventions had not made a significant impact. 
The Western Cape was the epicentre of the tuberculosis epidemic and 
concerns were raised regarding the advent of HIV and the negative impact 
this would have on current and future tuberculosis interventions. The 
global re-emergence of tuberculosis with the advent of HIV/AIDS has been 
compounded by an increase in MDR-TB. Rising tuberculosis mortality, as 
well as lengthy and expensive treatment, would not augur well for the new 
South Africa.  It was also repeatedly stated that delay in implementing 
interventions in the prevention, management and control of TB/HIV would 
result in the new South Africa facing a catastrophe of an unprecedented 
magnitude (Mohammed A, 1995). 
 
Failure of the South African Tuberculosis Programme has not only resulted 
in an increasing number of active infectious tuberculosis cases, but more 
importantly, it has increased the infected tuberculosis pool by exposing a 
susceptible population to an increased level of infection.  This failure to 
control the tuberculosis epidemic was further compounded by the inaction 
of the government in intervening prior to the increase in HIV incidence, 
resulting in an increasing number of TB/HIV co-infections. In 1996 the 
Western Cape declared a Provincial Tuberculosis Emergency.  This 
occurred three years after the WHO had declared tuberculosis a global 












HIV has not only increased the burden of tuberculosis programmes, but 
has crippled many existing health care delivery services in many high HIV 
prevalence countries that were already poorly resourced prior the advent 
of the HIV era. It is essential that the basics of tuberculosis control 
interventions are implemented in collaboration with HIV control 
programmes so that HIV-related tuberculosis interventions are prioritized 
both in respect of treatment and prevention (Maher M et al, 2005).   
The reason tuberculosis persists as a global problem is summed as 
follows (Benatar S, 2005): “Failure to appreciate that the emergence and 
spread of infectious diseases (afflicting predominantly the poor) are 
attributable to the ideology and economic forces that perpetuate poverty, 
will diminish our ability to control HIV/AIDS and tuberculosis and probably 
favour the emergence of more new infectious diseases.”  
 
2.1.4 Development of active tuberculosis in the HIV-infected 
HIV not only increases the risk of tuberculosis among those with LTBI 
(Bucher et al, 1999; Woldehanna S, Volmink J, 2004), but also the risk of 
tuberculosis following primary infection and re-infection (Daley CL et al, 
1992; Schafer RW et al, 1995).  
 
HIV-associated tuberculosis is mainly dependent on three factors. These 
are the population incidence and prevalence of infection with 
Mycobacterium tuberculosis, the population prevalence and incidence of 
HIV infection, and the extent to which these two populations of 
tuberculosis-infected and HIV-infected overlap.  
 
Three components of tuberculosis infection contribute to tuberculosis 
morbidity. Primary tuberculosis is defined as tuberculosis resulting from a 
single infection acquired within the past five years. Endogenous 











infection acquired more than five years earlier. A molecular study of TB 
latency for several years has shown late onset of TB has been attributed 
to the endogenous reactivation of dormant bacteria (Lillebaek T et al, 
2002). Exogenous re-infection TB is defined as TB resulting from a second 
(or several infections) acquired at any time following the first infection.  
 
The extent to which these different components contribute to the 
tuberculosis morbidity in the community is largely dependent on the 
prevailing risk of infection and the age of the population segment 
concerned. The number of tuberculosis cases and deaths that occur in the 
future are dependent on how well and how speedily the WHO TBCP can 
be implemented in countries with a high incidence of tuberculosis. 
 
HIV is the strongest risk factor yet identified for progression from LTBI to 
tuberculosis. There are several studies that have evaluated HIV as a risk 
factor for tuberculosis among persons with tuberculosis infection. The first 
study was in New York City among TST positive injection drug users 
enrolled in a methadone maintenance program. The risk of tuberculosis 
was about 8 per 100 person years (Selwyn PA et al, 1989).In a multi-
center study in Spain, the risk in HIV infected, TST positive patients of 
developing tuberculosis was about 16 per 100 person years (Gellar A, et 
al, 1993). In a multi-center study in Italy, the risk of developing 
tuberculosis, among the participants of the study, was about 5 per 100 
person-years (Antonucci G et al, 1995). 
 
The model developed by Cohen and colleagues (Cohen T et al, 2006), 
shows that the systematic use of IPT to prevent progression infections 
among HIV-infected individuals and will reduce the local burden of 
infection and active tuberculosis for several years. However, it is 
suggested that this benefit would be short-lived by the rapid emergence of 











program is insensitive to the prevalence of HIV and drug resistant 
tuberculosis. Hence it is believed that IPT would be best performed in such 
a setting where intensified diagnosis and treatment of tuberculosis is 
incorporated at the time of initiating IPT program. 
 
2.1.5 Impact of co-infection with HIV on the burden of TB 
HIV negative individuals infected with MTb have an estimated lifetime risk 
of 5-10% of active tuberculosis (Sutherland I, 1976; Vynnycky, E, 1997), 
as compared to a 50% lifetime risk of active tuberculosis among HIV-
infected persons (Pape JW, 2004). The annual risk of tuberculosis in 
persons co-infected with tuberculosis and HIV has been estimated to be 
about 10% (Bucher HC et al, 1999).  
 
The global targets for tuberculosis control were postponed from 2000 to 
2005 and further postponement will be necessary as a result of the HIV 
pandemic (Harries AD et al, 2005).  Preventing further infection of HIV is 
necessary if tuberculosis incidence in this region is to be successfully 
controlled.    
 
It was estimated globally that there were 8.3 million new tuberculosis 
infections in 2000, with an incidence rate of 137/100 000 population; 
ranging from 121/100 000 to 151/100 000. The highest incidence rates of 
290/100 000 population per year, (ranging from 265/100 000 to 331/100 
000) occurred in the WHO African region (Corbett EL et al, 2003), with a 
6% annual increase in the number of tuberculosis cases. It was estimated 
that 9% (ranging between 7%-12%) of all new adult tuberculosis cases 
(aged 15-49 years) were attributed to HIV infection but in the WHO African 
Region this proportion three times greater (Corbett EL et al, 2003).  In the 
WHO African region, 31% of new adult tuberculosis cases were HIV-











tuberculosis, 12% (226 000) were attributed to HIV. Tuberculosis in turn 
resulted in 11% of all adult AIDS deaths (Corbett EL et al, 2003). 
 
The overlapping of the tuberculosis and HIV epidemics is more noticeable 
in sub–Saharan Africa where 70% of co-infected people reside (Corbett EL 
et al, 2003). The co-infection prevalence rate equalled or exceeded 5% in 
8 African countries and in South Africa alone 2 million adults were 
estimated to be co-infected (Corbett EL et al, 2003).  
 
Concern has been raised with regards to the infection between 
susceptibility and MDR-TB of HIV positive patients. Recently, in January 
2006, the spectre of a more deadly form of MDR-TB outbreak was 
reported in Kwazulu Natal, South Africa with alarmingly high mortality 
rates. This more deadly form of MDR-TB termed as extensive drug 
resistant tuberculosis (XDR-TB), a form of MDR-TB, is resistant to three or 
more of the six classes of second-line anti-tuberculosis drugs. Of the 544 
patients studied, 221 had MDR-TB. Of the 221 MDR-TB cases, 53 were 
defined as XDR-TB. Of the 53 patients, 44 had been tested for HIV and all 
were HIV-positive. Fifty two of the 53 patients died, on average, within 25 
days, including those benefiting from ARV drugs. This emphasizes the 
strong relationship between HIV and MDR-TB and, more recently, HIV and 
XDR-TB (WHO 2006).   
 
The KwazuluNatal outbreak does not demonstrate a striking relationship 
between HIV and XDR-TB. It is yet another reminder that patients with 
advanced immunodeficiency are like canaries in a coal mine. Trends in 
recent transmission will appear first and foremost dramatically in this 













HIV increases the risk for reactivation (Selwyn PA et al, 1989) of LTBI 
(Edlin BR et al, 1992), in turn resulting in the rapid progression to AIDS 
(Bucher HC et al, 1999, Daley CL et al 1992; Shafer RW et al, 1995). This 
in turn increases the MTb transmission rates at the community level 
(Odhiambio JA et al, 1999; Corbett EL et al, 2003).  The implications of 
this are that the health of HIV negative persons is under threat not only 
from the increase of HIV–associated tuberculosis but also HIV–associated 
MDR-TB (Ritacco V et al, 1997; Agerton TB et al, 1999; Moss AR et al, 
1998). 
 
Among immunocomprised HIV-infected persons with LTBI, progression of 
primary tuberculosis (Edlin BR et al, 1992), reactivation (Selwyn PA et al, 
1989), or reinfection (Small PM et al, 1993) with active tuberculosis is 
much more likely to occur.  It has been determined that a CD4 count below 
200 cells/unit is a greatly associated risk of development of active 
tuberculosis (Halesy NA et al, 1993).  
 
A study in Cape Town (Wood R et al, 2000) demonstrated that HIV-
infected patients that were in WHO Clinical stage 3 or 4 had an adjusted 
risk ratio of 3.4 (95% CI: 1.8 - 6.4) for tuberculosis compared to those in 
WHO Clinical stage 1 or 2. The risk of developing tuberculosis thus 
increased markedly with advanced HIV disease.  Furthermore, this study 
also found that the annual risk of tuberculosis in high incidence 
tuberculosis communities was in excess of 30% in patients with advanced 
HIV disease (Wood R et al, 2000). A retrospective study of miners on four 
South African gold mines established that the risk of developing 
tuberculosis doubles within the first year of being tested HIV positive, with 
an adjusted case rate ratio of 2.11 (95% CI: 1.45 - 3.09) (Sonneberg P, 












2.1.6 Impact of Co-infection with tuberculosis on HIV 
HIV disease progression is accelerated by concurrent immune stimulation 
(Wodaz, D & Nowak, MA, 1999; Petruckevitch A et al, 1998).  
Opportunistic infections result in bursts of HIV replication that could 
possibly be contributing to high HIV transmission rates as observed in sub-
Saharan Africa (Corbett EL & De Cock KM, 2001). Quinn and colleagues 
based this theory (Quinn TC et al, 2000) on viral loads in plasma and 
genital secretions that were shown to correlate with each other and with 
infectivity. This high HIV transmission rate could also possibly be 
conducive to increase in HIV re-infection that could lead to more rapid 
progression of HIV to AIDS.  
 
The effect of active tuberculosis on HIV is less well understood.  Although 
earlier in vitro studies have indicated that the replication of HIV was 
induced by Mycobacterium tuberculosis (Lederman MM et al, 1994; Goletti 
D et al, 1996), clinical and public health findings are unclear (Corbett EL & 
De Cock KM, 2001).  An earlier study indicated that MTb appears to 
increase HIV replication both systematically and locally (Halvir DV & 
Barnes PF, 1998). This study demonstrated that some patients, just prior 
to diagnosis of active tuberculosis, had a substantial rise in HIV viral load. 
 
Furthermore, it has been reported that viral load is higher in HIV-infected 
patients with active tuberculosis than those without active tuberculosis 
(Goletti D et al, 1996 & Tossi Z et al, 2001). A recent study established 
that tuberculosis was associated with a small adjusted increase in HIV 
viral load.  Although this increase was not regarded as clinically significant 
in an individual, it was believed to have some effect on HIV disease 
progression and HIV transmission at population level (Day JH et al, 2004).  
 
However, patients in advanced stages of HIV infection (WHO Clinical 











(Markowitz N et al, 1997; Wood R et al, 1999) by either reactivation or 
reinfection and have a shorter survival once they have succumbed to 
tuberculosis. 
 
A cohort study reported that there were higher adjusted mortality and 
incidence rates of non- tuberculosis opportunistic infections (OIs) among 
patients with active tuberculosis as compared to those without active 
tuberculosis  attending an HIV clinic in Cape Town (Badri M et al, 2001). 
This study concluded that the onset of tuberculosis in HIV-infected patients 
is associated with an increased risk of AIDS (adjusted RR 1.65; 95% CI: 
1.08 - 2.41, p = 0.02) and death (adjusted RR 2.165; 95% C: 1.29 - 3.59, p 
= 0.003). This was believed to be as a result of prolonged immune 
activation induced by tuberculosis, resulting in increased HIV replication 
leading to accelerated HIV disease progression.  
 
Meta-analysis of LTBT in HIV-infected individuals with a positive TST 
demonstrated a significant reduction of subsequent tuberculosis incidence 
but with no significant impact on survival (Bucher HC et al, 1999). This 
could be explained by the fact that HIV-associated tuberculosis incidence 
may not be high enough to dominate HIV progression rates and mortality 
at population level (Corbett EL & De Cock KM, 2001). This would be very 
likely if the impact on HIV disease progression was exclusive to the 
tuberculosis cases that occurred early in the course of HIV disease, as has 
been demonstrated in some studies (Badri M et al, 2001; Whalen CC et al, 
2000). 
 
Whilst the prevention of tuberculosis is vital in the strategy for the 
reduction of HIV-related morbidity, it has been suggested by two studies 
(Morris L et al, 1998; Lawn SD et al, 1999), that the effect of tuberculosis 











effective anti-tuberculosis treatment; as has been observed in studies in 
sub-Saharan Africa of HIV-infected persons. 
  
2.2 Latent tuberculosis treatment (LTBT)   
 
2.2.1 Tuberculosis intervention control  
The intervention, control and management of tuberculosis involves the 
treatment of confirmed tuberculosis by chemotherapy; the prevention of 
tuberculosis infection with primary chemoprophylaxis in infants exposed to 
infectious tuberculosis cases (with no history of TB disease is usually 
referred as primary prophylaxis); and secondary chemoprophylaxis (LTBT) 
for those individuals that are asymptomatic and may have been infected 
and are at a high risk for the development of active tuberculosis.  
 
Prophylaxis is any medical or public health intervention (before the 
condition occurs) used to prevent rather than treat or cure a disease or 
infection. Prophylactic measures are divided into those that prevent the 
development of the disease (reinfection of tuberculosis and thus prevent 
active tuberculosis) and secondly to prevent the active tuberculosis) when 
infection has already taken place (reactivation).  
 
Prior to the diagnosis of tuberculosis, the individual may have infected 
several persons in close contact.  In theory it is quite likely that the direct 
effect of HIV on the epidemiology of tuberculosis that involves reactivation 
of latent tuberculosis that was acquired prior to HIV infection. However to 
date no such data is available to suggests this important hypothesis that 
has distinguished the contribution of latent tuberculosis acquired prior to 












Hence recent LTBI, because of the likelihood of development of active 
tuberculosis, is regarded as one of the most important public health risk 
factors. The direct impact of HIV on the epidemiology of tuberculosis 
involves the reactivation of LTBI acquired prior to HIV infection or the 
progression to active disease of LTBI acquired after HIV infection 
(Sutherland I, 1990). The indirect impact is the increased risk of MTb 
infection and development of tuberculosis among those not infected with 
HIV (Sutherland I, 1990). 
 
Although IPT will play no major role to the control of global tuberculosis, its 
role is likely to vary depending on local epidemiology of tuberculosis and 
relative importance of reactivation of LTBI compared with progression of 
recent and new disease episodes. Hence in developing countries where 
tuberculosis is endemic with higher tuberculosis and HIV incidences, the 
tuberculosis re-infection risk is greater and contributes to increase in active 
tuberculosis. In such a setting IPT is limited in its effect but could prevent 
new infection or prevent the rapid progression of new infection to active 
tuberculosis or both. The study by Casado (Casado JL et al, 2002) 
suggests that re-infection may be the main cause of failure of INH after 
LTBT in adherent patients. Hence in developing countries where 
tuberculosis is endemic with higher tuberculosis and HIV incidence, the 
long term protection against active tuberculosis, the combination of LTBT 
and ART would be required. 
 
2.2.2 Tuberculosis case detection   
HIV associated tuberculosis is frequently difficult to diagnose because of 
the increased proportion of smear negative and extra-pulmonary disease. 
This is particularly true of patients with clinically advanced HIV disease 
(WHO clinical stages 3 & 4) who are at high risk of developing tuberculosis 
(Wood R et al, 2000). Thus there is a need to develop and validate simple 











patients (Wkly Epidemiol Rec 1999), which should be capable of detecting 
tuberculosis in patients with advanced HIV as they frequently have 
constitutional symptoms. 
 
A screening instrument for tuberculosis should have a high sensitivity and 
negative predictive value in order to avoid false negatives, if tuberculosis 
preventive therapy is to be initiated (WHO.Wkly Epidemiol Rec 1999). The 
WHO and the CDC recommend chest radiographs as part of the screening 
process to exclude tuberculosis prior to initiating preventive therapy in HIV 
infection (WHO.Wkly Epidemiol Rec 1999; CDC/MMR 2000). However, 
they have argued that chest radiographs should be limited to symptomatic 
patients and probably only those patients whose sputum is smear negative 
(Harries AD et al, 1997). WHO/UNAIDS recommends a chest radiograph 
to be taken accompanied by medical history and symptom screening for 
tuberculosis in asymptomatic people before LTBT. A recent study has 
established that that a chest radiograph for screening is not required 
(Mosimaneotsile B et al, 2003). However, this study has weakness in 
terms of not using the gold standard sputum culture) for tuberculosis 
diagnosis.  But according to Chintu and colleague (Chintu C & Mwaba P, 
2003), not only are chest radiographs expensive in poor resource settings 
but too few active tuberculosis cases are diagnosed by this method.  
 
Active case finding, BCG, environmental factors, as well as the detection 
and treatment of LTBI remain important components of the tuberculosis 
control strategy. Confirmation of TST is universally accepted as the 
standard method for detecting LTBI (WHO, 1963) using the Mantoux test. 
The TST has been acknowledged to have certain limitations because 
antigens present in PPD are also present in BCG and in non-tuberculous 
mycobacteria (NTM); resulting in false positives commonly occurring (Pai 
M et al, 2004). Mahomed and colleagues showed that among HIV-
negative adults, the overall percentage agreement and the kappa score of 











generations of QuantiFERONs were low (Mahomed H et al, 2006). 
Although Mantoux test is regarded as the gold standard to determine the 
LTBI the QuantiFERON method (blood test for detection of immune 
responses to tuberculosis infection as an alternative for TST), in place of 
the Mantoux rest needs to be reviewed in the context of individuals 
residing in tuberculosis endemic areas with high tuberculosis and HIV 
incidence who are highly immunocopromised my yield a false negative 
TST.  
 
Studies suggest that the prevalence of tuberculosis among the HIV-
infected sub-population may influence the association between tuberculin 
reactivity and the risk of tuberculosis (Watkins RE et al, 2000). However, in 
the HIV-infected individual this may not necessarily be the case. The 
immune response of these individuals has been compromised by HIV and 
hence they may be unable to mount a delayed response to the PPD used 
in the TST, possibly resulting in a false negative TST. With HIV infection, 
the TST will thus underestimate the prevalence of LTBI. 
 
The validity of TST is expressed as the sensitivity, specificity and the 
positive predictive value (PPV); which in turn depend on the pre-
determined cut-off value for a positive test result confirming the presence 
of LTBI (Menzies RI,2000). The TST cut-off values are influenced by the 
prevalence of LTBI among the population being tested for Mantoux.Berkel 
and colleagues concluded that using a 10 mm cut-off value for Mantoux 
when LTBI prevalence in the population tested was at least 10%, the PPV 
was more than 75%. With a lower prevalence, a cut-off value of 15 mm 
was proposed since this yielded a higher PPV with no effect on the 
negative predictive value (NPV) (Berkel GM et al, 2005). 
 
The CDC guidelines for screening for tuberculosis and tuberculosis 











induration on the Mantoux test as a positive TST for detecting LTBI (MMR, 
1995). High-risk populations with ≥ 5 mm TST reading are defined as 
(MMR, 1995): 
 Persons with recent close contact with person/s who have active 
tuberculosis;  
 Persons who have HIV infection, or risk factors for HIV infection but  
unknown HIV status; 
 Persons with fibrotic lesions on chest radiographs consistent with 
healed untreated tuberculosis. 
 
2.3 Tuberculosis prophylaxis  
 
2.3.1 Advantage of tuberculosis prophylactic treatment  
Tuberculosis chemotherapy has two effects. At the individual level, it 
reduces the risk of death from tuberculosis and restores one‟s health. 
Epidemiologically, it interferes with transmission, by reducing exposure 
time in the community and thus the incidence of infection with MTb. 
Prophylactic treatment is normally defined as the provision of treatment for 
a person exposed but not yet infected with the aim of reducing the risk of 
acquisition of infection. Prophylactic treatment thus also reduces the 
incidence of LTBI. However, LTBI does not meet this definition since 
individuals are already infected with MTb; prophylaxis here is aimed at 
preventing active tuberculosis. But in the settings with a high prevalence of 
advanced immunodeficiency with a negative tuberculin skin test, a period 
of isoniazid treatment could be either prophylaxis or treatment of 












2.3.2. INH preventive therapy (IPT) 
The WHO, in light of the growing tuberculosis epidemic exacerbated by 
HIV in some settings, has recommended LTBT (WHO/CDS/TB/2002.296) 
because it is efficacious (Bucher HC et al, 1999) and potentially cost 
effective (Bell JC, 1999).  One of the primary reasons for poor LTBT 
outcomes is poor adherence (Perriens J & O‟Brian R, 1995). However, 
studies have indicated that poor adherence can be overcome with LTBT 
supervision (Ngamvithayapong J et al, 1997; Aisu T et al, 1995; WHO 
Wkly Epidemiol Rec, 1999; Calvacante S et al 1999) similar to that of 
DOTS supervisor. 
 
Before tuberculosis prophylaxis is widely adopted in sub-Saharan Africa, 
several questions need to be addressed regarding adherence, long term 
efficacy, adverse effects, resistance, and the danger of treating undetected 
active tuberculosis with monotherapy. One concern (Quigley MA et al, 
2001) is that with IPT, tuberculosis in HIV-infected individuals is delayed, 
rather than prevented especially in settings of high TB prevalence where 
reinfection makes a major contribution to active disease, and course of IPT 
of limited duration could be effective in LTBI.  Furthermore IPT could 
prevent new infection or prevent new infection progressing rapidly to 
disease or both. However, it would be expected not to provide long term 
protection in the absence of ART.  
 
The study by showed that a 2-month daily course of rifampin and 
pyrazinamide is similar in safety and efficacy to 12-month daily isoniazid to 
prevent tuberculosis in TST positive HIV-infected individuals. Despite 
toxicity being low in both treatment groups, the discontinuation was slightly 
higher in the rifampin and pyrazinamide (Gordin, F et al, 2000). However a 
multicentre trial for LTBT (Jasmer, RM et al, 2002), showed that a 2-month 
regimen of rifampin and pyrazinamide was associated with increased risk 











Although IPT is effective, the limitations can be overcome to achieve 
optimum benefit that would outweigh the risks. The concern of 9 – 12 
months IPT regarding poor adherence (CDC, 1995), can be overcome by 
assigning latent tuberculosis treatment supervisors (Heal, G, 1998). The 
second concern to IPT is isoniazid related hepatitis that could result in 
occasional fatality (Snider DR Jr & Caras GJ, 1992). This can be 
overcome by liver function test prior to initiating IPT and ongoing 
monitoring of the patient. The third concern is associated with increased 
occurrence of peripheral neuropathy in HIV-infected individuals (Bass, JB 
et al, 1994). This can be overcome by supplementing vitamin B12 with 
IPT. Finally it is believed that effectiveness of INH may decrease as INH 
resistant of Mycobacterium tuberculosis increase (Moore, M et al, 1997). 
 
Current recommendations for the duration of LTBT in HIV-infected individuals 
vary. A recent review (Padmapriyadarsini C & Swaminatrhan S, 2005) 
highlights the various duration for preventive therapy ranging from 6-12 
months of INH daily to short term (2 or 3 months) regimens. To date the 
efficacy of long-term (>12 months) regimens is currently being investigated. 
However, WHO continues to recommend self-administered INH for six 
months. The CDC recommended the administration of INH for nine months.  
Rifampicin and Pyrazinamide may be offered daily for two months to contacts 
of patients with INH resistance. The American Thoracic Society recommends 
INH for 9 months.  
 
Comstock concludes in his review article (Comstock GW, 1999) that: 
 6 months of preventive treatment does not give optimal protection and 
should not be considered the standard against which to judge the efficacy 
of short-course combined drug regimens. 
 More than 12 months of preventive therapy has not been shown to give 
added protection against tuberculosis. 
 The optimal protection from isoniazid appears to be obtained by 9 or 10 











Furthermore, the US Public Health Service trial suggests that among 
tuberculosis contacts that total duration of therapy is more important than its 
continuity (Ferebee SH, 1970) 
 
Meta-analyses (Woldehanna S et al, 2004; Buchner HC et al, 1999) on 
LTBT in HIV-infected adults have shown a significant reduction in the 
incidence of tuberculosis in participants with a positive TST, but not with a 
negative TST. However, participants with advanced HIV disease were 
under-represented in the placebo-controlled clinical trials. Two enrolled 
only asymptomatic participants (Pape JW et al, 1993; Fitzgerald DW et al, 
2001) and no AIDS cases were enrolled in three trials (Hawken MP et al, 
1997; Whalen CC et al, 1997, Mwinga A et al, 1998). Only two trials 
enrolled participants with AIDS, comprising 15% (Rivero A et al, 2003) and 
23% of their participants (Gordin, FM. et al, 1997). Both these two trial 
were conducted in developed countries.  CD4+ lymphocyte counts were 
recorded in only three studies, with the medians ranging from 230 to 334 
cells/ L (Rivero A et al, 2003; Gordin FM et al, 1997; Hawken MP et al, 
1997). 
 
The case for INH prophylaxis to prevent active tuberculosis among those 
with LTBI remains strong in comparison with other drugs used as a 
preventive therapy. A study of 135 HIV-positive individuals with LTBI that 
were administered Rifampicin/Pyrazinamine for 2 months were compared 
to historical controls of INH treatment for LTBI.  Although the completion 
rate of 92% was better in the Rifampicin/Pyrazinamine group as compared 
to 61% in the historical INH group, 5 individuals were reported to have 
stopped preventive therapy in the Rifampicin/ Pyrazinamine group due to 
severe side effects (Narita M et al, 2002). 
 
INH as a drug of choice for LTBT has been established in other studies. 











of LTBI in HIV-infected people with TST positive for PPD, those in the INH 
group had 1% risk of developing tuberculosis as compared to the 3.7% 
risk of developing tuberculosis in the Rifampicin and Pyrazinamide group 
after 10 months on entry to the study (Halesy NA et al, 1993).  
 
However, the overall follow-up after four years of this study established 
that there was no statistical significant difference between these groups 
regarding the incidence of active tuberculosis. A multicenter clinical trial 
conducted to compare the safety and tolerance of the two month regimen 
of Rifampicin and Pyrazinamide with that of INH for LTBT, found a 
significant association with an increased risk of grade 3 and 4 
hepatotoxicity with the two regimen drug as compared with 6 month INH 
(OR 8.46; 95% CI: 1.9 - 76.5; p = 0.033) (Jasmer RM, 2002). Since there 
appears to be no difference in efficacy between INH and the other 
regimens for preventive therapy for LTBI, INH would be the choice for 
LTBI because the risk of adverse effects is less as compared to other 
regimens.    
 
2.4 Tuberculosis prophylaxis trials 
 
2.4.1 Tuberculosis prophylaxis prior to HIV era 
Early tuberculosis prophylaxis trials prior to the HIV era, to establish the 
efficacy of preventive therapy with INH in reducing tuberculosis, had 
yielded definitive results. Four controlled clinical trials investigated the 
efficacy of preventive therapy (Ferebee SH et al, 1963; Mount FW et al, 
1962; Comstock GW et al, 1962; Horwitz O et al, 1966) with INH in 
reducing the risk of tuberculosis among persons with presumed long-












The number of cases emerging during the treatment year was small with 
wide 95% confidence intervals.  Only the study of villagers in Greenland 
(Horwitz O, 1966) demonstrated more than 60 % protection while the other 
three trials showed less than 40% protection from tuberculosis (Comstock 
GW et al, 1962; Mount FW et al, 1962; Ferebee SH et al, 1963). However, 
the study in Greenland was of a community wide design and not 
individually targeted IPT. Hence this might be expected to have much 
greater effect than individually targeted approach because the potential to 
interrupt TB transmission rather than simply prevent reactivation of 
reinfection within the individual. 
 
Studies of contacts of newly identified LTBI cases that were most likely 
infected in the recent past determined that the risk of tuberculosis was 
considerably higher than that of tuberculin reactors of unknown or long 
duration (Veening GJJ, 1968; Egsmose TL et al, 1965; Ferebee SH & 
Mount FW, 1962; Bush OB et al, 1965). 
 
In the Netherlands Navy, a case among recruits occurred and infected a 
large number of other recruits (Veening GJJ, 1968). This setting was used 
to test the efficacy of IPT compared to placebo. The Netherlands study 
yielded a 92 % protective efficacy, which provided the highest attainable 
efficacy as compared to 85% in a Kenyan study (Egsmose TL et al, 1965) 
and 75% in the USA (Ferebee SH & Mount FW, 1962 and 25% in Japan 
(Bush OB et al, 1965). However, the study in Japan did not yield 
statistically significant protection among the contacts. The contacts of 
newly identified tuberculosis cases who are tested TST positive are likely 
to have been infected in the recent past.  
 
The risk of development of tuberculosis in this group is considerably higher 
than those with a positive TST of unknown or long duration (Comstock 











OB et al, 1965). The Cochrane review (Woldehanna, S & Volmink, J. 
2004) of IPT in non-HIV-infected persons (2005), which included results 
based on 73,375 participants from 11 trials showed that TB incidence was 
reduced to 60% and deaths by 71%. 
 
2.4.2 Tuberculosis prophylaxis trials in HIV-positive individuals 
Whilst it is important to aim for early tuberculosis diagnosis in HIV-infected 
individuals, another strategy is to minimize the negative impact of 
tuberculosis on HIV disease progression with the use of prophylactic 
treatment.  
 
To date, several trials have been conducted to determine the efficacy of 
LTBT in HIV-positive individuals. The three meta-analyses of such trials 
that have been undertaken are shown in Table 1. All three (Wilkinson D, 
Squire SB & Gamer P, 1998; Bucher HC et al, 1999; Woldehanna S & 
Volmink J, 2004) showed a statistically significant reduction in tuberculosis 
i.e. 43%, 42% and 36% respectively. 
 
The Cochrane Systematic Review (Woldehanna S et al, 2004) of 
treatment of LTBI in HIV-infected persons included 11 randomised placebo 
controlled trials and found a statistically significant protective effect against 
active tuberculosis (RR 0.64; 95% CI: 0.51 - 0.81).  
 
However, this protective effect was more pronounced among TST positive 
patients. Furthermore, studies have shown that with preventive therapy 
there was a non-significant reduction in all-cause mortality with a more 
favourable trend in survival among TST positive patients (Woldehanna S 













Table 1: Efficacy of IPT:  Results from three meta-analyses* 
 
Author Country Relative risk (RR) or odds ratio (OR) for 
LTBT as compared to no LTBT (95% CI) 
  TST positive TST 
negative 
Total 
Wilkinson et al 
(1998) 
Haiti,  Kenya, 
Uganda, US 
OR = 0.32  
(0.19 to 0.51) 
 OR = 0.82 
(0.50 to 1.36) 
OR = 0.57 
(0.41 to 
0.79) 
Bucher et al 
(1999) 
Haiti, Mexico,  
Zambia, US,  
Uganda, Kenya 
RR = 0.41 
(0.24 to 0.71) 
 
RR = 0.94 
(0.52 to 1.38) 
 










RR = 0.38 
(0.25 to 0.57) 
RR = 0.83 
(0.58 to 1.18) 




An observational study (Churchyard GJ et al, 2003) among South African 
HIV positive mineworkers observed the incidence of recurrent tuberculosis 
between two cohorts in which one cohort received LTBT and the other did 
not. This study reported that treatment with INH reduced the number of 
active tuberculosis cases by half (Churchyard GJ et al, 2003). The 
protective effect appeared to be greatest in men with lower CD4+ 
lymphocyte counts.  Where the CD4+ lymphocyte count was below 200 
cells/ L, treating five people could prevent one active tuberculosis case as 
compared to treating 17 people to prevent one active tuberculosis case 
among the men with CD4+ lymphocyte counts above 200 cells/ L 
(Churchyard GJ et al, 2003). However, goldmines have extremely high 
incidence of tuberculosis and hence cannot be generalized to other 
settings.  
 
Casado (Casado JL et al, 2002) studied the risk factors for the failure of IPT 











months. It was shown that persistence of predisposing factors for exposure to 
tuberculosis infection, such as drug addiction or new prison admissions, was 
the main risk factor for infection (relative hazard, 3.17; 95% CI: 1.56 - 17, p < 
0,001). This study suggests that re-infection may be the main cause of failure 
of INH after LTBT in adherent patients. Hence in developing countries where 
tuberculosis is endemic with higher tuberculosis and HIV incidence, the 
tuberculosis re-infection risk is greater and contributes to increase in active 
tuberculosis. In such a setting LTBT is limited in its effect but could prevent 
new infection or prevent the rapid progression of new infection to active 
tuberculosis or both. Hence in such a setting to ensure the long term 
protection against active tuberculosis, the combination of LTBT and ART 
would be required. 
 
As shown in Table 1, IPT has been demonstrated in several RCTs to 
reduce the risk of active tuberculosis in HIV infected patients, especially 
among those TST positive. Early INH prophylaxis studies among HIV-
infected adults thus indicate that INH is more effective in patients who are 
TST positive (Wilkinson D, 1999; Pape JW et al, 1993; Whalen C et al, 
1997). Further studies conducted showed consistent benefit of preventive 
therapy, especially among TST positive patients (Halsey NA et al, 1998; 
Mwinga A et al, 1998; Quigley MA et al, 2001; Martinez PA et al, 2000).   
 
In the Cochrane Systematic Review (Woldehanna S & Volmink J, 2004) 
of 13 trials (for HIV-infected individuals), preventive therapy (by any anti-
tuberculosis drug), reduced the risk of tuberculosis by 36% (RR 0.64; 
95% CI: 0.51 - 0.81) when compared with the placebo. When only INH 
was considered (in the seven of these 13 trials) and compared to the 
placebo, the tuberculosis risk reduction was 33% (RR 0.67; 95% CI: 0.51 
- 0.87) with limited data suggesting that that the initial protective effect 












The benefit of INH prophylaxis is short-lived. It has been demonstrated 
that subsequent to six months preventive therapy the benefit declined after 
the first year and after 18 months the rates of tuberculosis in the treated 
and placebo arms were similar (Quigley MA et al, 2001). A recent study 
indicated that the duration of effect of INH is dependent upon the duration 
of the therapy. Treatment with INH for six months was effective for a 
median of 8 months, treatment for 12 -24 months was effective for 22 
months; and for those receiving 24-36 months of IPT, duration of effect 
was 40 months. The results of this study were statistically significant 
(Fitgerald DW et al, 2000).  
 
The first IPT trial in HIV-infected patients (Pape JW et al, 1993) showed 
the efficacy of 1-year IPT in symptom free HIV positive patients with a  
protective effect (RR 0.62; 95% CI: 0.39 - 0.97) with a median follow-up of 
1.8 years for both TST positive and negative participants. Quigley (Quigley 
et al, 1998) reported diminishing protective effect of INH over time. In the 
study by Quigley (Quigley et al, 1998), it was reported that the cumulative 
risk of tuberculosis in the first 2.5 years was lower in the INH group (RR 
0.52; 95% CI: 0.27 -1.00, p = 0.046) than in the placebo. A significantly 
lower risk of active tuberculosis after a mean of 15 months of IPT was 
demonstrated in participants with TST positive status, (RR 0.29; 95% CI: 
0.12 - 0.67) (Whalen et al, 1997). It was noted in this study that the long 
term benefit remained statistically significant for the Rifampicin regimen 
but not for INH. 
 
Of the of 13 preventive therapy trials (Woldehanna S & Volmink J, 2004), 
only seven were INH placebo trials (Hawken MP et al, 1997; Mwinga A et 
al, 1998; Pape JW et al, 1993; Whalen C et al, 1997; Fitzgerald DW et al, 
2001; Gordin, FM et al 1997; Rivero A et al, 2003), with only three trials 
having included only TST negative individuals (Fitzgerald DW et al, 2001; 
Gordin, FM et al,1997; Rivero A et al, 2003). Two trials included only 











Whereas in the Whalen trial (Whalen C et al, 1997), which excluded 
advanced HIV diseased patients where the negative TST anergic patients 
were randomly assigned to INH or placebo (RR 0.86; 95% CI: 0.59 – 1.26) 
which compared the efficacy of different anti-tuberculosis drugs (i.e. INH 
and Rifampin or INH, Rifampin and Pyrazinamide or INH or Placebo).   
However all the participants in the Gordin and Rivero trials (Gordin, FM. et 
al, 1997; Rivero A et al, 2003) were symptomatic, anergic and TST 
negative with RR 0.48 (95% CI: 0.12 - 1.91) and RR 0.66 (0.19 – 2.31) 
respectively.  
 
Whilst the Gordin trial (Gordin, FM. et al, 1997) involved INH and placebo 
only, the Rivero study (Rivero A et al, 2003) evaluated the risk of 
developing tuberculosis with any of anti-tuberculosis regimens. The 
relative risk of INH treatment with the various regimens versus no 
treatment was for 6INH vs. 3HR 1.09 (95% CI: 0.22 - 5.41); 6INH vs. 2RZ 
2.76 (95% CI: 0.29 - 0.26); 6INH vs. no treatment group (NT) 1.07 (95% 
CI: 0.24 - 4.80); 3HR vs. 2RZ 2.53 (95% CI: 0.26 – 0.24); 3RZ vs. NT 0.98 
(95% CI: 0.22 – 4.4) and 2RZ vs. NT 0.39 (0.04 -3.48).  
 
The wide 95% CI confirms that the sample size was too small to make any 
definite conclusions about efficacy of LTBT of anergic HIV-infected 
patients, especially the 6INH vs. NT (placebo).  
 
Furthermore, no distinction was made among patients on the trial 
regarding their WHO Clinical stage of HIV infection of the participants. 
More importantly the Rivero trial (Rivero A et al, 2003) was conducted in 
Spain in a low tuberculosis incidence setting and the results cannot be 












The Gordin trial involving anergic HIV-infected persons who were at a high 
risk for development of tuberculosis (Gordin, FM et al, 1997) concluded 
that INH was not efficacious. This trial included children aged 13 years and 
older with a study population consisting of 33% females was conducted in 
the US making it difficult to infer conclusions to developing countries. The 
diagnosis of primary tuberculosis in children in this trial required a different 
diagnostic protocol to that of pulmonary tuberculosis in adults making the 
study difficult to infer to adults. The diagnosis in children is not only 
difficult, but imprecise (Schaaf HS et al, 1995).  
 
Hence, it is very likely that some of the primary tuberculosis cases in this 
trial could have been missed despite the paediatric definition was used 
consistently in both arms of the Gordin trial. Therefore while 
misclassification may not have occurred, there is no reason to suspect that 
this occurred in a differential fashion between the two randomized arms. 
Finally, not but most cases of active TB in this trial were culture positive.    
 
The Gordon‟s trial (Gordin, FM et al, 1997) showed that the placebo group 
had a higher proportion of people who had been unemployed for year or 
more and also included a higher proportion of people who had lived with a 
person with active tuberculosis for one year or more at the time of 
enrolment for Gordin‟s study. This possible bias and the fact that this study 
was conducted in a low tuberculosis incidence setting render the 
conclusion of the Gordin‟s study debatable.  
 
The Whalen trial (Whalen C et al, 1997), fails to answer whether INH 
preventative therapy would benefit HIV-infected adults with clinically 
advanced disease (WHO Clinical stage 3 or 4) who were TST negative, 












2.4.3 Tuberculosis prophylaxis trials in TST negative HIV-positive 
adults  
People infected with MTb and have a positive TST have greater risk of 
developing active tuberculosis as compared to those people not infected 
with MTb (Watkins RE, Brennan R & Plant RJ, 2000). However, the 
proportion of TST negative individuals with LTBI is higher in HIV positive 
individuals than those who are not infected with HIV (Daniel T, Boom WH 
& Ellner JJ (2000). Thus the treatment of LTBI has been shown ineffective 
(RR 0.83, 95% CI 0.58 to 1.18.) in TST negative participants in the seven 
trials conducted to date (Woldehanna S & Volmink J, 2004, Bucher HC et 
al, 1999). Table 2 summarizes the outcome of these seven trials.  
 
The possible reasons for this lack of efficacy of INH in the treatment of 
LTBI in TST negative participants in previous trials has already been 
covered (please refer the section 1.4 of the Introduction chapter. But 
importantly the two (Gordin, FM. et al, 1997; Rivero A et al, 2003) which 
included symptomatic, anergic and TST negative participants made no 
distinction of participants on the trial regarding their WHO Clinical stage of 
HIV infection and cannot be generalised to developing countries where 
tuberculosis is endemic.  
 
Only two trials enrolled patients with AIDS (Table 2), comprising 15% 
(Rivero A et al, 2003) and 23% of their participants (Gordin, FM. et al, 
1997). CD4+ lymphocyte counts were recorded in three studies: medians 
ranged from 230 to 334 cells/ L (Rivero A et al, 2003; Gordin FM et al, 
1997; Hawken MP et al, 1997). Thus the IPT efficacy of HIV-infected WHO 
Clinical stage 3 or 4 with TST negative patients have to date as yet not 



















HIV Symptoms AIDS 
 
RR of TB  
(95% CI) 
Pape JW et 
al,1993 
ND Asymptomatic 0% 0.70 (0.15, 
3.28) 
Hawken MP et 
al,1997 
334 8.5% Thrush 0% 1.31 (0.54, 
3.20) 
Whalen C et 
al,1997 
ND 28% Thrush/Zoster 0% 0.86 (0.59, 
1.26) 
Mwinga A et 
al,1998 
ND 3.7% Thrush 0% 0.77 (0.39, 
1.51) 
Gordin D et al, 
1997 
ND Symptomatic 23% 0.66 (0.19, 
2.31) 
Fitzgerald DW et 
al,2001 
ND Asymptomatic 0% 1.32 (0.38, 
4.56) 
Rivero A et al, 
2003 
230 Symptomatic 15%  0.74 (0.30, 
1.79) 
ND = Not displayed 
 
Besides the small proportion of AIDS participants WHO Clinical stage 3 or 
4 with TST negative patients in the Rivero and Gordin trials (Rivero A et al, 
2003; Gordin, FM. et al, 1997), these two trials conducted in developed 
countries, cannot be generalised for developing countries, especially 













2.5 Adherence and adverse effects of INH  
 
2.5.1 Adherence  
This section deals with adherence of INH prophylaxis and studies 
highlighting improved adherence among symptomatic tuberculosis patients 
and the complications that could result from non-adherence. But more 
importantly in order to reduce the risk of resistance from IPT it is more 
important to exclude active TB prior to starting IPT. The need to monitor 
adherence and adverse effects and toxicity of INH is of paramount 
importance. However this needs to be balanced whilst still focusing on the 
need to ensure that the benefit of IPT outweighs the risk of adverse effects 
in patients. 
 
In the case of symptomatic HIV-infected patients, tuberculosis treatment 
adherence may be better than asymptom tic HIV-infected patients, A Thai 
study (Ngamvuthayapong J et al, 1997) confirmed that adherence with 
INH prophylaxis was better in symptomatic patients.  A Kenyan study 
reported poor adherence in those patients who were only mildly 
immunosuppressed (Hawken MP et al, 1997).  
 
Regarding supervised therapy of tuberculosis patients, the estimated 
lifetime mortality rates (including deaths from relapses and subsequent 
complications) of HIV negative individuals with smear positive tuberculosis 
were estimated to be 5% to 15% among those treated by DOTS, as 
compared to 10% to 30% in those individuals that were not treated with 
DOTS (Dye C et al, 1999; Mallory KM et al, 2000).  
 
Non-adherence to tuberculosis treatment is one of the major factors in the 
development of relapse (Weis S et al, 1994; Havlir DV & Barnes PF, 











treatment as outpatients had high rates of non-adherence (Rocha M et al, 
2003). Those that were non-adherent had an OR (for no tuberculosis cure) 
of 29.2 (95% CI: 2.43 - 350.1). Non-adherence was the strongest 
determinant associated with no tuberculosis cure or death (Rocha M et al, 
2003). 
 
Because of prolonged administration of LTBT, the risk of adverse effects 
(especially to the liver) is of great concern. Although poor adherence could 
theoretically lead to INH resistant tuberculosis, there is no data to support 
this statement. However, it is more important to exclude active 
undiagnosed tuberculosis prior to starting IPT monotherapy, which may 
generate INH-resistant MTb. Unsupervised INH preventive chemotherapy 
for six months in two suburbs in Cape Town, South Africa reported poor 
adherence (Marais BJ et al, 2003).  These studies highlight the strategies 
needed to enhance adherence by shortening the duration of IPT and/or 
supervision of IPT. Intensification and improved treatment literacy for 
those patients that have been selected to be on IPT could be another way 
to promote and enhance adherence to IPT. 
 
A study conducted in Thailand, reported that TST status was not a 
predictor for adherence to LTBT once therapy commenced (Hiransuthikul 
N, 2005). However, a higher drop-out rate was associated for LTBT prior 
to commencement of therapy in this study. When this group was 
compared to the control group that was administered LTBT without 
conducting a TST, the adherence to LTBT was estimated to be 84.5% and 
79.7% respectively, but with no significant difference in adherence 
between the two groups. Furthermore, this study also reported a good 
correlation between adherence measured by pill counts and self-report.   
 
Of the INH and placebo controlled trials of TST negative patients,  Pape 











patients on the daily self administration of INH and B6 as compared to B6 
(placebo). These patients and adherence were clinically assessed at 
intervals of three months for 12 months (Pape JW et al, 1993).  
 
The study by Hawken (Hawken MP et al, 1997). of daily self administration 
(SAT) of INH for six months based on three adherence measures (pill 
count, patient report of defaulting and urine analysis) showed good 
agreement between the three categories of adherence i.e. adherent, mildly 
non-adherent, moderately non-adherent groups (Hawken MP et al, 1997). 
However, this study should be viewed with caution since in the INH group 
only 145 (45%) patients had tested positive for presence of INH, and no 
analysis of the incidence of tuberculosis among those who were poorly or 
non-adherent was performed. In another study (Whalen CC et al, 1997), 
INH was self-administered for six months and evaluated monthly for 
adherence. Adherence was compared by four different methods: by 
monthly scheduled visits, self reports, urine tests for INH as well as 
random INH urine tests of unscheduled visits of patients on INH. Of the 
1754 (90%) patients tested, 75% tested positive for INH and of the 97 
randomly tested for INH, 78 (80%) tested positive for INH, with higher 
proportion on scheduled monthly urine tests as compared to unscheduled 
tests (82% versus 46%, p < 0.001) (Whalen CC et al, 1997).   
 
The Gordin study (Gordin, FM et al, 1997) which also involved self 
administration of INH or placebo and where each group also received B6 
on a daily basis for six months, makes no mention of adherence.  Another 
RCT with twice weekly intermittent self administration of INH for 12 months 
used pill count as a means of measuring adherence (Pape JW et al, 
1993); 777 (74%) were adherent, 718 (92%) were probably adherent and 












A further RCT compared three regimens with the no treatment group 
(Rivero A et al, 2003), where INH self administered daily for six months, 
was one of the regimens.  Patients were evaluated every 15 days for two 
months and thereafter on a monthly basis. Although adherence was 
assessed by the doctor in a patient oral interview, report of adherence 
data in this study was not given (Rivero A et al, 2003). The Fitzgerald et al 
study (Fitzgerald DW et al, 2001), which  involved the self administration of 
INH on a daily basis for 12 months with monthly visits and thereafter at 
three monthly visits, also makes no mention of measurement of 
adherence.  
 
2.5.2 Adverse effects and toxicity of INH 
As INH has been shown to have minimal risk of adverse effects, the 
benefit of INH in LTBT far outweighs the risk of minimal adverse effects as 
can been noted from the following studies. In a meta-analysis (Ena J & 
Vallis V, 2005) a shorter course of preventive therapy was compared as an 
alternative to the standard INH therapy and found that both regimens were 
equally effective where low tuberculosis transmission setting could likely 
influence the effect of dura ion of IPT. The short course therapy with two 
drugs was equivalent to standard INH with regards to efficacy (pooled risk 
difference 0%; 95% CI: -1% - 2%); severe side effects (pooled risk 
difference -1%; 95% CI: -7% to 5%) and mortality (pooled risk difference -
1%; 95% CI: -4% - 2%). 
 
A study by Mitchison (Mitchison DA, 1985) graded six anti-TB drugs 
(Pyrazinamide, Thioacetazone, Ethambutol, Streptomycin, Rifampicin and 
Isoniazid) based on three properties. These included the ability to prevent 
drug resistance, the killing ability of the drug in early bactericidal activity 
and the drug sterilizing activity. This study ranked Isoniazid the highest in 
its ability to prevent INH resistance (when active undiagnosed TB was 











activity in comparison to Rifampicin, Ethambutol, Streptomycin, 
Pyrazinamide and Thioacetazone (in the pre ART era). As for the drugs 
sterilizing activity, Isoniazid was ranked third, with Pyrazinamide ranked 
second and Rifampicin ranked as first.  This indicates that, isoniazid is 
highly effective at preventing the emergence of resistance to other drugs in 
a multi drug regimen such preventing the emergence of rifampicin 
resistance. Also data from a very early trial of isoniazid monotherapy for 
active tuberculosis suggested that higher doses of isoniazid modestly 
decreased the rate of emergence of isoniazid resistant strains. However, 
this rationale may not be applicable to IPT.  
 
Concern has been raised regarding the adverse effects of INH.A seven 
year survey from a Public Health Tuberculosis Clinic where INH was used 
for LTBT determined that the rate of INH hepatoxicity was lower than 
previously reported (Nolan C et al, 1999). An earlier study had 
demonstrated that the risk of hepatitis resulting from the administration of 
INH in the first two to three months was the greatest (Riska N, 1976). A 
recent study has demonstrated that INH was tolerated by all in the study 
and that hepatotoxicity was not a major problem among patients that were 
administered INH (Agarwal SK, 2005; Sadaphal P, 2001; Wilkinson D, 
2000). When one considers the benefit outweighing the risk of adverse 
effects in patients in terms of tuberculosis preventive therapy, the drug of 
choice would be INH.  
 
In the seven INH placebo RCTs of HIV-infected patients (Pape JW et al, 
1993; Hawken MP et al, 1997; Whalen C et al, 1997; Gordin, FM et al, 
1997; Mwinga A et al, 1998; Fitzgerald DW et al, 2001; Rivero A et al, 
2003), adverse effects were minimal (RR 1.66; 95% CI: 1.09 – 2.51).  
 
The Rivero and Whalen studies (Rivero A et al, 2003; Whalen C et al, 1997), 











statistically significantly higher adverse events which led to stopping 
treatment of trial the participants. The relative risk of adverse effects in the 
PPD positive and negative groups were RR 12.07; 95% CI: 0.69 – 210.76 
(Rivero A et al, 2003) and RR 2.60; 95% CI: 0.27 – 24.88 respectively. The 
RR for anergic group in the Whalen study was no estimable (Whalen C et al, 
1997). Pape (Pape JW et al, 1993) had no participants withdrawn as a result 
of adverse effects or laboratory reported abnormalities. No statistically 
significant adverse effects were observed in the Hawken trial (Hawken MP et 
al, 1997) where the adverse effects was compared to the placebo with RR 
2.20 (95% CI: 0.77 - 6.26),  with a few cases of mild reversible hepatitis were 
reported and no reported cases of clinical hepatitis.  
 
However, of the 1631 participants evaluated during routine tests, seven 
clinical hepatitis cases were reported in the Whalen trial (Whalen C et al, 
1997). Six of these cases were anergic TST positive (5 received INH, R 
and Z). Only one TST positive case received only INH. The cumulative 
incidence of reported adverse events for placebo of 22 (6.8%) and INH of 
31 (7.8%). In this same study, 43 patients had to discontinue treatment 
with the number of adverse events reported in the TST positive treatment 
group greater than that in the placebo group and greatest in the group 
receiving Pyrazinamide.  
 
In the Gordin study (Gordin FM et al, 1997), there was no difference 
between the 29 (11.2%) and 30 (11.7%) reportable adverse events in the 
INH and the placebo groups. Nine percent in each group of this study, 
discontinued treatment due to adverse effects of INH,  where more than 
50% of these patients discontinued during the first two months. A total of 
29 (3%) participants were withdrawn from the Mwinga study (Mwinga A et 
al, 1998) because of adverse reactions. Four of these 29 patients were 
withdrawn because of raised liver enzymes (of which three received INH 
and one Pyrazinamide); seven with rash (of which one received INH and 











received placebo, five INH and five Pyrazinamide); and seven with various 
other complaints (of which two received placebo, three INH and two 
Pyrazinamide).  
 
In the Rivero trial (Rivero A et al, 2003), 34 patients experienced side 
effects that led to their withdrawal from the trial. However there were no 
significant differences between the treatment groups. Of the nine patients 
with hepatoxicity, only one was removed from the 6-month INH treatment 
group, as a result of symptomatic hepatitis.  The remaining eight patients 
were removed as a result of asymptomatic hepatitis (four of these 
participants wee treated with the Rifampicin and Pyrazinamide regimen) 
that showed an increase in transaminases that were 3-fold higher than 
basal value in the absence of symptomatic hepatitis. 
 
The Fitzgerald study (Fitzgerald DW et al, 2001) made no mention of 
adverse effects due to treatment. As with any drug, there is a therapeutic 
margin constituted by the difference between the minimum drug 
concentration for inhibition of MTb and the maximum concentration that 
can be administered without inducing adverse effects (drug toxicity). This 
therapeutic margin varies for different anti-tuberculosis drugs (Peloquin CA 
et al, 1999; Acocella G, 1978; Pahlka R et al, 1999; Davidson PT et al, 
1986; Grosset J et al, 1970; Zierskie M, 1981).  
 
Some studies have shown that difficulties with IPT include poor adherence 
(O‟Brian RJ & Perriens JH, 1995), hepatoxicity (Byrd RB et al, 1979) and 
the development of isoniazid resistant bacteria (Pablo-Mendez A & 
Ravigione MC & Laszlo A, 1998).  
 
However, the results of the meta-analysis (Ena J & Vallis V, 2005), one 











Rifampicin) is equivalent to standard INH had no difference in terms of 
efficacy, proportion, with severe side effects and mortality. Furthermore, 
the adverse effects to INH are minimal and that hepatotoxicity is not 
considered a major problem among patients that were administered INH 
and monitored regularly.   
 
Thus based on this study (Ena J & Vallis V, 2005), and previous studies 
(Martinez, PA et al, 2000; Whalen CC et al, 1997) both in RCT and IPT 
programmes, one can conclude that use of INH prophylaxis outweighs the 
risk to the patient when administered correctly with regular monitoring both 
in terms of clinical and/or biomedical monitoring. However, one should 
note that the risk to the individual could vary substantially depending on 
age and risk of liver disease and that the potential benefits similarly will 
vary depending on the estimated risk of developing tuberculosis. 
 
IPT is regarded safe with minimal intervention cost that has the potential to 
reduce morbidity and mortality resulting from development of tuberculosis 
especially in HIV-infected individuals (Baicells ME et al, 2006). The main 
cause for INH resistance is because of inadequate diagnosis and 
treatment of active tuberculosis prior to initiating IPT. Hence the risk for 
any small increase of INH resistance attributable to IPT should be weighed 
against the benefit of reducing tuberculosis among the given population in 
their respective settings. Twice weekly dose of INH (intermittent) may be 
substituted for daily does of INH, provided a nurse or health care worker or 
latent treatment supervisor observes and record the ingestion of the 












2.6 Patient supervision 
 
2.6.1 DOTS as part of the global plan to stop tuberculosis 
The number of tuberculosis cases and deaths that will occur in the future 
will depend on how well and how quickly the WHO recommended 
tuberculosis control strategy is implemented. WHO predicts that in the 
period between 1997 and 2020, 39 million infections and 17 million deaths 
can be prevented in Southeast Asia, sub-Saharan Africa and the Western 
Pacific. This staggering number of cases and deaths could be prevented 
only if it is feasible to achieve complete implementation of the DOTS 
strategy by the year 2010.  Enormous efforts thus lie ahead for the world 
community to improve the epidemiologic situation of tuberculosis and to 
alleviate human suffering and prevent unnecessary deaths.  
 
The Global Plan to Stop TB for 2001-2005 has been extended to continue 
from 2006-2015 and is to incorporate three key events: (Editorial: Int J 
Tuberc. Lung Dis, 2006): 
 Incorporation of tuberculosis control among the top public health 
priorities within UN Millennium Development Goals (MDGs) 
 The decision by WHO to enhance the DOTS strategy and launch 
the new Stop TB Strategy, built around DOTS but going beyond it 
 The decision in May 2005 by the 58th World Health Assembly 
(WHA) to foster sustainable financing for tuberculosis control    
 
It is not surprising to note that that one of these three key events includes 
the enhancement of DOTS, thus emphasizing the vital importance of this 
essential component of the tuberculosis control, prevention and 












2.6.2 Directly observed treatment short course chemotherapy 
DOTS was introduced by WHO in 1997/8 as a Tuberculosis Control 
strategy with implementation in all 22 high tuberculosis burden countries 
identified (WHO, 1998).  By 2002, the DOTS Strategy had been 
implemented in 25 more countries, resulting in 69% of the world‟s 
population covered by DOTS.  Of the 3 million tuberculosis cases treated 
by DOTS globally, 1.4 million were confirmed to be smear positive cases. 
This was in contrast to the total of 13.3 million tuberculosis cases 
(including 6.8 million smear positive cases) treated by DOTS during 1995-
2002 (WHO Global TB RPT, 2004). 
The global treatment success rate of DOTS in 2000 and 2001 was 
reported to be 82%.  In 2002 there were 98% tuberculosis cases covered 
by DOTS in South Africa, compared to 43% in 1999.  However, the 
treatment success rate by DOTS strategy in 2001 was only 58% as 
compared to 39% under the non-DOTS strategy in the same year. The six 
most important constraints for not being able to reach targets for case 
detection and cure in South Africa are (WHO Global TB RPT, 2004): 
 Poor laboratory infrastructure  
 Human Resources 
 HIV/AIDS 
 Political Commitment 
 Monitoring 
 Decentralization of Health Services 
 
2.6.3 Treatment supervisors for DOTS versus LTBT  
Whilst the DOTS supervisor supervises the administration of tuberculosis 
medication to individuals on tuberculosis treatment, to enhance good 
adherence, the LTBT supervisor supervises the administration of 











The introduction of effective LTBT treatment supervisors in the control of 
tuberculosis in South Africa could at the very least mitigate the negative 
impact of the six constraints (i.e. laboratories, human resources, 
HIV/AIDS, political commitment, monitoring and decentralization of health 
services) inhibiting the achievement of set tuberculosis targets. With the 
introduction of the LTBT treatment supervisors, a reduction of active 
tuberculosis could result. This could result in the reduction of the number 
of laboratory diagnosis and thus the LTBT treatment supervisors, would 
not only be complimenting the existing health professional staff but at the 
same time assist in the decentralising the health services by making it 
more accessible within the communities. But more importantly it would 
translate the political will into action whilst at the same time the LTBT 
treatment supervisors could be catalyst to the HIV/AIDS campaign. 
 
However, a study (White MC et al, 2003) to determine the effect of directly 
observed preventive therapy supervisors for patients with LTBI showed 
that after having controlled for sex, age and race, the patients on directly 
observed preventive therapy supervisors were nearly twice as likely to 
complete IPT (OR 1.93; 95% CI: 1.25 - 3.00) as compared to the patients 
that were in the self-administered treatment group. Furthermore, 70.3% 
patients in the directly observed preventive therapy supervisors‟ (DOPTS) 
treatment group were reported to have completed therapy as compared to 
the 47.9% patients in the SAT group. This difference in completion of 
preventive therapy between the two groups was statistically significant (p < 
0.001).  
 
There is a paucity of studies of IPT supervision especially among HIV-
infected individuals. This may be attributed to the fact that individuals with 
LTBI are not sick (and are asymptomatic) and may not be motivated to 
take their medication by SAT or DOTS. Unlike the individuals being 











symptomatic) associate the compliance to the medication as a means to 
them being rendered asymptomatic and being cured of tuberculosis.  
 
In addition to this reason, various risk factors activating LTBI such as HIV, 
social conditions, homelessness and alcohol abuse (CDC, MMR Wkly Rpt, 
2000), may have contributed to placing the focus and research on IPT 
supervision among the vulnerable groups, low on the priority list. In our 
INH/placebo trial we have attempted to overcome some of these 
challenges with participants requiring to nominate their supervisor for IPT 
whilst still maintaining the confidentiality of the patients‟ HIV status, where 
it was required to do so,  
 
The DOTS supervisor may be a lay health worker (LHW). They may be 
selected or nominated from the community and may or may not be 
remunerated.  The DOTS supervisor is supported by the health system, 
whilst not forming part of it (Kahssay H et al, 1998; Lewin SA et al, 2004). 
The DOTS supervisor ensures adherence support and supervision of 
tuberculosis therapy. In contrast, the LTBT treatment supervisor manages 
those patients that have not yet, but are identified as being at great risk of 
developing tuberculosis. Supervision is needed to enhance adherence, since 
it maximizes the effectiveness of IPT and increase the probability of the 
successful completion of preventative therapy. Both patient and IPT 
supervisor are informed of the great risk of development of tuberculosis and 
the need to be adherent. The treatment supervisor for IPT has a similar role. 
 
To date, two RCTs have not conclusively determined the impact of DOTS 
on treatment outcomes (Kamolratanakul P et al, 1999; Walley JD et al, 
2001). A RCT conducted in South Africa (Zwarenstein M et al, 1998), 
found that the DOTS supervision and SAT in new patients had the same 











treated with DOTS showed significantly poorer results than those assigned 
to SAT.  
 
In cases where tuberculosis patients were given the opportunity to choose 
their treatment supervisor, the treatment outcomes showed an 
improvement, especially in resource poor settings and among re-treatment 
cases (Lienhardt C & Ogden JA, 2004, Kironde S & Meintjies M, 2002). 
The most recent unblinded cluster RCT that evaluated impact of lay health 
care workers on tuberculosis control programmes among farm worker 
patients showed that the successful treatment completion rate among the 
supervised group was significantly better (18.7% improvement, p = 0.042, 
95% CI 0.9-3.64) than in the SAT group (Clarke M et al, 2005).   
 
A Cochrane Review (Volmink J et el, 2006) of DOTS for treating 
tuberculosis concluded that the treatment outcomes were similar for 
participants in the DOTS and SAT arms with no significant difference for 
people cured (RR 1.02; 95% CI: 0.86 – 1.21); cured or completed 
treatment (RR 1.06; 95% CI: 1.00 – 1.13); or those who had completed 
their treatment. This review also concludes that there was no rigorous 
evidence that supported the DOTS prophylaxis for persons with LTBI. 
 
The authors have acknowledged that bias may have influenced the results 
in some of the DOTS trials where only four trials were adequately blinded 
and only three involved the blinding of the outcome assessors. 
Furthermore, the factors that determine the usefulness of DOTS in various 
settings and the quality of the interaction between the DOTS supervisors 
and the patients explored. Nor was the quality of clinic supervision and 
follow-up of patients evaluated. Despite the findings from Cochrane 
Review on DOTS (Volmink J et el, 2006), DOTS still remains the 












However, despite the Cochrane findings, programmatic evidence of studies 
of the effectiveness of DOTS in China showed that the global target of an 
85% cure rate was quickly achieved, and the level of drug-resistance was 
probably reduced by this project. However, case-detection did not reach the 
70% global target (Xianyi C et al, 2002). The DOTS program in Peru has 
been a model of DOTS implementation with regard to reaching the WHO 
targets of 70% case detection and 85% cure. Peru‟s DOTS program can now 
also be held as an example among high-burden countries of what is feasible 
in terms of reducing numbers of cases and deaths (Sua´rez PG et al, 2001). 
 
We are of the belief that LTBT treatment supervisor, like the DOTS 
supervisor, does not dilute the responsibility of the clinic for patient 
management, patient care and record keeping. The DOTS or LTBT 
treatment supervisor supplements the health care facility (Dudley L, 2003). 
 
The DOTS strategy includes the following components and 
implementation approaches: 
 Political commitment with increased and sustained financing 
 Case detection through quality-assured bacteriology 
 Standardize treatment with supervision and patient support 
 An effective drug supply and management system 
 Monitoring and evaluation system and impact measurement 
 
Thus the LTBT treatment supervisor‟s role with the direct observation of 
the standardized treatment with supervision and patient support 
compliments one aspect of the DOTS strategy. This is contributes to the 
improvement and enhancement of patient treatment outcomes as well as 
the involvement of patient care by DOTS/LTBT supervisor, in the 











services that has been made more accessible to patient within the 
community. Thus the DOTS/LTBT treatment supervisor support for the 
DOH/Health facility/clinic, community and the patient forms one of the 
cornerstones of the DOTS strategy.  
 
In a study treatment success rate of patients was 78% and 77% by DOTS 
from community volunteers and from government health workers 
respectively (Singh AA et al, 2004). Effectiveness of community volunteers 
in treating tuberculosis with DOTS, showed treatment success rate 
increased significantly from 13% in 2000 to 25% in 2002, even in absence 
of financial incentives (Singh AA et al, 2004). 
 
The purpose of DOTS as a public health strategy is aimed at reducing the 
transmission rate of tuberculosis (Golub JE et al, 2006) and the likelihood 
of poor adherence to tuberculosis regimens (Bam TS et al, 2006, Juan G 
et al, 2006) that could lead to drug resistance (Anuradha B et al, 2006). 
The purpose of directly observed IPT is focused on adherence and the 
prevention of the development of active tuberculosis in high risk groups 
and thus indirectly reducing the tuberculosis transmission rate and 
tuberculosis drug resistance.  
 
The cohort study in rural South Africa (Rowe KA et al, 2005) showed 
lamentably poor adherence to LTBT in rural South Africa among HIV-
infected individuals. This study highlighted that LTBT was underpinned by 
a complex interaction between health services and the social, economic 
and cultural environment of the residential areas. An interesting finding of 
this study where all participants were HIV-infected only 47.1% had 
completed therapy, where only five had disclosed their HIV positive status 












CHAPTER 3: METHODS 
 
3.1 Study design 
 
3.1.1 Setting of the study in the Western Cape 
The study was conducted in three established hospital-based HIV clinics; 
based at Groote Schuur, Tygerberg and New Somerset Hospitals in Cape 
Town, South Africa.  For much of the study period these clinics were the 
only public sector HIV outpatient facilities available and thus did not serve 
only as specialist referral centres.  
 
3.1.2 Epidemiological study design  
This study was based on a randomised double blinded clinical trial, with 
INH versus placebo administered on a twice weekly basis by patient 
nominated supervisors. The study commenced in early 1998 and was 
unblinded at the end of 2004.  
 
3.2 Recruitment and selection of participants 
 
3.2.1 Participant recruitment and selection 
Clinicians in the three hospital-based adult HIV clinics in Cape Town, 
South Africa were requested to refer patients based on set criteria outlined 
in the memorandum. The three hospitals were Groote Schuur Hospital, 
Tygerberg Hospital and New Somerset Hospital. Memoranda were also 
circulated to various other hospitals and day clinics to refer patients who 











3.2.2 Trial entry criteria 
Inclusion and exclusion criteria targeted participants in WHO Clinical stage 
3 or 4 stratified by TST status. The reasonable distance of the participants‟ 
residence to one of the three hospital based clinic trial sites was also taken 
into consideration before enrolling participants. More importantly, the 
screening process was designed to exclude participants with active 
tuberculosis (WHO Wkly Epidemiol Rec, 1999; Burgess AL et al, 2001; 
Aisu T et al, 1995; Espinal MA et al, 1995). 
 
3.2.2.1 Participant inclusion criteria   
Adults aged 18 years or older with confirmed HIV infection (WHO Clinical 
stage 3 or 4) were invited to participate were TST negative. All participants 
who consented to the study were required to nominate a treatment 
supervisor. Eligible participants were briefed about the trial in English, 
Afrikaans or Xhosa. Participants were requested to read and sign the 
consent form (Appendix 1). This signed informed consent form was 
obtained prior to participant screening for enrolment.  
 
3.2.2.2 Participant exclusion criteria   
Clinicians were asked not to refer patients with suspected tuberculosis or 
those with active tuberculosis.  Exclusion criteria were one or more of the 
following; history of tuberculosis within the past five years (prior to date of 
enrolment), active alcohol abuse (based on clinicians report of clinical and 
patient history) or pregnancy (based on baseline questionnaire) or chronic 
liver disease  (based on clinicians report of clinical and patient history), 
patients with a Karnofsky Performance score [KP<50 (Appendix 6)] and 
treatment with antiretroviral therapy [ART (which was not available in the 
South African public sector at the time of commencement of the study)]. 
Participants not residing within relatively easy reach of the IPT trial clinic 











Some participants accessed anti-retroviral therapy (ART) by enrolling in 
clinical trials that occurred sporadically during the study. Participants were 
censored at the time of initiation of ART. 
 
The method of screening for tuberculosis (Mohammed A et al, 2004) 
excluding active tuberculosis prior to enrolment of participants to this IPT trial 
is described in detail in section 3.4 of this chapter. All participants underwent 
a screening symptom questionnaire, clinical examination, chest radiograph 
and sputum for smear and mycobacterial culture. Enrolment in the trial 
occurred four weeks after screening, when the sputum culture results were 
available. 
 
The WHO clinical staging of all participants referred to the IPT trial was 
confirmed by clinicians based at one of the three hospital-based HIV 
clinics. The Karnofsky (KP) Scale Score of each participant was also noted 
to determine the participants‟ performance of activities of daily living. 
Participants with a Karnofsky score of less than 50 were not enrolled in the 
trial (Appendix 6).  A KP Score ≥ 80 indicates the ability to carry on normal 
activities and to work with no special care required whereas a KP score 
between ≥ 50 and 70 indicates the inability to work but ability to live at 
home and care for most personal needs with varying amounts of 
assistance needed.  A KP score of < 50 indicates an inability to care for 
oneself, i.e. where the disease may be progressing rapidly, requiring the 
equivalent of institutional or hospital care (Appendix 6). 
 
3.2.3 Race classification of participants 
The racial terms and race classification has been used in the context of 
South Africa‟s past legacy of Apartheid. Apartheid sought to categorise all 
South Africans into one of the four racial groups: Asian (or Indian) (2.6 
percent of the population, 1996 census), African (or black) (76.7 percent), 











group reflects enduring historical disparities in socioeconomic status, 
housing and access to medical care, and consequently in disease risk.   
 
3.3 Tuberculin skin test (TST) and anergic tests 
 
The Mantoux and Multipuncture tests to determine TST status and degree 
of anergy were performed on all participants that that granted written 
consent. The Mantoux and Multipuncture were done on the left and right 
mid forearm of all participants. The Mantoux test was performed on the 
same day as the Multitest® CMI Test (Pasteur Mérieux, Maidenhead, 
Berkshire, UK), according to the manufacturer‟s instructions and the 
administration of the structured questionnaire to the participants. Neither 
Mantoux nor the Multitest® CMI Test (Pasteur Mérieux) was conducted if 
the participants were excluded from the LTBT trial based on the entry 
criteria. 
 
3.3.1 Mantoux test to determine TST status 
The Mantoux test involved the intradermal injection of PPD on the area of 
the left mid forearm. The e syringes filled with the required amount of PPD 
were ordered from the Pharmacy of Groote Schuur Hospital for each of the 
patients who were to be screened for the LTBT trial at all of the three 
hospitals, to ensure consistency and avoid possible loss of potency of the 
tuberculin (Marks J, 1964). The left arm of the participant was firmly 
supported by the nurse or relative or placed on the table, prior to 
intradermal injection. The intradermal injection area of the participant‟s mid 
forearm was cleaned with an alcohol swab (Appendix 7).   
 
Once the area had dried, a tuberculin syringe and an intradermal needle 
(No 25G 16 mm long with a short bevel) was used to inject 0,1ml of PPD 











wheal of about 5 mm diameter (Caplin, Maxwell, 1980). From its medial 
aspect the needle was introduced into the skin with the bevel facing 
upwards. Before injecting the PPD, the skin was gently elevated, so that 
the needle was advanced until the bevel was about 1 mm under the skin.  
  
The Mantoux tests were read at 72 hours, by which time the area of the 
induration generally exceeds the area of the erythema (DHSS, 
Memorandum, 1972; Weston WL et al, 1976).  On reading the Mantoux 
tests, the induration was first palpated with a finger and the edge of the 
diameter of the induration was marked both transversely and 
longitudinally, under good light with a ballpoint pen. The measurements 
were done with the aid of Vernier Callipers. The average of the transverse 
and the longitudinal diameter of induration in millimetres (Neville IK, 1957) 
was recorded as the final reading of the Mantoux tests for the respective 
patient.  
 
A negative Mantoux test was interpreted at 72 hours as a PPD induration 
<5 mm. A patient with such a Mantoux result would be termed TST 
negative. A significantly positive Mantoux test (for HIV positive 
participants) was interpreted at 72 hours as PPD induration ≥5 mm. A 
patient with such a Mantoux result would be termed TST positive.  
 
3.3.2 Multipuncture Test to assess degree of anergy  
All participants referred for LTBT were assessed for anergy at the same time 
as the Mantoux Test. This measurement was performed by administering the 
Multitest® CMI Test (Pasteur Mérieux) on the participant‟s right mid forearm. 
The Multitest® CMI test is an acrylic resin applicator comprising of eight 
heads fixed to the base and loaded with seven different standard antigens 












These seven antigens are tetanus, diphtheria, streptococcus, tuberculin, 
proteus, trychophytron and candida. The antigens on this applicator enable 
one to measure the degree of immunodeficiency and responses have been 
shown to correlate with the severity of HIV infection (Hersch EM et al, 1984a; 
Mathur-Wagh U et al, 1984; Hersch EM & Reuben JM, 1984b). The Walter 
Reed Army Institute in the US has used this method to determine the degree 
of response anergy as a means of classification of the stages of HIV infection 
(Redfield RR, 1986). 
 
As in the case of the Mantoux test, the area of the right mid forearm was 
cleaned with alcohol and allowed to dry before applying the Multitest® CMI. 
This was removed from the refrigerator one hour before the tests to facilitate 
the removal of the caps from the antigen heads. Before the removal of the 
caps, the protective film covering of these caps was faced upwards and the 
bar of the Multitest® CMI was tapped on a hard surface. This was to ensure 
consistent impregnation of the antigens on the surface of the right mid 
forearm of the participant. 
 
The Multitest® CMI was held on the T-bar; the protective film and antigen 
head caps were removed and the applicator was applied to the right mid 
forearm to enable the heads to make small punctures on the surface of the 
skin and release the antigens. This was achieved by maintaining a firm 
pressure on the surface of the arm for at least five seconds and then rocking 
the applicator from side to side and from top to bottom.   
This enabled one to clearly see the circular impression on the participant‟s 
skin, where the skin perforations for each of the antigen heads resulted in 
the shining liquid (antigen) being impregnated in each of the square 
perforated areas on the right mid forearm. 
 
The Multitest® CMI tests were read at 48 - 72 hours.  As with the Mantoux 











average of the transverse and the longitudinal diameter of induration for 
each of the antigens were recorded in millimetres.  
 
Positive results for individual antigens were defined by an induration size 
of 2 mm or more. A score for each participant was derived based on the 
sum of the average of all the positive reactions (indurations). From this 
score a compound score was calculated to determine the degree of 
anergy. The compound score was calculated based on the sum of all 
average positive indurations (≥2 mm) which was divided by the number of 
positive antigens (≥ 2mm).   
 
The interpretation of Multitest® CMI tests for the degree of anergy of the 
participant was based on the calculation of the compound score. If these 
compound scores were below the manufacturer‟s cut-off points then the 
participant was confirmed as anergic. These cut-off scores were termed 
the alarm score. The alarm score for female patients was ≤5 mm and for 
male patients was ≤10 mm. Any value scored below these alarm scores 
was interpreted as anergic in accordance with the specifications of the 
manufacturers.  
 
3.4 Screening of participants referred for IPT  
 
3.4.1 Screening of participants 
The screening of participants for the RCT involved the administration of 
the structured symptom questionnaire, chest radiography, sputum 
tuberculosis microscopy and tuberculosis culture, determining the 
participant‟s Karnofsky Score), patient‟s anergy and TST status, as well as 
various other tests (refer to section 3.5.5 of Methods chapter). A simple 











who had consented to partake in the trial prior to them being enrolled for 
IPT. 
 
Once the referred eligible participants had given their written consent they 
were included to partake in the IPT trial. Enrolment occurred four weeks 
after screening of participants when the sputum culture result was made 
available.  
 
3.4.2 Structured symptom questionnaire and patient record  
The initial screening process involved the administration of a structured 
questionnaire (Appendix 2) to the potential participants by the nurse, at the 
initial interview, using a translated questionnaire with an option of the 
participant to have it administered in English, Afrikaans or Xhosa. The 
whole patient record consisted of four sections:  
 Demographic and clinical data of the participants; 
 Tuberculosis screening and baseline investigations; 
 Monthly screening and monitoring of participants; 
 Tuberculosis test  and cytometer readings for CD4 determination at 6 
monthly intervals. 
 
3.4.3 Chest radiography  
A single investigator (GM) who was blinded to the laboratory diagnosis of 
tuberculosis assessed the chest radiographs prior to the patient being 
enrolled into the trial. The radiographs were interpreted as normal, 
abnormal but not suggestive of active tuberculosis, or abnormal 













3.4.4 Sputum tuberculosis microscopy and culture  
One sputum sample was collected at the clinic visit if the patient was able 
to produce sputum.  If the patient was unable to produce sputum at the 
clinic, a container was given to the participant to produce an early morning 
specimen.  Sputum microscopy (auramine stain) and mycobacterial culture 
(radiometric Bactec® system) were performed in all patients.  Participants 
returned after 4 weeks when the sputum culture result was available. 
Participants with non-tuberculosis mycobacteria were excluded from the 
study,  
  
Tuberculosis was classified as definite (culture-positive together with 
appropriate symptoms or radiographic appearances), probable (smear-
positive) and possible (clinical diagnosis together with a response to 
therapy). These definitions were also used to define cases of tuberculosis 
occurring after enrolment. 
 
3.4.5 Other tests    
Blood was collected to determine the baseline CD4+ lymphocyte count. At 
each clinic visit the following were assessed for each participant: 
symptoms of tuberculosis, adverse effects by symptom screening (i.e. rash 
hepatitis and neuropathy) and weight (measured with a beam balance 
scale zeroed at each session). The body temperature of the participant 
was also recorded and urinalysis (to detect bilirubinuria as a screen for 
hepatitis) was done. However, routine liver function tests were not done. 
 
3.4.6 Use of TB screening instrument prior to initiating IPT 
Previous studies have shown that tuberculosis was identified prior to 
treatment particularly in HIV testing centres in developing countries, as a 
result of active case findings where undetected cases were confirmed 











All participants (referred for this trial) who were screened for active 
tuberculosis were required to return to clinic after four weeks when the 
sputum culture and other various test results were available. The ability of 
symptoms, measured weight loss and radiographic abnormalities to 
predict active tuberculosis singly or in combination was assessed. 
Participants identified as having active tuberculosis based on one of the 
three definitions of active tuberculosis were excluded from the LTBT trial 
and referred to the clinic for tuberculosis treatment. 
 
3.5 Randomization of participants enrolled for IPT  
 
3.5.1 Sample size 
The sample size was calculated using an estimated tuberculosis incidence 
of 30% per annum in the placebo control group, based on published data 
from HIV-infected patients with WHO clinical stage 3 and 4 (Pape JW et al, 
1993) and an anticipated 80% reduction in tuberculosis incidence among 
TST-negative patients receiving INH compared to placebo. This estimated 
reduction was based on a study using INH for 12 months, which reported 
reductions in tuberculosis incidence of 71% on their whole population and 
83% in TST positive participants (Pape JW et al, 1993). A one-tailed test 
significance tailed was done to detect tuberculosis risk in the intervention 
group since it was believed that this reasonable given what is known about 
IPT in the TST negative patients with advanced HIV disease. 
 
Based on this premise, that patients with advanced disease had near-
universal exposure to tuberculosis because of the very high prevalence of 
LTBI and the high tuberculosis incidence in our area (Rangaka MX et al, 
2007). Given that TST is increasingly likely to become negative in 
advanced HIV disease, it was reasoned that although participants were 
TST negative they had LTBI. With Type-1 and -2 error proportions of 0.05 











participants would be needed in each trial arm to be followed-up for 24 
months.  
 
3.5.2 Randomisation          
Randomisation was conducted by a computer programme permuted in 
blocks of 20 with 1:1 ratio, to ensure that equal numbers of participants 
were selected between INH and placebo groups throughout the 
recruitment phase. Treatment allocation was kept in a sealed envelopes 
and the randomization code was passed on to an independent pharmacist 
who numbered the monthly INH/placebo packs appropriately. TST 
negative participants were assigned treatment numbers in numerical order 
at the time of enrolment. The participants with their unique number which 
matched the matching INH or placebo number, was maintained throughout 
the trial.  
 
The blinding‟ of the RCT for participants researcher and clinicians was 
maintained till the analysis of the data was completed.  An independent 
person held the sealed randomization code until the end of the study. TST 
positive participants (who were not randomised) were assigned to the 
open-label INH and underwent the same enrolment and follow-up 
schedule as trial participants. 
 
TST negative participants in WHO Clinical stage 3 or 4 who qualified to be 
enrolled in the IPT trial were randomised to receive INH or matching 
placebo to be administered by a patient nominated supervisor (who had 
been briefed on his/her role as a supervisor). Participants in WHO Clinical 
stage 3 or 4 testing TST positive in the INH open-label arm were also 
required to nominate a treatment supervisor.  
 
INH/placebo was administered for 12 months and all were followed for 24 











Participants in the trial did not have access to ART via the public health 
facilities at the time.  
 
3.5.3 Participant nominated treatment supervisor for IPT trial 
One of the major concerns raised in IPT, is non-adherence that could lead 
to INH resistance. In an attempt to reduce this risk of poor adherence 
(Ngamvithayapong, J et al, 1997; Aisu T et al, 1995; WHO Wkly 
Epidemiolo Rec, 1999; WHO/TB98.242; Calvacante S et al 1999), 
participants were required to nominate their treatment supervisors who 
would ensure the compliance of the intermittent INH and Pyridoxine during 
the period of the IPT trial. Both TST negative and positive participants 
were thus assigned to their nominated treatment supervisor to enhance 
participants‟ treatment adherence and to report any adverse effects of the 
trial medication.  
 
These treatment supervisors were categorized into one of the following 
groups depending on their site: home, community or work. The home 
supervisors were defined as members residing in the home of the 
participant who may or may not be related to the participant. The 
community supervisors were defined as persons who were volunteers 
from community based organisations (CBOs), non-governmental 
organisation (NGOs), faith based organisations (FBOs) or community 
based organisations (CBOs) or neighbour, friend, or nurse at the clinic 
nearest to the participants‟ residence. The work supervisors were defined 
as people based at the participants‟ place of work. Treatment supervisors 
were asked to directly observe and administer the twice weekly doses of 
INH/placebo with Pyridoxine and to complete a monthly tick sheet of 
observed doses. The treatment supervisors were briefed on the need to 
ensure that support and encouragement were rendered to the participants 
for 12 months. Participants and their treatment supervisors were educated 











(Comstock GW, 1986), and advised to report to the clinic immediately if 
these developed. 
 
Participants were issued with a monthly clinic visiting card (Appendix 3), 
which in addition to indicating the scheduled dates of the monthly clinic 
visits of the participant, had an enforcing message on the need to be 
adherent and reiterating that tuberculosis was preventable, treatable and 
curable if medication was taken regularly as prescribed.  
 
3.5.4 Trial medication and dosage 
The TST negative participants were randomized to receive twice weekly 
INH (15 mg/kg/dose: 900 mg for those weighing 55 kg or more and 800 
mg for those that weighed less than 55 kg) or matching placebo for 12 
months. This dose was well tolerated and effective in a secondary 
prophylaxis trial in Zaire (Perriens JH et al, 1995); a primary prophylaxis 
trial in Haiti (Halsey NA et al, 1998) and in Zambia (Mwinga A et al, 1998). 
INH/placebo was stopped after 12 months or if participants had defaulted 
therapy for a period of 3 consecutive months. INH/placebo was 
discontinued permanently in participants defaulting for three or more 
consecutive months.  
 
All participants were also supervised twice weekly with 25 mg Pyridoxine 
that was also administered and supervised by the treatment supervisor. All 
participants also received Cotrimoxazole 480 mg (Boeree MJ et al, 2005) 
daily as per clinic protocol. Cotrimoxazole was self-administered by the 
participants on a daily basis (without participant supervision). Adherence 
to INH/placebo, Pyridoxine and Cotrimoxazole was assessed by pill count 
at the participants' monthly clinic visit as well as on the monthly supervisor 
tick list report (Appendix 4) that was completed and by the treatment 











3.5.5 Intervention: Monthly evaluation of LTBT trial participants 
A nurse and the study co-ordinator reviewed each participant monthly for the 
first 12 months (Comstock GW, 1999). Thereafter, participants were followed 
up at three monthly intervals for 12 months. At each clinic visit, the 
participants were assessed for symptoms of tuberculosis, adverse effects of 
INH and cotrimoxazole, weight, temperature and urinalysis (to detect 
bilirubinuria as a screen for hepatitis). Routine liver function tests were not 
done since hepatotoxicity was uncommon in prior studies (Wilkinson D, 2000, 
Agarwal SK, 2004). The same procedure was applied to the participants who 
were placed in the INH open-label arm.  
 
A further 12 months of self administration of Cotrimoxazole was monitored 
and the participants were followed up at three m nthly intervals for this 
period and referred to a clinician for clinical examination at six monthly 
intervals. Clinicians reviewed each participant at 6-monthly intervals. Chest 
radiographs and sputum (for smear and mycobacterial culture) were 
repeated every 6 months until month 24. If participants had features 
suggestive of tuberculosis before the 6-monthly visits, tests for tuberculosis 
were conducted as clinically indicated. CD4+lymphocyte counts were done 
every six months. 
 
If participants were suspected to have tuberculosis during any of the 
monthly clinic visits prior to the six monthly clinician visit, chest 
radiographs, sputum (for smear and mycobacterial culture) were 
requested and participants were referred to the clinician for further clinical 
assessment and confirmation or exclusion of active tuberculosis. The 
same procedure was applied to the participants who were placed in the 
INH open-label arm. Attempts were made to trace patients missing two 
consecutive monthly clinic visits with a home visit. Participants who could 
not be traced after defaulting for three consecutive months were regarded 












3.5.6 Endpoints of the study   
The primary endpoint of this study was the development of active 
tuberculosis based on the case definitions of tuberculosis was classified as 
definite tuberculosis (culture-positive together with appropriate symptoms 
or radiographic appearances), probable tuberculosis (smear-positive) and 
possible tuberculosis (clinical diagnosis together with a response to 
therapy). The secondary endpoints were death, hospitalisation, 
adherence, change in CD4+ lymphocyte counts and adverse drug effects.  
 
3.5.7 Data analysis  
The confirmation of a TB culture was used as the „gold standard‟ for a 
confirmed TB case. The test validity characteristics against the „gold 
standard‟ of the screening instrument for diagnosing active TB in HIV-
infected adults with advanced disease were calculated with their 95% 
confidence intervals. A logistic regression model was used to assess the 
independent predictive effects in identifying active tuberculosis of the 
„different tests‟. 
 
Data were analyzed using the statistical programme SAS Version 9.0 (SAS 
Institute, Cary, NC, USA). All trial analyses were by intention-to-treat. The 
distribution of predictors of tuberculosis risk at baseline was assessed using 
the Student‟s t-tests, Wilcoxon rank-sum tests, and Fisher‟s exact tests, as 
appropriate.  
 
The effect of INH versus placebo on the rate of tuberculosis disease was 
based on person-time calculated from the date of randomization into the trial 
until the earliest of three endpoints: documented tuberculosis disease, 
censoring (due to loss to follow-up, initiation of ART or death due to other 
opportunistic infections), or the end of the study in December 2004, when all 
participants had completed 24 months of follow-up. Kaplan-Meier analyses 











curves were compared using log-rank tests. Cox‟s proportional hazards 
analyses were used to examine the effect of treatment on the rate of 
tuberculosis disease after adjusting for minor imbalances in baseline 
covariates.  
 
Adherence was analysed by pill count as the percentage of doses taken by 
the participants over a period of 12 months at intervals of four weeks, over 
the percentage prescribed doses.  
 
3.6 Ethical issues 
 
The study was approved by the Ethics and Research Committees 
(Appendix 5) of the Universities of Cape Town and Stellenbosch.  Signed 
informed consent was obtained from each participant prior to screening 
and prior to enrolment into the LTBT trial.  
 
The participants were briefed about the trial in English, Afrikaans or 
Xhosa. Once verbal consent was obtained the participant was requested 
to read and sign the consent form in the language of their choice before 
initiating the screening process with the aim of enrolling eligible 
participants into the trial.   
 
Participants whose TST status was positive were excluded from the 
randomised LTBT trial but were given the option of joining the open label 
INH arm. This was done on purely ethical grounds, since studies had 
already established the benefit of LTBT among HIV-infected individual who 
are TST positive (Woldehanna S & Volmink J 2004; Bucher HL et al, 
1999). These TST positive participants in the open label INH arm were 
followed up in the same manner as the TST negative participants who 












Participants were required to nominate treatment supervisors who were 
aware of the participants‟ HIV status and those treatment supervisors were 
informed about the importance of maintaining confidentiality. If the 
participant did not wish to have their HIV status divulged to the treatment 
supervisor, confidentiality was assured to the participant and their 
treatment supervisors were informed that the trial was being undertaken to 
prevent tuberculosis in the participant who was being supervised.  
 
All participants who were identified with active tuberculosis during the 
screening process or developed tuberculosis whilst on the IPT trial were 
referred to the nearest clinic for tuberculosis treatment. On enrolment and 
at the time of signing the consent form (Appendix 1), participants were 
once again reminded that their participation in the IPT trial was voluntary 
and that they had the right to withdraw from the trial at any time if they so 
wished.  
 
All Participants were also advised of the possibility of adverse effects due 
to Cotrimoxazole, and that if such a reaction occurred, this antibiotic would 
be discontinued and replaced with another antibiotic. In the rare event of 
serious adverse effects due to INH, participants were informed that they 
would be taken off the IPT trial. Such adverse effects were defined as new 
skin rash, itchiness, pins & needles, numbness of the limbs and nausea). 
 
Participants who had enrolled for the IPT trial were served with tea, coffee 












CHAPTER 4: RESULTS  
 
4.1 Background of participants for IPT trial 
 
4.1.1 Recruitment and enrolment of participants for IPT trial 
A total of 160 participants were referred for enrolment in the IPT trial. 
Figure 1, which presents the outcome of the 160 participants; the number 
of participants excluded prior to screening, the number of participants 
excluded upon screening and those participants on the LTBT trial who 
were observed for the period of 24 months.  
 
Of these 160 individuals, 31 (19.4%) were excluded from enrolment which 
resulted in 129 (80.6%) individuals being screened for tuberculosis prior to 
the enrolment as recommended by WHO to prevent drug resistance 
(WHO, 1999). Of this group of 129 participants, an additional 11 (8.5%) 
participants were excluded based on the screening tests and the outcome 
of confirmatory tests confirming active tuberculosis status (Mohammed A 
et al, 2004), resulting in 118 eligible participants enrolled for the LTBT trial 
of which 20 (12.5%) participants were TST positive.  
 
The 20 TST positive participants enrolled for the trial were not randomised 
in the double blind IPT trial, owing to the confirmation of their TST positive 
status, based on the Mantoux test. However, these 20 TST positive 
participants were placed in the open-label arm and administered INH. Both 
the 98 (83%) TST negative participants in the randomized trial arms 
(INH/placebo closed label arms) and the 20 (17%) TST positive 
participants in the open-label arm were treated and followed up in the 











The majority of the 64 (54.2%) participants enrolled for the LTBT trial were 
based at Groote Schuur Hospital, with 42 (35.6%) participants based at 
the New Somerset Hospital and 12 (10.2%) participants based at 
Tygerberg Hospital.  
 













4.1.2 Participants enrolled for IPT in the Trial 
In the following section outlines the characteristics of all participants in the 
randomised arms as well as the open-label arm (INH). 
 
4.1.2.1 Race, gender, sexual orientation and religion.  
The race distribution (refer to preceding paragraph for explanation of the 
use of race classification) of the 118 participants in both the closed and 
open INH label arms was 82 (69.5%) Blacks, 29 (24.6%) Coloureds, 3 
(2.5%) Indians and 4 (3.4%) Whites. The race distribution of participants in 
the closed INH label comprised 66 (67.7%) Blacks, 25 (25.5%) Coloureds, 
3(3.1%) Indians and 4 (4.1%) Whites.  
 
Graph 1 displays the age distribution of this group. The mean age was 
38.3 years with a standard deviation of 10.9 (range of 20 to 70 years). The 
gender distribution of the 118 participants was 63 (53.4%) females and 55 
(46.6%) males. The religious distribution of participants in the closed and 
open INH label were 109 (92.4%) Christians and 9 (7.6%) Muslim. A total 
of the 113 (95.8%) participants were reported to be heterosexual, 2 (1.7%) 
bisexual and 3 (2.5%) homosexual.  
 
The main mode of HIV transmission was thus by heterosexual means. 
However, among the 113 participants who reported a heterosexual 
orientation, one participant had reported HIV infection via blood 
transfusion and another participant reported HIV transmission as a result 
of rape. None of the participants had reported HIV transmission via 














Graph 1: Age distribution of participants 
 
 
4.1.2.2 Residential area of participants  
An overwhelming majority of the participants enrolled for the IPT trial were 
from lower socio-economic residential areas (historically disadvantaged 
townships), in Cape Town. The majority of the participants [62 (52.5%)] 
resided in Khayelitsha, Guguletu, Nyanga, Crossroads and Langa, 
previously designated Black townships; as well as predominantly Black 
informal settlements such as Brown‟s Farm, Philippi, Blue Downs, 
Mandalay and Milnerton. All of these residential areas, with an exception 
of two, were easily accessible to the Tygerberg, Groote Schuur and New 
Somerset Hospitals. An exception was made for two participants from 
distant areas, based on assurance of their regular clinic visits for the 
duration of the IPT trial. The clinic in Grabouw arranged transport for one 
participant‟s monthly visit to Tygerberg Hospital for the duration of the 
LTBT trial. The second participant from Atlantis commuted to Cape Town 











arranged to coincide with her monthly visit to Groote Schuur Hospital for 
the duration of the IPT trial. 
 
4.1.2.3 Marital, educational, occupational status  
The marital, educational and occupational status of participants enrolled 
on the LTBT trial is presented in Tables 3, 4 and 5. Only 28 (23.7%) of the 
participants enrolled for IPT were married, as compared to the nine 
participants that reported having a common law spouse. The majority of 
the 81 (76.3%) participants enrolled on this trial were without a partner; 
single, separated, divorced or widowed. Most of the 63 (53.4%) 
participants reported being single.  
 
Table 3: Marital status of participants   
Marital Status % Frequency 
Married 28 (23.7%) 
Divorced   6 (5.1%) 
Separated   6 (5.1%) 
Widowed   6 (5.1%) 
Common Law Spouse   9 (7.6%) 
Single 63 (53.4% 
Total 118 (100%) 
 
Only three participants reported no schooling (Table 4) and 18 participants 
reported having received tertiary education. Of these 18 participants who 
received tertiary education, one had completed a Masters degree in 














Table 4: Educational status of participants  
Level of Education  % Frequency 
Primary Schooling 42 (35.6%) 
Secondary Schooling 57 (48.3%) 
Tertiary Education 16 (13.6%) 
No Schooling 3 (2.5%) 
Total 118 (100%) 
 
A total of 59 of the participants were unemployed (Table 5). Only 44 
participants were employed. The other 15 participants were either in the 
category of pensioner, student, housewife, or had been medically retired.  
Of the 44 (37.3%) participants who were employed, 35 participants were 
permanently employed, five temporarily employed and one employed on a 
part-time basis. Three participants did not respond to the question 
regarding their employment status.  
 
Table 5:  Occupational status of participants  
Occupational Status % Frequency 
Employed 44 (37.3%) 
Unemployed 59 (50.0%) 
Pensioner 3 (2.5%) 
Housewife 1 (0.8%) 
Student 8 (6.8%) 
Other 3 (2.5%) 
Total 118 (100%) 
 
4.1.2.4 Distribution of social class  
Table 6 outlines the 118 participants placed into social class categories 











Research Unit (SALDRU, 1983).  There were 67 participants who were 
placed in the „partially or unskilled‟ social class category based on their 
current or previous work and designated position at workplace. 
 
Table 6: Social class category of participants    
Category Social Class  % Frequency (n = 118) 
I Professional 1 (0.8%) 
II Intermediate 3 (2.5%) 
IIIa Skilled Non-Manual 19 (16.1%) 
IIIb Skilled Manual 28 (23.7%) 
IV Partially Skilled 49 (41.5%) 
V Unskilled 18 (15.3%) 
 
The monthly income .ranged between from <R500.00 to ≥R3000.00 with 
72 (61%) participants‟ income ranging between < R500.00 and R1499.00 
per month.  
 
Table 7: Income category of participants   
Category (Income per month) Frequency  % Frequency 
< R500.00 24 20.3 
R500.00 – R999.00 22 18.6 
R1,000.00 – R1,499.00 26 22.0 
R1,500.00 – R1,999.00 4 3.4 
R2,000.00 – R2,499.00 4 3.4 
R2,500.00 – R2,999.00 1 0.8 
≥ R3000.00 5 4.2 
Dependent on family/external support 32 27.1 











From Table 7, 44 participants reported being sole supporters of family or 
providers of household income. Seventeen participants reported that they 
did not or were not able to contribute at all to the family or household 
income. 
 
Table 8 illustrates the supporting role of a family or a household member 
to the participant enrolled in the trial.  
 
Table 8: Participants supporting role in family or household  
 
Category Frequency  % Frequency 
Sole supporter of family / household   44   37.3 
Not sole supporter of family / household   57   48.3 
Not contributing of support to household   17   14.4 
Total 118 100.0 
 
4.1.3 Participants’ sexual behaviour and practice in relation to HIV 
 
4.1.3.1 Number of sexual partners and condom use of participants 
There were 72 (61%) participants who reported no sexual partners within 
the 6 months prior to enrolment. A total of 40 (33.9%) participants had 
reported having one sexual partner within the six months prior to 
enrolment; 4 (3.4%) participants reported two sexual partners; with only 2 
(1.7%) participants reported having had three or more sexual partners 
within the 6 months prior to enrolment.  
 
Table 9 presents the responses regarding participants‟ use of condoms. 
There were 57 participants who reported that they abstained from sex.  Of 











reported using condoms every time as compared to 12 participants who 
used condoms sometimes and 22 participants who never used condoms.  
 
Table 9: Participants’ use of condoms 
Condom Use % Frequency 
Abstained from sex   57 (48.3%) 
Always use condom   27 (22.9%) 
Sometimes   12 (10.3%) 
Never   22 (18.6%) 
Total 118 (100%) 
 
4.1.3.2 Partners’ awareness of participants’ HIV status 
A total of 63 (53.4%) participants reported that their partners were aware 
of their HIV positive status, as compared to 41 (34.7%) participants who 
had partners who did not know of their HIV positive status. Only 14 
(11.9%) participants reported that they did not know if their partner knew of 
their HIV positive status.  
 
4.1.4 History of TB and household tuberculosis contacts  
 
4.1.4.1 History of TB five years prior to enrolment for IPT Trial 
The criteria aimed to exclude participants who had a history of tuberculosis 
within five years prior to enrolment. However, 18 (15.3%) participants who 
reported history of tuberculosis more than five years previously were 
eligible to be enrolled. Twenty seven (22.9%) participants reported having 
had a household member who had been diagnosed with and treated for 
tuberculosis. Six (5.1%) participants did not know if they had ever been in 












4.1.4.2 Participants’ history of BCG and BCG scar 
The relationship between participants‟ reports of having received BCG and 
the presence of the BCG scar was checked on enrolment. Table 10 
illustrates the relation between reported BCG and the observed BCG scar 
No BCG scar was observed among 43 (54.4%) of the 79 participants who 
reported having received BCG. However, among the 37 participants with a 
BCG scar, 36 (97.3%) participants had reported that they had received 
BCG. Thus only one (0.8%) participant with a BCG scar reported no 
recollection of having received BCG. In 18 (15.3%) participants there was 
agreement between absence of a BCG scar and a report of not having 
received BCG vaccination.  
 
Table 10: Relationship between reported BCG and observed BCG scar 
Reported to have received BCG vaccination 
BCG scar observed Yes No Don’t Know Total 
Yes 36 0 1 37 
No 43 18 20 81 
Total 79 18 21 118 
 
4.1.5 Tuberculin skin test (TST) 
Two types of skin tests were performed on all participants. The Mantoux 
test was performed to ascertain the TST status of the participant, whereas 
the Multipuncture Test (Multitest® CMI) conducted at the same time 
assessed the degree of anergy of the participants. 
 
4.1.5.1 Mantoux test 
Of the 129 individuals tested with Mantoux test, 26 (20.2%) were TST 
positive and of the 26 TST positive participants, six (23.1%) participants 
were confirmed as having active tuberculosis at enrolment based on the 











Of the 103 TST negative participants, five (4.8%) were confirmed with 
tuberculosis based on the screening instrument.  
 
Graph 2: Participants screened by Mantoux test 
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Thus eleven (8.5%) participants were excluded (because of active 
tuberculosis) from the IPT trial and were referred to the clinic nearest to 
their residence for tuberculosis treatment. Graph 2 shows the distribution 
of the results of the Mantoux test of the 118 (98 TST negative and 20 TST 
positive) enrolled for the IPT trial 
 
4.1.5.2 Multipuncture test result (Multitest® CMI) 
In Table 11, all of the 26 (20.2%) TST positive participants (both male and 
female) had a compound score (refer to section 3.4.2 of Methods chapter) 
exceeding the alarm score, indicating that this group did not display a high 
degree of anergy. However, the 103 (79.8%) participants in the TST (PPD) 
negative cohort (both male and female) all had a compound score of zero 
and well below the alarm score indicating that the participants in this 











Table 11: Participants screened (Multitest® CMI) for level of anergy. 
Patient 
ID 
Sex 1 2 3 4 5 6 7 8 Score Compound 
Score 
301 F 0 0 0 11.5 0 0 0 0 11.5 11.5 
302 F 0 0 0 10.0 0 0 0 0 10.0 10.0 
303 F 0 0 0 10.0 0 0 0 0 10.0 10.0 
304 F 0 0 0 11.8 0 0 0 0 11.8 11.8 
305 M 0 0 0 10.2 0 0 0 0 10.2 10.2 
306 M 0 0 0 10.1 0 0 0 0 10.1 10.1 
307 M 0 0 0 13.8 0 0 0 0 13.8 13.8 
308 F 0 0 0 10.2 0 0 0 0 10.2 10.2 
310 F 0 0 0 8.0 0 0 0 0 8.0 8.0 
311 M 0 0 0 10.5 0 0 0 0 10.5 10.5 
312 F 0 0 0 10.5 0 0 0 0 10.5 10.5 
313 M 0 0 0 12.0 0 0 0 0 12.0 12.0 
314 F 0 0 0 14.0 0 0 0 0 14.0 14.0 
315 F 0 0 0 8.0 0 0 0 0 8.0 8.0 
316 M 0 0 0 10.1 0 0 0 0 8.0 8.0 
317 F 0 0 0 6.0 0 0 0 0 10.1 10.1 
318 M 0 0 0 10.2 0 0 0 0 6.0 6.0 
319 F 0 0 0 8.0 0 0 0 0 10.2 10.2 
320 F 0 0 0 7.0 0 0 0 0 8.0 8.0 
321 M 0 0 0 11.0 0 0 0 0 7.0 7.0 
X1 F 0 0 0 5.2 0 0 0 0 5.2 5.2 
X3 M 0 0 0 10.1 0 0 0 0 10.1 10.1 
X6 M 0 0 0 10.2 0 0 0 0 10.2 10.2 
X10 M 0 0 0 10.5 0 0 0 0 10.5 10.5 
X11 F 0 0 0 5.3 0 0 0 0 5.3 5.3 
X31 F 0 0 0 8.3 0 0 0 0 8.3 8.3 
Key to Antigens: 1 = tetanus; 2 = diphtheria; 3 = streptococcus; 4 = 











4.6 Tuberculosis screening  
 
All individuals who consented to participating in the IPT trial were 
microbiologically tested for active tuberculosis prior to enrolment to the IPT 
trial. The following section outlines the level of performance of the 
tuberculosis screening instrument among the 129 individuals that had 
indicated their willingness to participate in the trial. 
 
4.6.1 Tuberculosis screening instrument performance  
One hundred and twenty nine patients were screened for tuberculosis. 
tuberculosis was diagnosed in 11 (8.5%) patients ten definite and one 
possible (fever and meningitis with cerebrospinal fluid negative for 
cryptococcal antigen and negative cultures for bacteria, fungi and 
mycobacteria and a good response to anti- tuberculosis therapy). 
 
The performance of the individual screening elements for these 11 cases 
of tuberculosis is shown in Table 12. A screening instrument defined as 
two or more signs/symptoms of measured weight loss, cough, night 
sweats or fever had a sensitivity of 100% [(lower 95% confidence interval 
(CI): 67.9)] and specificity of 88.1% (95% CI 80.6 – 93.1).  In logistic 
regression analysis, these four variables were all independent predictors 
of tuberculosis. The positive and negative predictive values of this 
screening instrument were 44% and 100% respectively (likelihood ratio 
positive 8.43). In logistic regression modelling this screening instrument 
provided the best fit (Wald statistic 19.64, p < 0.001).  
 
Adding the Mantoux or chest radiograph result did not improve the 
performance of the screening instrument. If only one of the four variables 
was used for screening, the specificity was reduced to 53.4% (95% CI 44–











(weight loss, cough, night sweats or fever) were 82% and 97% 
respectively; and for all four were 27% and 100%, respectively. 
 
Table 12: Performance of individual tuberculosis screening elements in HIV WHO 
Clinical Stage 3 or 4 patients  
 
* Odds ratios of association between symptom & active tuberculosis adjusted in logistic 
regression; 
** Fishers exact 2-tailed test 
 
4.6.2 Chest radiographs, sputum tuberculosis microscopy and 
culture  
Table 13 illustrates that in accordance with trial protocol, chest 
radiographs, sputum microscopy and culture for tuberculosis were 
conducted at 6-monthly intervals for 24 months, with assessment by 
clinicians.   





 2.5% in 4 weeks 
81.8% 78.8% 12.6 (2.9-55.3) < 0.01 
Cough > 2 weeks 81.8% 88.1% 20.7 (4.8-89.7) < 0.01 
Night Sweats > 2 
weeks 
72.7% 88.1% 12.9 (3.7-45.1) < 0.01 
Fever > 2 weeks 72.7% 83.1% 9.6 (2.7-33.9) < 0.01 
Mantoux  5 mm 
induration 
54.5% 83.1% 4.8 (1.6-14.4)   0.01 
Chest X-ray 
suggestive 
27.3% 95.8% 5.7 (1.9-17.3)   0.02 
Sputum smear 
positive 
54.5% 100% N/A   N/A 
Sputum culture 
positive 











Of the 6-monthly tests conducted; 198 (68.3%) of the 290 required chest 
radiographs were done with 7 (3.5%) suggestive of tuberculosis; 197 
(65.7%) of the 300 required sputum microscopy were done of which three 
(1.5%) were smear positive; and 193 of the 294 (65.6%) required sputum 
cultures were done of which 6 (3.1%) were culture positive for 
tuberculosis.  Follow-up and outcome data are listed in Table 13. Of the 15 
participants in the randomised trial arms diagnosed with tuberculosis, 6 
(40%) were detected during routine clinic visits (two possible; one 
probable and three definite tuberculosis). 
 
Table 13: Six-monthly tests of chest radiographs, microscopy and culture over a 
period of 24 months 
Type of Tests Total number (n) 
done  
Total number 




198 [7 (3.5%)TB 
suggestive] 
290 68.3% 
Microscopy 197 [3 (1.5%) 
smear positive] 
300 65.7% 
Culture* 193 [6 (3.1%) 
culture positive] 
294 65.6% 
* Remaining four tuberculosis cases were detected on signs & symptoms alone  
 
4.6.3 Karnofsky performance scale score   
Table 14 presents the assessment of the Karnofsky Performance Scale 
Score (KP) of all participants prior to enrolment to LTBT. The Karnorfsky 
Performances Scale Score allows one to classify the participants‟ 
functional impairment into three broad categories. Only 14 of the 













Table 14: Karnofsky Performance Score for TST +ve & -ve participants 
Karnofsky Score PPD-ve PPD+ve  Total 
50 2 (2.0%) ---- 2 (1.7%) 
60 11 (11.2%) 1 (5.0%) 12 (10.2%) 
70 35 (35.7%) 2 (10.0%) 37 (31.4%) 
80 21 (21.4%) 7 (35%) 28 (23.7%) 
90 29 (29.6%) 10 (50.0%) 39 (33.1%) 
Total 98 (83.1%) 20 (16.9%) 118 (100%) 
 
There was significantly statistical association between participants with a 
Karnofsky Score ≤ 70 and a TST negative status with a OR 5.44 [95% CI: 
1.50 -19.76 (Table 15)],   
 
Table 15: Association between Karnofsky Score and TST Status 
Karnofsky Score PPD-ve PPD+ve  Total 
≤ 70 48 3 51 
> 70 50 17 67 
Total 98 20 118 
 
4.6.4 Baseline characteristics, clinical features & laboratory 
results of enrolled participants 
As can be seen from Table 16, the baseline characteristics of 
demographics, clinical features and laboratory results of the enrolled 
participants in the randomised trial arms were well matched. However, the 
TST positive participants had less severe HIV disease in comparison to 
the randomised trial arms, as assessed by the higher Karnofsky score (p = 
0.013), higher CD4 count (p = 0.001) and lower proportion with WHO 











Table 16: Baseline comparison of study arms 
 












Mean age in years 39.7 37.8 0.38 35.9 
Male 25 (52%) 22 (44%) 0.54 11 (55%) 
Race (African)** 33 (69%) 39 (78%) 0.29 10 (50%) 
Unemployed 21 (44%) 26 (52%) 0.43 6 (30%) 
≥ Secondary Education 31 (65%) 30 (60%) 0.68 11 (55%) 
Social Class 
       Classes I - III  










Patient nominated supervisors: 
        Home-based  
        Community-based  

















Mean Body Mass Index (BMI) 23.1 23.5 0.68 23.8 
Previous TB diagnosis 5 (10%) 10 (20%) 0.26 2 (10%) 
Household contact with TB 8 (17%) 15 (30%) 0.15 6 (30%) 
WHO stage 4 22 (46%) 23 (50%)  0.99 1 (5%) 





Median CD4 (μL) 
count (IQR) 
99 (24-269) 117 (56-236) 0.55 
354 (191-
466) 
 * It is between the randomised arms (INH & Placebo) 











4.7 Follow-up and outcomes 
 
The section deals with follow-up and outcomes in respect of tuberculosis 
between the treatment and control arms (INH and placebo closed–label 
arms) over the period of 24 months.  
 
4.7.1 Person years of observation   
Total person-years of observation in the trial was 160.4 person-years.  
 
There was no difference in the total person-years of observation between 
randomised participants of the INH group (50.09 per person-years) and 
the placebo group (51.80 person-years). Among the open label INH group 
the period of observation was 58.25 person-years. 
 
No statistically significant differences between participants in the 
randomized trial arms with regards to adherence, follow-up observation, 
hospitalization, CD4+ lymphocyte count decline, tuberculosis and death 
















Table 17: Follow-up and outcomes 
 
Randomized Arms INH Open 











(161 to 1592) 
358  
(151 to 721) 
N/A 1130  
(381 
to1581) 
Median % of doses taken 
IQR* 
87 
(68 to 93) 
81.2 




(82 to 96) 
Median change in CD4 μL 




(-201 to 692) 
-32 
 





Hospitalized during 24 months 
follow-up period 
45.9 per 100 p-y** 46.3 per 100 p-y 0.99 12.0 per 
100 p-y 
Censored: 
Initiating ARV therapy 
Lost to follow-up 
19 
  6 
13 
15 








Death (All cause) 14 18 0.32 0 
Tuberculosis 9 6 0.42 4 
Person years of observation  50.09 51.80 0.76 58.25 
TB incidence (by any 
definition) 
18.0 per 100p-y 
(95% CI:8.2-34.1) 
11.6 per 100p-y 
(95% CI 4.2-
25.2) 















4.7.2 Tuberculosis incidence & mortality of participants in IPT trial 
Fifteen tuberculosis cases occurred in the randomized trial arms. In the 
randomised arms, nine (18.8%) of the 48 participants allocated to the INH 
arm developed tuberculosis compared with six (12%) of the 50 participants 
allocated to the placebo arm over a period of 24 months. Seven (46.7%) 
tuberculosis cases were diagnosed as definite, two (13.3%) were probable 
and six (40%) were possible (as previously defined).  
 
Figure 2: Kaplan-Meier analysis of the development of tuberculosis in RCT arms  
 
Tuberculosis free survival 
 
Number starting 
interval/ Number of 










INH 48 36/5 24/1 15/2 7/1 











The overall tuberculosis incidence by any definition among the two groups 
of the closed label arms was 14.7 per 100 person-years (95% CI: 8.2 - 
24.2). In the INH group it was 18.0 per 100 person-years (95% CI: 8.2 - 
34.1) compared to 11.6 per 100 person-years in the placebo group (rate 
ratio 1.55; 95% CI: 0.49 - 5.30, p = 0.42).  The overall tuberculosis 
incidence rate by any definition among the open label INH group was 6.86 
per 100 person-years (95% CI: 2.18 - 16.56). There was no difference if 
the results were restricted to definite/probable tuberculosis cases. 
 
Mortality from any cause was compared using the Kaplan-Meier survival 
graphs as shown in Figure 3. The Log rank test had a p-value = 0.598 
(survival proportion) for the comparison of randomized groups. There was 
thus no significant difference observed between the INH and placebo 
groups in overall mortality.  
 
The Cox proportional hazards model of risk of tuberculosis infection by 
randomised trial arms, in univariate (unadjusted) form, is presented in 
Table 18.  The results are presented as Hazard Ratios (HR) and 
corresponding 95% Confidence Intervals (CI). The only statistically 
significant predictor was a history of tuberculosis five years or more prior 













Figure 3: Kaplan-Meier analysis of all cause mortality in RCT arms 
 




Table 18 presents the risk of tuberculosis infection in the randomised trial 
arms, in a hazards univariate model of risk of tuberculosis by randomized 
arms. Age was not included since it did not fit into the model and nor did it 
yield a significant outcome. The p value for trend of three or more 
categorical variables was done (i.e. BMI & income) and nor did this yield a 
significant outcome, because of the small size. 
Number starting 
interval  / Number 











INH 48 23/4 23/3 19/3 14/2 











Table 18: Cox Proportional Hazards Univariate Model of risk of tuberculosis by RCT 
arms 
Variable HR 95% CI p value 
Trial arm (INH versus Placebo) 1.59 0.57-4.49 0.38 
Participant sex [Female=1; Male=0] 1.01        0.37-2.79  0.98 
Baseline CD4 count [per 50 cell increase] 1.05 0.87-1.27 0.61 
Baseline WHO stage [stage 4=1; Stage 3=0] 1.56       0.55-4.45  0.40 
Employed [Unemployed/Housewife=1; 
Work/Student=2] 
0.58 0.19-1.71 0.58 
BMI: Overweight baseline (any category*) 
Obese/Obese/Excessively Obese 
              Normal 










Income: Wholly dependent 
              < R1000.00 per household 










Karnofsky Score: Score 50-70 
                             Scor  80 










History of TB (≥ 5 years prior to enrolment to trial) 4.02 1.41-11.45 0.01 
Contact TB Household case 0.29 0.38-2.19 0.23 
Social Class 1.26 0.45-3.54 0.66 
Hospital Events (hospitalisation of participant)  1.94 0.68-5.51 0.21 












Table 19 presents the risk of tuberculosis infection in the randomised trial 
arms, in a multivariate Cox HR model adjusted for all covariates with 
corresponding 95% confidence intervals. 
 
Table 19: Cox Proportional Hazards: Multivariate Model of risk of tuberculosis by 
trial arms 
Variable HR 95% CI p vale 
Trial arm [INH = 1, Placebo = 0] 2.02 0.65-5.23 0.22 
Participant sex [Female = 1; Male = 0] 1.02        0.55-2.93  0.98 
Baseline CD4 count [per 50 cell increase] 1.06 0.83-1.34 0.66 
Baseline WHO stage [Stage 4 = 1; Stage 3 = 0] 1.56       0.55-4.45  0.40 
History of TB (5 years prior to enrolment to trial) 3.48 1.11-10.92 0.03 
 
4.7.2.1 INH/placebo adherence  
The administration of intermittent supervised INH/placebo and Pyridoxine 
adherence was measured by pill count on the monthly clinic visit and the 
monthly patient nominated supervision tick sheet. A strong correlation was 
observed between Pyridoxine adherence and INH/ Placebo adherence (r = 
0.97, p < 0.0001).  
 
There was no statistically significant change (p=0.11) in the median 
adherence of INH over time assessed quarterly in the randomised trial 
arms.  There was a good correlation between pill counts and the monthly 
tick sheet by the patient-nominated supervisor (Spearman‟s (r2=0.704). 
The median INH adherence in the randomised trial arms was 85% (not 
significantly different in the INH and placebo arms) and 92% in the INH 
open label arm. However, INH/placebo adherence was significantly higher 











supervisor (87.3% by the monthly pill count) than compared with the 
home- or community-based patient-nominated supervisors (76.7% and 
71.1% respectively).  
 
In a multivariate logistic regression model of predictors for adherence 
(Table 20) the following factors were found to be associated with high 
adherence (≥ 80% adherence): lower age, INH open label, work-based 
supervisor, higher social class and participants who had completed 
secondary schooling.  
 
Table 20: Multivariate predictors of ≥ 80% adherence to INH  
Variable Adjusted Odds Ratio  
Age (continuous) 0.97  (95% CI: 0.92 – 0.99) 
Race (Black vs. other groups) 0.55  (95% CI: 0.21 -1.46) 
Randomisation arm 
 Placebo 1.0 (Reference) 
 INH 1.38    (95% CI: 0.56 – 3.40) 
 Open-label 5.79    (95% CI: 1.47 – 22.75) 
Supervisor category 
 Home-based 1.0 (Reference) 
 Community-based 0.76   (95% CI: 0.26 – 2.25) 
 Work-based 5.76   (95% CI: 1.47 – 22.75) 
Social Class (I – III vs. IV – V) 2.61   (95% CI: 1.05 – 6.481 
Did not complete secondary school 0.37   (95% CI: 0.148 – 0.92) 











4.7.2.2 Adverse effects of INH  
No major adverse effects of INH were observed among the 68 participants 
that received INH. However, three (2.5%) with mild peripheral neuropathy 
were reported in the randomised INH arm and none in the placebo arm     
(p = 0.114; Fisher exact test). No cases of hepatitis occurred.   
 
4.7.2.3 Adverse effects due to cotrimoxazole  
Four (3.4%) participants were identified as having had adverse effects to 
cotrimoxazole prior to enrolment and three (2.6%) participants developed 
adverse effects to cotrimoxazole while on the IPT trial and cotrimoxazole 
was stopped for these participants. These adverse effects were skin 
rashes.  
 
4.7.2.4 Cotrimoxazole (CTX) Adherence 
Cotrimoxazole adherence was measured during the monthly clinic visit by 
means of a pill count in both the open and closed label arms. The Shapiro-
Wilk W test was used to test for the normality of adherence in the INH and 
the cotrimoxazole groups. Neither INH nor cotrimoxazole adherence was 
normally distributed and hence the Wilcoxon Matched Pairs Test was used 
to test any difference between the two groups.  
 
The median cotrimoxazole adherence [73.5%; (IQR) 58.3-83.9] of 
participants in the randomised trial arms was significantly lower (p = 0.026) 
than the median cotrimoxazole adherence [84.6%; (IQR) 70.2 - 88.9] of 
the participants in the INH open-label arm, based on the Mann-Whitney 
test.  However, there was no statistical difference (p = 0.831) between the 
median of SAT of cotrimoxazole adherence in the (INH closed-label arms) 
INH arm [73.7%; (IQR) 57.3-84.4] as compared to the placebo arm 











all three arms (including the open-labelled INH arms) was [73.3% (IQR) 
61.4, 84.5], 
 
However when the median intermittent supervised INH adherence of 
[83.9% (IQR) 66.7, 92.5] in the closed-labelled arms was compared to the 
median daily SAT of cotrimoxazole adherence in all three arms [73.3% 
(IQR) 61.4, 84.5) among the same participants, it was higher Thus 
intermittent supervised INH adherence in the closed-labelled arms had a 
significant statistically higher (p < 00.1) adherence than the daily SAT of 
cotrimoxazole adherence in all three arms of the same participants. 
 
Figure 4, shows that survival of participants with a threshold of ≥70% 
cotrimoxazole adherence (good adherence) had a significantly (p = 
0.0002) better survival than those participants with a threshold of <70% 
cotrimoxazole adherence (poor adherence).   
 
The participants with a poor cotrimoxazole adherence had a survival rate 
of 50% at one year as compared to a 75% survival rate among participants 
with good cotrimoxazole adherence.  
 
However, the result shows that mortality in the <70% cotrimoxazole 
adherence group was lower but not significant as compared to the ≥70% 
cotrimoxazole adherence group (HR 1.28; 95% CI: 0.59 – 2.70). The large 
confidence interval indicates that the sample size is small when using 

















Figure 4: Kaplan-Meier analysis of cumulative proportion of survival comparison 
between participants of < 70% Cotrimoxazole adherence group (0) and ≥ 70% 
Cotrimoxazole adherence group (1) 
 
<70% Cotrimoxazole Adherence Group:  
≥70% Cotrimoxazole Adherence Group:  

















CHAPTER 5: DISCUSSION 
 
5.1 Main findings  
 
5.1.1 Tuberculosis screening instrument  
The tuberculosis screening instrument of two or more symptoms 
developed in this study was able to detect 11 active tuberculosis cases in 
adults (8.5%) with clinically advanced HIV disease who had previously 
been assessed for active tuberculosis by the referring clinicians.  
 
A simple screening instrument of two or more of symptoms (persistent 
cough, night sweats or fever) plus documented weight loss is thus capable 
of detecting tuberculosis in this population. This screening instrument had 
a sensitivity of 100% and specificity of 88.1%, (against the „gold standard‟ 
of tuberculosis culture) and had positive and negative predictive values of 
44% and 100% respectively (likelihood ratio positive 8.43). 
 
5.1.2 IPT trial  
There was no detection of any benefit of INH prophylaxis in TST negative 
participants with clinically advanced HIV disease for the primary end point 
of tuberculosis. There was no significant (p = 0.32) difference in the deaths 
9all causes) between the INH closed-labelled arm and the placebo arm. 
Nor was there any significant difference in hospitalization of participants 
during the 24 months follow-up period with the 45.9 per 100 p-y in the INH 
closed-labelled arm, as compared to 46.3 per 100 p-y (p = 0.99). The 
median CD4 μL count the INH closed-labelled arm at 12 months follow-up 











5.1.3 Adherence  
There was a good correlation between pill counts and the monthly tick 
sheets completed by the patient nominated supervisors. This confirmed 
the inter-method reliability of the two methods of measuring supervised 
intermittent adherence to INH/placebo (Sumartojo E, 1993). Adherence 
was 85% in the randomized arms and 91.7% in the INH open arm. There 
was no statistically significant change in the median adherence of INH 
over time assessed quarterly in the randomised trial arms. The good INH 
adherence was attributed to the patient-nominated supervisors.  
 
Adherence was significantly higher among the participa ts with work-
based treatment supervisors than among those with home or community-
based supervisors.  
 
The adherence to the daily SAT of Cotrimoxazole by participants in the 
randomised trial arms (INH/placebo closed arms) was significantly lower 
than that by the participants in the INH open label arm. The reason for this 
difference could be that participants in the INH open label arm were in the 
less advanced disease stage. Furthermore, the participants in the INH 
open label arm were TST positive had observed the PPD induration on 
their arm prior to enrolment which could have been a strong motivating 
factor in them being more adherent.  
 
Although the median (of all three arms) adherence to cotrimoxazole was 
good (73.3%; IQR: 61.4 - 84.5), the median INH adherence in all three 
INH/Placebo arms (among the intermittently supervised participants) was 
significantly higher. This difference may be important as pparticipants with 
a cotrimoxazole adherence >= 70 had a statistically significant higher 
survival rate than those participants with a cotrimoxazole adherence 











This difference between median intermittent supervised INH adherences in 
the closed-labelled arms as compared to the median daily SAT of 
cotrimoxazole adherences in all three arms among the same participants 
could be attributed to many factors.  
 
Firstly the comparison was made between intermittent supervision of 
INH/placebo as compared to the daily self administration of cotrimoxazole 
by the participant. Secondly, the adherence was calculated based on 
different dosages required dosage for INH and cortimoxazole. And thirdly 
the different type of medication (size, shape, taste and taste) of 
INH/placebo and cotrimoxazole could also have been another contributing 
factor to the difference in adherences between the supervised and self 
administered medication among the same participants.    
  
However, when the median intermittent supervised INH adherence of 
[83.9% (IQR) 66.7, 92.5] in the closed-labelled arms was compared to the 
median daily SAT of cotrimoxazole adherence in all three arms [73.3% 
(IQR) 61.4, 84.5) among the same participants, it was higher Thus 
intermittent supervised INH adherence in the closed-labelled arms had a 
significant statistically higher (p < 00.1) adherence than the daily SAT of 
cotrimoxazole adherence in all three arms of the same participants. 
 
One should bear in mind that missing a 900mg dose of INH administered 
twice a week would be equivalent to missing ~ 3 doses of daily INH 
(300mg). Therefore, although adherence was better with supervised IPT 
compared to self administrated CTX (85% vs 73.3%), the (estimated) 
effective adherence to IPT and CTX is similar (72,6% vs 73.3%). This 















5.2.1 Tuberculosis screening study 
One study (Finch D & Beaty C, 1997) has shown that a single sputum 
culture specimen has been shown to be sufficient to establish the 
diagnosis of pulmonary tuberculosis in HIV-infected patients. However, 
participants with extra-pulmonary tuberculosis, as in one of the cases in 
this study, would not be detected using sputum culture only. It is thus 
possible that we may have under diagnosed tuberculosis during the 
screening process. Thus the limitation of using culture positive only as a 
„gold standard‟ versus applying case definitions to TB cases which would 
allow one to exclude false positive cultures and include TB cases that are 
smear and culture negative, but have documented response to treatment. 
 
A limitation on generalisability of this study is that the patient selection 
process was hospital based, consisting only of patients with advanced HIV 
disease. Also clinicians were referring patients who had already been 
previously screened routinely for tuberculosis and who referred patients to 
the trial whom did not suspect to have active tuberculosis. 
 
It is possible that the investigator who reviewed the radiographs may have 
underreported chest abnormalities as the pathology of tuberculosis is 
different and may be difficult to interpret in adults with advanced HIV 
infection. A South African study at a VCT Centre found that only 44% of 
patients with confirmed PTB during screening prior to preventive therapy 
had suggestive findings on chest radiographs (Naidoo, P et al, 2002). 
Thus underreporting of tuberculosis based on chest abnormalities of chest 












Of the 11 active cases of tuberculosis only one case was identified as 
extra pulmonary tuberculosis based on the tuberculosis symptom 
screening instrument and the chest radiographs in addition to the 
radiologist were reviewed by an independent clinician as well. However, 
undetected extra pulmonary tuberculosis cannot be ruled out despite the 
fact that there were no active tuberculosis cases detected in participants 
within the first three months of entry to the trial.  
 
5.2.2 IPT trial  
The lack of efficacy of INH prophylaxis suggested by these results may be 
due to the limited statistical power of the trial. The major limitation of our 
study is that it was underpowered to detect a clinically significance (an 
intervention that makes a genuine, palpable, practical and noticeable 
difference to the everyday lives of the participants in the trial) in the 
reduction in tuberculosis incidence attributable to INH. In our calculation of 
sample size we assumed that nearly all participants would have LTBI (i.e. 
that the findings in TST positive subjects in other studies would apply to 
our participants), and we estimated an 80% reduction in tuberculosis 
incidence based on the only placebo-controlled trial that evaluated 12 
months of INH (Hawken MP et al, 1997).  
 
Therefore it is likely that we over-estimated the efficacy of INH in this 
sample size calculation. In a meta-analysis pooling the results of the 
Hawken study of 12 month INH prophylaxis with those of three other 
studies of 6 months of INH, the reduction in tuberculosis incidence was 
62% in TST positive subjects (Woldehanna S & Volmink J, 2004). In 
addition, in our study there were high rates of death and loss to follow up 
among study participants, which is not unexpected as participants had 













The incidence of tuberculosis in this study was also substantially lower 
than had been previously reported (Wood R, Maartens G & Lombard CJ, 
2000). This could have been due to under-diagnosis of tuberculosis, but 
this is unlikely given the comprehensive diagnostic measures taken 
(symptom screening at each visit, and 6-monthly sputum culture and chest 
radiograph).  
 
A more likely explanation for the lower than expected tuberculosis 
incidence could be because of the prior exclusion of potential participants 
with a history of tuberculosis within the previous five years. These 
individuals are likely to have had a greater risk of developing tuberculosis 
than individuals admitted into this study. This possibility is supported by 
our finding that previous tuberculosis was associated with an increased 
risk of recurrent tuberculosis (HR 3.48; 95% CI: 1.11-10.92). This has 
been shown in other local studies. For example, in a study of HIV-infected 
South African gold miners, previous tuberculosis approximately doubled 
the risk of another event of tuberculosis (Grant A et al, 2005). It is also 
possible that unrecorded or tuberculosis could have been a possible cause 
of death or loss to follow up in some of the participants in this trial. 
 
Secondly the lower than expected incidence of tuberculosis during the 
follow-up could also have been contributed by the fact that all participants 
were screened for tuberculosis prior to their entry to the trial and in the first 
three months of follow-up of these participants, there were no tuberculosis 
cases diagnosed. Thirdly most participants prior to their death had left for 
their rural home to die. Hence the exact cause of death could not be 
established since no identity number of the participants was collected to 
confirm exact cause of death from the death certificates. And finally we 
had looked hard for tuberculoses did six monthly cultures of all participants 
on the trial and it is quite likely that we could have missed tuberculosis 












It has been shown that the risk of active tuberculosis  in individuals with a 
positive TST is increased by 12.9 cases per 1 000 in those who had been 
infected by this organism within less than one year as compared to 1.6 per 
1 000 increase in those had been infected between 1 and 7 years 
previously. With HIV infection the active tuberculosis risk among recently 
infected individuals increased by 35 - 162 per 1 000 persons within this 
group (CDC MMWR 2000). 
 
It is believed that had patients who had a history of tuberculosis less than five 
years prior to their entry to the trial and especially those of patients who had 
recently been treated for active tuberculosis may have decreased the event 
rate in this trial. Thus the increased the number of tuberculosis cases in both 
randomized arms (INH versus placebo), may have perhaps have enhanced 
the validity of the outcomes. 
 
5.2.3 Adherence study 
A limitation of adherence detection in this study was that adherence was 
not verified by routine or random urine analysis. However, the adherence 
to INH/placebo was verified by monthly pill count and compared with the 
monthly tick sheet of the patient-nominated supervisors. There was a good 
agreement between pill counts and the monthly tick sheets.  
 
In a previous study (Whalen CC et al, 1997), of 97 participants who were 
randomly selected for a single urine spot check of INH at a home visit 
between clinic visits, 78 (80%) tested positive for INH. It was noted that 
those participants with a positive home spot urine test for INH had a higher 
proportion of positive INH tests at the regular clinic visit than those with 












As participants were required to nominate supervisors, some of whom had 
no knowledge of the participant HIV status, maintaining confidentiality 
became an issue. Patient-nominated treatment supervisors who were not 
aware of participant HIV status were informed that this was a trial to 
prevent tuberculosis. It cannot be ascertained whether the outcome with 
regard to adherence was different in those participants whose patient-
nominated treatment supervisors who were aware of participant‟s HIV 
status compared to those treatment supervisors who were not aware.   
 
The assessment of SAT cotrimoxazole adherence was also based on pill 
counts without the validation of routine laboratory assessment. However, 
we believe that this was not a major limitation, based on a study 
conducted by the National Tuberculosis Control Programme of Malawi. 
The cotrimoxazole pill count in that study (Zachariah R et al, 2001) was 
verified against gas chromatography/mass spectrometry (GC/MS) as a 
gold standard. This yielded a sensitivity of 91.5%, specificity 60%, PPV 
97.4%). 
 
5.3 Relationship to literature 
 
5.3.1 Tuberculosis screening 
The 11 (8.5%) active tuberculosis found among 129 adults (10 definite and 
1 possible) with clinically advanced HIV disease is similar in proportion to 
that found in similar settings where tuberculosis is endemic. (Burgess A L 
et al, 2001; Aisu T et al, 1995 & Espinal MA et al, 1995).   
 
In this study a simple screening instrument of symptoms and documented 
weight loss was capable of ruling out tuberculosis. A high sensitivity and 
negative predictive value, i.e. avoiding false negatives, is more important 











tuberculosis preventive therapy. This is in order to prevent the 
development of drug resistance (WHO, 1999). The 88% specificity of the 
screening instrument means that 12% of patients (false positives) without 
active tuberculosis would be excluded from tuberculosis preventive 
therapy. Since the aim of screening is to exclude those patients with 
tuberculosis from IPT, the 12% exclusion of participants (without active 
tuberculosis) is a reasonable level of margin of error of the unintended 
exclusion of participants for IPT. 
 
Kimerling and colleagues (Kimerling ME et al, 2002), found that using 
„symptoms only‟ had a lower positive predictive value than in our study 
(Mohammed A et al, 2004). This may have been due to their different 
patient population who were all based in home care, or because weight 
loss was not measured. Despite this, 95% of their tuberculosis cases had 
reported symptoms (Kimerling ME et al, 2002). Active tuberculosis was 
also reported to be frequently found in screening for tuberculosis in HIV 
testing centres in developing countries (Aisu T et al, 1995; Espinal MA et 
al, 1995). Hence the integration f tuberculosis screening in high HIV and 
tuberculosis prevalence settings provide early diagnosis and treatment of 
tuberculosis as well as prevention and reduced risk of nosocomial infection 
(Burgess AL et al, 2001) 
 
The WHO and the US Centers for Disease Control and Prevention 
recommend chest radiograph as a component of the screening process to 
exclude tuberculosis prior to preventive therapy in HIV infection (WHO, 
1999; CDC MMWR, 2000). We found that chest radiograph did not 
improve the performance of the tuberculosis symptom screening 
instrument. However, in a recent study (Day JH et al, 2006) chest 
radiography did improve sensitivity of tuberculosis screening in a 
population of gold miners with WHO stage 1-4, with 46% of the 
participants in WHO stage 1. The reason for this outcome differing from 











infected gold miners in South Africa being different from our study which 
included only WHO 3 and 4). The prospective study of  chest radiograph in 
Botswana to screen for tuberculosis showed only 1 (0.2%) participant was 
diagnosed with tuberculosis and the study recommends that routine chest 
radiograph should not be routinely used for persons to be enrolled for IPT 
especially in settings which is able to screen for signs and symptoms of 
tuberculosis (Mosimaneotsile RN, et al, 2003) 
 
5.3.2 IPT trial  
The lower limit of the 95% confidence interval for the relative hazard of 
tuberculosis in TST negative participants receiving INH (0.57) rules out 
benefits associated with IPT, i.e. the 80% reduction which has been shown in 
previous studies of TST positive individuals (and which guided our sample 
size calculations). Thus this study has shown that lower limit of the 95% 
confidence interval for the relative hazard of tuberculosis in TST negative 
participants receiving INH are compatible with no effect and hence the 
outcome is neither  clinically or statistically significant for those participants 
that are in the advanced stage of HIV-infection (WHO 3 & 4). Hence this 
study adds no evidence to refute the hypothesis that INH is ineffective in TST 
negative patients with advanced stage of HIV-infection.  
 
The lack of IPT effect in this study, among participants (particularly those 
with lowest CD4 counts) could possibly be attributed to their high risk of 
death that may have resulted in them not having survived long enough to 
develop tuberculosis. And secondly, those participants that had died out of 
Cape Town or elsewhere, may have had undiagnosed tuberculosis, that 
may not have been detected just prior to their death. As indicated that the 
finding of this study is thus broadly consistent with previous meta-analyses 













In HIV-infected patients TST are more likely to be negative as CD4+ 
lymphocyte count declines (Markowitz N et al, 1993) The risk of HIV-
associated tuberculosis increases with advancing immune suppression as 
assessed by CD4+ lymphocyte count or disease stage (Holmes CB et al, 
2006; Wood R, Maartens G & Lombard CJ, 2000). In areas endemic for 
tuberculosis such as the Western Cape, the majority of HIV-seronegative 
adults have LTBI as assessed by a positive TST (Rangaka MX et al, 
2006). In this setting most HIV-infected patients with a negative TST would 
thus be anergic owing to advanced HIV disease, and thus at high risk of 
tuberculosis (Holmes CB et al, 2006; Wood R, Maartens G & Lombard CJ, 
2000), rather than being uninfected with MTb. It is therefore surprising that 
treatment of LTBI has been shown to be ineffective in TST negative 
participants in trials conducted thus far (Bucher HC et al 1999; 
Woldehanna S & Volmink J, 2004).  
 
This lack of effect in other studies could be explained by the fact that 
participants with advanced HIV disease were under-represented in the 
placebo-controlled clinical trials conducted in areas where tuberculosis is 
endemic (Pape JW et al, 1993; Hawken MP et al, 1997; Mwinga A et al; 
Fitzgerald DW, et al, 2001). TST negative participants in these trials could 
thus have been more likely to be “true negatives” (i.e. did not have LTBI).  
 
Previous studies following standard 6-month treatment of PTB have 
estimated relapse rates to be 1% to 2% at 24 months (British Thoracic 
Association, 1982). Host factors such as sex, disease factors and 
treatment-related factors interact to cause relapse (Tam CM, et al, 2002). 
We would have excluded these high risk patients from our trial because of 
the five year tuberculosis history exclusion criterion.  
 
A recent study showed that relapse occurred within one year after 











were in the advanced stage of the disease. This was significantly higher 
than among HIV-negative patients (Domoua K, 2005). However, where 
HIV-infected patients received tuberculosis treatment for ≥ 9 months with 
the concomitant administration of HAART (resulting in undetectable viral 
load), the relapse-rate was 1.9/100 patient years (95% CI: 1.8 – 2.0) 
compared to those who had tuberculosis treatment of 6 – 7 months (with 
no HAART), the relapse rate was 42.8/100 patient years (95% CI: 39.1 – 
46.5) (Lopez-Cortes LF et al, 2005). This tuberculosis relapse among 
patients receiving tuberculosis treatment for ≥ 9 months was similar to that 
observed in non immuno-compromised patients who received the standard 
6-month anti-tuberculosis regimen (Chaisson RE et al, 1996). Hence, as 
the result of the entry criteria of selecting trial participants who had a 
history of tuberculosis of five years or more may have impacted on the 
outcome tuberculosis among participants in the trial. 
 
Tuberculosis patients cured by short course treatment in trial conditions 
had at least a 7% recurrence of tuberculosis within 1 - 2 years (El-Sadr 
WM et al, 2001). A study in a high-incidence area where tuberculosis was 
successfully treated showed the risk of reinfection was approximately 2% 
per annum. The rate of reinfection resulting in tuberculosis was 
approximately seven times the crude incidence rate and approximately 
four times the age-adjusted incidence rate of tuberculosis. The likely 
reinfection disease rate/100 person years in this study was 2.4 (95% CI: 
1.4 – 3.8) and 1.4 (95% CI: 0.5 – 3.3) for those that were cured and 
completed treatment respectively (Verver S et al 2005).  
 
Yew (Yew WW, 2005) has proposed that the selection of individuals with 
predisposition to tuberculosis infection/disease or that tuberculosis itself 
increases the vulnerability or both these factors may possibly explain the 
increased vulnerability of HIV positive patients treated for tuberculosis as 
compared to HIV negative patients treated for tuberculosis. This view is 











where it was demonstrated that a higher proportion of recurrent tuberculosis 
was caused by reinfection among HIV-positive individuals for tuberculosis as 




5.3.3.1 INH/placebo  
The strength of our study was the high level of INH adherence which was 
higher than in most other trials reporting adherence (Hawken MP et al, 
1997; Mwinga A et al, 1988; Whalen CC et al, 1997). A recent cohort study 
of adherence to preventive therapy for HIV-infected patients in rural South 
Africa showed poor adherence, with only 47% patients completing 
treatment (Rowe KA et al, 2005).  
 
Our study did not have a clinic DOTS comparison group. However, a 
Cochrane Review (Volmink J & Garner P, 2006) of DOTS for treating 
tuberculosis concluded that there was no statistical difference in treatment 
outcome of cure or treatment completion between DOT and self treatment 
arms. There was also no difference in cure or treatment completion 
between family member and clinic supervision.   
 
The medications of INH/placebo in the previous seven trials of TST 
negative adults with advanced HIV disease were all self-administered in 
contrast to our participant nominated treatment supervisors.. The 
adherence in these trials varied greatly and did not achieve the high 
adherence we achieved in this trial. In three of these trials (Pape JW et al, 
1993; Gordin FM et al, 2000; Fitzgerald DW et al, 2001), no mention of 












Hawken and colleagues (Hawken MP et al, 1997) measured INH versus 
placebo adherence by tablet count at scheduled visits, the total number of 
weeks missed of trial medication in six months as well as random urine 
tests by a technician blinded by the trial code. Although there was no 
significant difference in effect of INH on tuberculosis incidence across the 
three levels of adherence measurement, the overall adherence in this trial 
was poor. The estimated number of treatment weeks missed by 
participants for one week, 1 - 4 weeks and > 5 weeks was 281 (41.7%), 
183 (27.1%) and 210 (31.2%) respectively. Of the 315 participants 




We believe that this is the first study that compares the good and poor level 
of cotrimoxazole adherence in relation to the mortality among adults with 
advanced HIV disease, where the threshold of ≥70% cotrimoxazole  
adherence has shown a statistically significant higher survival rate than 
participants with the threshold <70% CTX adherence. 
 
The cotrimoxazole  adherence in our study where 62.2% of participants had 
a (median ≥70%) cotrimoxazole  adherence that was relatively better than a 
previous study conducted by CDC in Uganda (Lule JR at al, 2002) where 
adherence was excellent for 42% of participants, good for 41% and poor for 
17% by pill count. In a cohort study Rwanda to (Nagaba W et al, 2004) to 
assess the feasibility of the use of cotrimoxazole prophylaxis and drug 
adherence showed that a total of 60 patients (36%) admitted to have taken 
their doses as expected. Whereas the study (Hausler HP et al 2002) of IPT 
and cotrimoxazole  in South African pilot districts, adherence to six months of 
cotrimoxazole  prophylaxis varied from 5% in Ugu South to 32% in Bushbuck 












The possible reason why cotrimoxazole adherence was good in this study 
(with majority of participants in the threshold of ≥70% cotrimoxazole   
adherence, could be attributed to counseling of the participant on 
enrolment on the need to adhere strictly to their prescribed medication. 
This message was reinforced with an appropriate message on the 
specially designed clinic card for the participant‟s enrolled on the RCT. 
These clinic cards in addition to indicating the scheduled dates of the 
monthly clinic visits of the participants had also an enforcing message on 
the need for participants to be adherent and reiterated that tuberculosis 
was preventable, treatable and curable if medication was taken regularly 
as prescribed (Appendix 3).    
.  
A study by Balestra  and colleagues (Balestra P et al, 1996) showed in a 
multiple logistic regression analysis a significant association of non-
adherence  with a CD4+ count less than 100/mm3 (OR:4.7,95% CI:1.2-10.1) 
and cotrimoxazole  prophylaxis (OR:2.5,95% CI:1.1-5.8). This study identified 
during the interview reasons for non adherence could be attributed to belief 
of ineffectiveness of the drug; denial of the HIV status; self-perception of 
adverse effects. We have during the enrolment process and at the monthly 
clinic visit of the participant have adequately addressed these factors on an 
ongoing basis. 
 
The reason for the overall cotrimoxazole adherence (all three arms) to 
being significantly lower than the adherence among the same participants 
in the INH/Placebo groups (including open INH arm) is presumably 
because the INH/placebo was supervised whereas the cotrimoxazole   
was SAT on a daily basis. However, the reasons for cotrimoxazole   
adherence being significantly higher in the INH open-label arm than the 
cotrimoxazole adherence in the randomised arms could be attributed to 











their TST positive. Thus this group of participants were informed that they 
were at risk of developing tuberculosis and were required to strictly adhere 
their prescribed medication (including SAT cotrimoxazole, since this 
medication was known to reduce the risk of the development of 
tuberculosis. Thus the observation of PPD induration by the participant 
may have positively enhanced their perceptions of the severity of their 
illness and risk of developing opportunistic infections, as well as a positive 
attitude toward the healthcare system and their perceived relationship with 
the healthcare provider (Hall RA et al, 2001). 
 
The assessment of the SAT cotrimoxazole adherence, based on pill 
counts without the validation of routine laboratory assessment was a 
limitation in this study. However, we believe that this may not have been a 
major limitation since a study conducted by the National Tuberculosis 
Control Programme of Malawi. (Zachariah R et al, 2001) showed that pill 
count of cotrimoxazole was verified by gas chromatography/mass 
spectrometry (GC/MS) as a gold standard which yielded sensitivity of 
91.5%, specificity 60%, PPV 97.4%). 
 
The number of adverse effects to cotrimoxazole  among the participants 
in our trial were reported to be seven (5.9%) of whom four participants 
had adverse effects prior to enrolment to the trial and three (2.6%) 
participants developed skin rash. while on the IPT trial. This result is 
consistent with study (Zachariah R et al, 2003) in Malawi, where 
tuberculosis patients diagnosed with HIV were administered 




This study has demonstrated that a simple screening instrument can 











hospital based setting. Once tuberculosis has been excluded, TST can be 
done to assess eligibility for preventive therapy.  
 
We have shown that patient nominated supervisors for preventive therapy, 
and particularly if based in the workplace, are effective and practical for 
resource-limited settings. Randomised studies of patients with tuberculosis 
thus indicate that directly observed therapy supervised by guardians or 
family members is at least as effective as supervision in the clinic or 
community. Cotrimoxazole by SAT also had good adherence especially 
among the TST positive participants with greater benefit in survival among 
participants with ≥70% adherence. There were minimal adverse events (of 
skin rash) consistent with previous studies.   
 
However, we found no benefit associated with INH preventive therapy in 
participants with clinically advanced HIV and negative TST in an area with 
a very high tuberculosis incidence. Although our findings are consistent 
with meta-analyses, they should be interpreted with caution owing to our 
small sample size. Access to antiretroviral therapy is rapidly increasing in 
resource-limited settings and an important research question is the role of 
INH or other preventive therapy in patients receiving combination 
antiretroviral therapy. 
 
The daily SAT cotrimoxazole showed a good adherence especially among 
the TST positive participants. This study also shows that there was a greater 
benefit in terms of survival among participants with a threshold of ≥70% CTX 
adherence. There were minimal adverse events which was consistent with 














The WHO and the US Centres for Disease Control and Prevention 
recommend chest radiograph as part of the screening process to exclude 
tuberculosis prior to preventive therapy in HIV infection (WHO, 1999; CDC, 
MMWR 2000). Chest radiographs alone in this study had a sensitivity of 
27%. Hence it is recommended that chest radiography as part of TB 
screening, based on the results of this study can only apply to HIV-infected 
individuals with advanced HIV disease. 
 
Active tuberculosis case finding should be an integral component of HIV 
management at primary care and VCT Centers (Naid o P et al, 2002). We 
have demonstrated that a simple screening instrument can effectively 
exclude tuberculosis in patients with advanced HIV disease. Once 
tuberculosis has been excluded, TST can be done to assess eligibility for 
preventive therapy. As in our study, nurses could apply the screening 
instrument. 
 
Based on the good adherence observed in this study, it is recommended 
that since patient nominated supervisors are effective and practical for 
resource-limited settings they should become an integral part of IPT, at 
least in adult patients.  
 
Although no benefit was associated with IPT in participants with clinically 
advanced HIV and negative TSTs, (consistent with meta-analyses), 
access to antiretroviral therapy (ART) is increasing in resource-limited 
settings and hence there is a need for further investigation of the role of 















A recent survey of international public health agencies highlighted the 
need for four additional interventions needed to control HIV related 
tuberculosis (Maher D et al, 2005). Two of these four interventions were 
tuberculosis preventive therapy and intensified tuberculosis case finding.  
 
The Maher (Maher D et al, 2005) review has further identified the need to 
focus on the cost effectiveness of screening LTBI. Such research needs to 
determine the number of persons with LTBI for IPT needed to prevent one 
case of tuberculosis as well as focus on methods of effective screening for 
extra-pulmonary tuberculosis prior to enrolling patients on IPT.   
 
Although, it is more important to exclude active undiagnosed TB prior to 
starting IPT monotherapy, which may generate resistance, there is no data to 
date to support whether poor adherence to IPT could lead to INH resistant 
TB. In theory, poor adherence to IPT could lead to INH resistant TB. Hence, 
another research focus area could be to determine the association of poor 
adherence and IPT resistance, since good adherence is important to 
maximize the effectiveness of IPT.  
 
Based on the results of this IPT trial we recommend that the tuberculosis 
screening study be replicated in a clinic setting in a form of operational 
research, with trained nurses using this screening instrument. In addition, 
the validity and  cost effectiveness of using a simple tuberculosis 
screening for active tuberculosis  case finding at Primary Care and VCT 













Although, the study demonstrated no benefit associated with IPT among 
participants with clinically advanced HIV and negative TSTs, this result 
should be viewed with reserved degree of uncertainty because of the 
under powering and the exclusion of patients to the study with ≤5 years 
history of tuberculosis on entry to the trial. Hence any future studies in this 















CHAPTER 6: EPILOGUE 
 
6.1 The way forward? 
 
The spectre of a more deadly form of MDR-TB termed XDR-TB that was 
reported in Kwazulu-Natal (the province in South Africa with the highest 
HIV prevalence), in January 2006 (WHO 2006), is an indictment of the 
failure of the NTBCP. By February 2007, 269 XDR-TB cases had been 
reported in South Africa, which spread to all nine provinces, and an 
estimated mortality rate of 85% (Kapp C, 2007).  
 
The emergence of XDR-TB does not augur well for the Global 
Tuberculosis Control Programme, especially for developing countries such 
as South Africa with one of the highest HIV prevalence in the world. South 
Africa has in excess of five million HIV positive persons that are potentially 
at risk of being infected with XDR-TB.  
 
Although South African health legislation is empowered to detain those 
with infectious disease until it is no longer a threat (in line with WHO 
guidelines), this is not a viable option. This would further exacerbate the 
stigma associated with tuberculosis and HIV.  
 
The emergence of XDR-TB with the need to use of detention as an 
isolation measure thus threaten to undermine any attempts in the 
prevention, control, management and care of patients with tuberculosis, 












To effectively begin to deal with MDR-TB and XDR-TB requires a return to 
the basics of the prevention, control and management of the tuberculosis 
Control Programme. Figure 5 outlines a four pronged strategy in 
combating tuberculosis, focusing on tuberculosis case finding and case 
holding (i.e. incorporating 70% tuberculosis detection rate and 85% 
tuberculosis cure rate with the DOTS strategy); the prevention of 
tuberculosis by prophylaxis (in most vulnerable groups) and BCG (in 
children to prevent tuberculosis meningitis); improvement of socio-
economic conditions (skills building and income generating projects) and 
the intensification of the HIV/AIDS strategy (especially the treatment 
programme). 
 
Figure 5: The Four Pronged Tuberculosis Strategy   
Case finding & case holding 
(i.e. 70% TB detection 













of the HIV/AIDS 
programme 
(i.e. ART roll-out) 
 
Prevention of active TB 
(i.e. prophylaxis especially 
for HIV adults with TST 
positive status & BCG) 
Source: Mohammed, A. Towards the conquest of TB in the 21
st
 century. Conference 
paper presented at the International Conference (TB Strategies for Africa): 18-20 











I am of the firm belief that instituting these four strategies religiously and 
calling on all intersectoral stakeholders we could substantially control 
tuberculosis, HIV/AIDS, MDR-TB and XDR-TB.    
 
It is my recurring nightmare that a day will soon dawn where South Africa, 
could as a result of its failure in the prevention, control and management of 
TB, HIV/AIDS, MDR-TB and XDR-TB, declare martial law because the 
wards of hospitals being filled to capacity with one or more of these 
diseases especially XDR-TB. South Africa would be unable to cope with 
the over-burdening morbidity and mortality rates and related costs 
exacerbated by succumbing to these four concurrent epidemics 
indefinitely. This would have dire consequences for this very young 
democratic country with such abundance of potential and resources. How 
many eyes will have to close into eternity before we open our eyes to this 
global public health emergency?  
 
We are fortunate in knowing enough, early enough, to prevent such an 
impending catastrophe. But the time to act is now.  In the words of Mario 
Raviglione (Director of Stop TB at WHO): “The local, national and 
international response to the spread of XDR-TB was too little too late. This 
is an absolute emergency. It is the most urgent thing I have ever seen in 
my 15 years of working in tuberculosis: a highly resistant strain that is now 
killing HIV-positive people and spreading very rapidly… Nobody is moving 
fast enough (Kapp C, 2007).  
 
We have already seen the indicators for this impending catastrophe. On 
Friday 23 April, 1993 WHO declared tuberculosis a global public health 
emergency.  Three years later, in 1996, Minister Ebrahim Rasool, the 
former MEC of Health of the Western Cape, (South Africa) declared 
tuberculosis a provincial emergency.  In 2006 an outbreak of XDR-TB was 











confirmed of which 44 patients were HIV-positive. Fifty two of the 53 
patients died, on average, within 25 days. Now in 2007 XDR-TB has been 
reported in all nine provinces in South Africa.  
 
What is next? Total drug resistant tuberculosis (TDR)? The implications of 
such an outbreak as is occurring with XDR-TB are unthinkable. But to 
avert this imminent „holocaust‟ we need to act now while in this period of 
the window of opportunity. 
 
“Never before has Man had such a capacity to control his own 
environment; to end thirst and hunger; to conquer poverty and to end 
disease; to banish illiteracy; and massive human misery. We have the 
power to make this the best generation of mankind in the history of this 
world or the make it the last” 
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Participant informed consent form for INH/Placebo trial 
HIV slowly destroys an important White Blood Cell (CD4 cell). This
weakens the body and allows the other germs to cause sickness. Many of 
these sicknesses can be prevented by taking tablets. Tuberculosis (TB) is
most common sickness in patients infected with HIV in South Africa. This
study will observe if TB or any other common sickness can be prevented
among HIV-infected patients in Cape Town with the use of certain tablets
under supervision of TB Supervisor whom you will be required to
nominate.
TB can be prevented by using the tablet named isoniazid (INH). Studies
have shown that INH prevents the development of TB in HIV patients who
have been tested positive for skin test. Therefore, all HIV patients who are
tested positive for a skin tests (enrolled in this trial) will receive INH every 
month for 12 months with the supervision of their nominated supervisor.
We believe that because TB is a very serious problem in Cape Town, that
INH may also prevent the development of TB in HIV patients who have
been tested negative for a skin tests. Because we are not sure if INH really 
works in HIV patients with negative skin test, some patients will get INH 
and others will get a placebo (looks like INH, but does not have effect like
INH). Each patient participating in this trial will have an equal chance of 
receiving INH or placebo. All those involved in this trial (i.e. doctors,
nurses, researchers, patients and supervisors), will not know who was
allocated INH or placebo, until the completion of the trial.
At the beginning of the trial, you will get a TB skin test (a small injection on 











multipuncture skin tests. You will also be tested to determine if you have 
TB. If you are confirmed to have TB, you will not be eligible for the trial but 
instead will be referred to the clinic nearest to your home for TB treatment. 
 
On your enrolment to the trial you will be supplied with INH/placebo, 
vitamin (pyridoxine) and an antibiotic (cotrimoxazole) at each monthly 
clinic visit. The INH and vitamin tablets will taken by you twice weekly 
under the supervision of your supervisor for 12 months, whilst you will be 
required to take the antibiotic (cotrimoxazole) daily (without supervision) to 
prevent other common sickness. Studies have shown that this antibiotic 
does work in patients infected with HIV, so everyone on this trial will 
receive cotrimoxazole. This antibiotic can sometimes cause skin rash and 
you will be observed for any such reaction. If this happens this happens 
this antibiotic will be discontinued and replaced with another antibiotic. 
 
INH can sometimes cause skin rashes or damage to the liver (causing 
nausea, or yellow colour in the eyes or brown colour in the urine) or 
damage the nerves (which will cause tingling or numbness in the feet). 
You will be checked for these problems every month and would be 
required to let your doctor, nurse, research or supervisor if these problems 
occur. You should not drink alcohol while on the study as this makes the 
problem of damage to the liver or nerves happen more often. If serious 
side effects to INH occur, you will be taken of the trial. 
 
Entry to this trial is voluntary. Your refusal to enter and participate into this 
trial or your decision to discontinue participation in the trial at any stage will 
not prejudice your standard treatment that will be rendered to you on your 
regular visit to the HIV clinic. If you decide that you do not want to carry on 
with the study, you may do so. However the medication prescribed for you 
will be discontinued, but you will continue to get standard treatment from 











on the positive result of your skin test, you will continue to receive INH in 
addition to the standard treatment from the clinic you had previously 
attended.   
 
On your decision to participate in this study, details of your sickness (HIV 
status) will not be revealed to anyone not directly involved in this trial 
including the treatment supervisor.  
 
If you have any questions during this study, please feel free to contact:  
Ashraf Mohammed at (telephone 404-9111, page 1503) or                    
Prof Gary Maartens (telephone 404-9111, page 1306).  
 
I, Doctor …………………………………………… (please print) confirm that 
the risks and benefits of the trial (study) have been explained to the patient 
……………………………………………………… (please print) with 
following folder number ……………………………… 
 
Doctor‟s signature………………………           Date: ……………….. 
 
Patient‟s signature: ……………………… Date: ……………….. 
 













Appendix 2  
Part 1 - Questionnaire patient interview: Demographic & 
clinical history 
 
Name of Clinic  Study ID Number   
1. Surname   First name  
2. Date of 
Clinic Visit 
Day  Date  Month  Year  
3. Type of Clinic Visit:   
4. Clinic Visit Number  
5. Name of hospital referred from (Tick response) 
 New Somerset Hospital 
 Groote Schuur Hospital 
 Tygerberg Hospital 
 Other (Specify)  
6. Name of Referring Dr  
7. Patients Hospital Folder 
Number 
 
8. Date of Birth  
9. Gender (Tick response) 
 Male  
 Female 
10. Race (Tick response):   (a) White 
                                            (b) Coloured 
                                            (c) African 
                                      (d) Asian  
11. Residential address 
 
Telephone………………… 















 „Common Law Marriage‟ 
 Single 
13. What is your Occupational Status (Tick response) 
 Employed White 
 Unemployed 




 Other (Specify ………………)   
If unemployed, are you on: (Tick response) 
(a) Disability grant 
(b) Pension 
(c) Boarded 
(d) Unemployment fund 
(e) On severance package 
(f) None of the above 
(g) Other income (Specify ………………)   
If employed, are you: (Tick response) 
(a) Permanent 
(b) Temporary 
(c)                Part-time 




 No Schooling 
15. Have you had BCG? (Tick response) 
 Yes  
 No 
 Don‟t know 
16. Do you have any scarring on the arm (Tick response) 












17. Have you ever in the past been diagnosed with tuberculosis? 
     (Tick response) 
 Yes  
 No 
 Don‟t know 
If YES: 
 Was it TB of the lungs? 
 Where were you treated? 
 When were you treated? 
18. Have any of your household members residing with you been diagnosed with TB in 
the last year? (Tick response) 
 Yes  
 No 
 Don‟t know 
If YES: 
What is the household member‟s relation to you? 
 Name: 
 Age: 
 Where was s/he treated? 
 When was s/he treated? 
19. What was your current /last employment status? (Tick response) 
 Professional 




 Not applicable 
20. Name the company where you last worked? 
21. Workplace address & telephone? 
22. Are you on Medical Aid?  (Tick response) 
 Yes  
 No 
If YES: Name of Medical Aid 
23. Are you the sole supporter of your family/household? (Tick response) 












24. What is your monthly income? (Tick response) 
 <R500.00 
 R500.00 – R999.00  
 R1000.00 – R1499.00  
 R1500.00 – R1999.00  
 R2000.00 – R2499.00  
 R2500.00 – R2999.00  
 ≥R3000.00 
25. Do you have any dependents? (Tick response) 
 Spouse 
 1 Child  
 2 Children 
 3 or more children 
 None 
 Other dependents (Specify ………………)   
26. Is your partner aware of your HIV status?  (Tick response) 
 Yes  
 No 
 Don‟t know 
27. How many sexual partners have you had in the last 6 months? 
 None   
 1 
 2 
 3 or more 
If your response is one or more partners in the last 6 months, have you used a 




28. Are you or (is your wife/girlfriend) pregnant? (Tick response) 













29. Are you currently on contraception?  (Tick response) 
 Yes  
 No 





(e) Other (Specify ………………..) 
30. If you have child aged 5 years or less, what is the HIV status of the child?  (Tick 
response) 
 HIV +VE  
 HIV -VE 
 Don‟t know 
31. What is your sexual orientation?  (Tick response) 

















Part 2: Baseline tests / investigations 
 
33. Measured Height  
34. Measured Weight  
35. Multipuncture Test Result (Multitest® CMI) 
Date test administered 
Date test result read 
(a) 1 = Tetanus antigen 
(b) 2 =  Diphtheria 
(c) 3 = Streptococcus C antigen  
(d) 4 = Tuberculin antigen 
(e) 5  = Glycerine (Control) 
(f) 6 = Candida albicans (antigen) 
(g) 7 = Trichophyton mentagrophytes antigen 




36. Baseline TB Tests Results 
(a) Sputum Smear Microscopy 
(b) Sputum Culture 
(c) Chest Radiography 
 
37. Baseline Cytometer Readings 
(a) CD4 Count 
(b) CD8 Count 
(c) CD4: CD8 Ratio 
(d) TLC 
(e) Other Test/s (Specify …….) 
 
38. WHO Clinical Stage  






40. Designated Area of TB Lay Supervisor & „Relation‟ of TB 















41. Karnofsky Performance Scale Score (Circle appropriate 
score) 
(100) Normal, no complaints, no evidence of disease 
(90)   Able to carry on normal activity: minor symptoms of 
disease 
(80)   Normal activity with effort: some symptoms of disease 
(70)  Cares for self, unable to carry on normal activity or 
active work 
(60)  Requires occasional assistance but is unable to care 
for needs 
(50)  Requires considerable assistance and frequent 
medical care 
(40)  Disabled: requires special care and assistance 
(30) Severely disabled: hospitalization is indicated, death 
imminent 
(20) Very sick, hospitalization necessary: active treatment 
necessary 
(10)  Moribund, fatal processes progressing rapidly     
 
42. Have you had persistent cough for more than 2 weeks?      
 Yes 
 No 




43. Have you had drenching night sweats in the last month? 




44. Have you had fever in the past month? (Tick Response)     
 Yes 
 No 
 Not sure/Cant recall 
If YES, was the fever  
(a) intermittent  
(b) Constant 
 












46. Have you had chronic diarrhea for month or more? (Tick 














Part 3: Monthly screening/monitoring of patient clinic visits 
 
Name of Clinic  Study ID Number   
47. Surname   First name  
48. Date of Clinic 
Visit 
Day  Date  Month  Year  
49. Type of Clinic Visit:   
50. Clinic Visit Number  
51. Potential Side effects to drug (Circle response) 
 New skin rash 
 Itchiness 
 Pins & Needles 
 Numbness of the limbs 
 Nausea 







52. Have you had persistent cough for more than 2 weeks?      
 Yes 
 No 
If YES, did your sputum contain blood (Tick response) 
 Yes 
 No 
53. Have you had drenching night sweats in the last month? (Tick Response)     
 Yes 
 No 
54. Have you had fever in the last month? (Tick Response)     
 Yes 
 No 
 Not sure/Cant recall 
If YES, was the fever  
(a) intermittent  
(b) Constant 














56. Have you had chronic diarrhea in the last month? (Tick Response)     
 Yes 
 No 
57. In the past month have you been to visit the any other outpatients clinic/hospital or 
private doctor? (Tick Response)     
 Yes 
 No 
If YES, which outpatient clinic/hospital/doctor attended to you?          
58. Urine Dipstick 
(a) Billirubin 
(b) Other (Specify …….) 
 
59. Previous month‟s weight  
60. This months weight difference  
61. % Weight difference  
62. Urine Dipstick 
(a) Billirubin 
(b) Other (Specify …….) 
 
63. Previous month‟s weight  
64. This months weight difference  
65. % Weight difference  
66. Is the Patient „TB Suspect‟ (Yes  ≥ 2 Symptoms: cough, sweats, fever, temperature and 
weight loss 2.5% within a month) 
 Yes 
 No 
 Not sure        
67. Urine Dipstick 
(a) Billirubin 
(b) Other (Specify …….) 
 
68. Was the clinic visiting card allocated to you at the beginning of this trial/study study 
shown to the attending doctor/nurse? (Tick Response)     
 Yes 
 No 












69. Urine Dipstick 
(a) Billirubin 
(b) Other (Specify …….) 
 
70. Previous month‟s weight  
71. This months weight difference  
72. % Weight difference  
73. Is the Patient „TB Suspect‟ (Yes  ≥ 2 Symptoms: cough, sweats, fever, temperature and 
weight loss 2.5% within a month) 
 Yes 
 No 
 Not sure        
74. Any other relevant notes on the Patient? 
 
75. The number of Cotrimoxazole administered to the patient for 
the forthcoming 4 weeks (should always be 28 tablets. One 
tablet to be taken daily unsupervised by the patient. 
 
Number of Cotrimoxazole 
tablets returned by patient 
= 
76. The number of Pyridoxine (Vitamin B6) administered to the 
patient for the forthcoming 4 weeks (should always be 8 tablets. 
One tablet to be taken twice weekly with INH/Placebo under the 
supervision of „TB Lay Supervisor‟ 
Number of Pyridoxine 
tablets returned by the 
patient = 
77. The number of INH/Placebo administered to the patient for 
the forthcoming 4 weeks (should always be 30 tablets and was 
under the supervision of the „TB Lay Supervisor‟ on a twice 
weekly basis. The dosage for patients 
 < 55kg was 4.5 tablets twice weekly 
 ≥ 55kg was 5 tablets twice weekly 
Number of INH/Placebo 
tablets returned by the 
patient = 
78. Patient‟s next monthly clinic visit? 
 Date: 













Part 4: TB tests & cytometer readings at 6-monthly intervals 
 










79. Six monthly TB Tests Results 
(a) Sputum Smear Microscopy 
(b) Sputum Culture 
(c) Chest Radiography 
    
80. Six monthly Cytometer Readings 
(a) CD4 Count 
(b) CD8 Count 
(c) CD4: CD8 Ratio 
(d) TLC 
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Monthly supervisor tick sheet of participant:‘TB lay 
supervisors’ monthly report of TB preventive supervised 
therapy 
 
Month   Year  
Area/Location of TB Lay Supervisor  
Name of TB Lay Supervisor  
„Relation‟ of TB Lay Supervisor to Patient  
The tablets attached to this note are for the patient listed below. Please make sure that 
this patient takes the tablets regularly as prescribed. 
The patient should take: 
1. Trial Tablet (INCH/Placebo: TB Drug): …….  tablets 2 times a week 
2. Vitamin Tablet (Pyridoxine):1 tablet 2 times a week 
3. Please record and advise clinic/researcher of any side effects or 
advise patient to report to clinic  
4. Please return all unused tablets with patient at monthly clinic visit 
5. With the unused tablets, please  
6. Complete this form with a tick and initial corresponding to date to the 
tablets taken by patient 
7. Hand completed form to the patient, to be submitted at the next  
clinic visit as a record of patient‟s monthly intake of trial medication (tablets),  
8. You may comment on the patient‟s general health or any other 
general information you may wish to inform us regarding this patient 













Patient‟s surname  
Patient‟s first name  
Patient‟s folder number  
Patient‟s medication number  





1 Monday     
 Thursday     
2 Monday     
 Thursday     
3 Monday     
 Thursday     
4 Monday     
 Thursday     
      






























Karnofsky performance status scale definition rating criteria 
KP Score ≥ 80 indicates the ability to carry on normal 
activities and to work with no special care needed 
100 Normal, no 
complaints, no 
evidence of disease 
90 Able to carry on 
normal activity: minor 
symptoms of disease 
80 Normal activity with 
effort: some 
symptoms of disease 
KP Score between ≥ 50 and 70 indicates the inability 
to work but able to live at home and care for most 
personal needs with varying amount of assistance 
needed 
70 Cares for self, unable 
to carry on normal 
activity or active work 
60 Requires occasional 
assistance but is 
unable to care for 
needs 
50 Requires considerable 
assistance and 
frequent medical care 
KP score of < 50 indicates the inability to care for
oneself and requires equivalent of institutional or
hospital care and where the disease may be
progressing rapidly
40 Disabled: requires 
special care and 
assistance 








10 Moribund, fatal 
processes 
progressing rapidly  
0 Dead 
